Application of Pharmacometric Methods to Improve Pediatric Drug Development by Lala, Mallika
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2011
Application of Pharmacometric Methods to
Improve Pediatric Drug Development
Mallika Lala
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/2467
 School of Pharmacy 
Virginia Commonwealth University 
 
This is to certify that the dissertation prepared by Mallika A. Lala entitled 
APPLICATION OF PHARMACOMETRIC METHODS TO IMPROVE PEDIATRIC 
DRUG DEVELOPMENT has been approved by her committee as satisfactory 
completion of the dissertation requirement for the degree of Doctor of Philosophy (Ph.D.) 
 
 
Jogarao V.S. Gobburu, FDA      and     F. Douglas Boudinot, School of Pharmacy  
 
 
Jurgen Venitz, School of Pharmacy 
 
 
Patricia W. Slattum, School of Pharmacy 
 
 
D’arcy P. Mays, College of Humanities and Sciences 
 
 
Susanna Wu-Pong, Graduate Program Director, School of Pharmacy 
 
 
Victor A. Yanchick, Dean, School of Pharmacy 
 
 
Dr. F. Douglas Boudinot, Dean of the Graduate School 
 
 
May 9th, 2011 
 
i
  
 
 
© Mallika A. Lala              2011 
All Rights Reserved 
 
 
ii
APPLICATION OF PHARMACOMETRIC METHODS TO IMPROVE PEDIATRIC 
DRUG DEVELOPMENT 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
by 
 
MALLIKA A. LALA 
Bachelor of Pharmaceutical Science, UICT, India, 2006 
Ph.D. in Pharmaceutical Science, VCU School of Pharmacy, 2011 
 
Co-advisor: JOGARAO V.S. GOBBURU, Ph.D. 
Director, Division of Pharmacometrics, U.S. Food and Drug Administration 
 
Co-advisor: F. DOUGLAS BOUDINOT, Ph.D. 
Professor, School of Pharmacy, Virginia Commonwealth University 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2011 
 
iii
Acknowledgement 
 
This dissertation is dedicated to my deceased grandfather Mr. Murli Lala, the need to 
fulfill whose last desire of me led me to the U.S. to obtain my Ph.D. I dedicate this work 
also to my parents, Anil and Mita Lala, whose unconditional love and support is integral 
to my success. 
 
There are several people who warrant acknowledgement. 
 
The person I thank first and with utmost gratitude is my advisor Dr. Joga Gobburu. He 
has been the best mentor I could ask for, a friend and role model. He not only bailed me 
out of a crisis that struck mid-way through my degree program but also provided me with 
the rare opportunity to complete my dissertation research at the FDA. He has taught me 
to learn and apply and has helped me transform into an independent thinker and 
researcher. I owe most of my professional prowess to him. Thank you very much. 
 
The next person I thank whole-heartedly is my advisor Dr. Douglas Boudinot. He stepped 
up to shoulder my responsibility and support me through the finish of my degree when I 
was in need. He has been a kind and helpful mentor and a solid anchor for me at VCU.  
Sincere thanks to you Dr. Boudinot. 
 
I thank all my committee members – Dr. Patrcia Slattum, Dr. Jurgen Venitz and Dr. 
D’Arcy Mays for their constant guidance and support along the entire course of my 
research. They have helped me think through my work and provided valuable feedback. 
In particular, I thank Dr. Slattum who has always been there as a guide and friend 
through my five years at VCU, helping me in several ways. I also thank Dr. David 
Holdofrd for his motivating words and for being a helpful member of my original 
committee. 
 
 
iv
My colleagues at the Division of Pharmacometrics at FDA all warrant a special 
acknowledgement. I have learnt tremendously from the unique, stimulating work 
environment they create together. My particualr thanks to Dr. Pravin Jadhav, Dr. Satjit 
Brar, Dr. Yaning Wang and Dr. Christopher Tornoe for mentoring and befriending me 
and helping me develop the skills I have. 
 
Finally, I acknowledge the ones whose love and faith have made this possible – my 
family and friends. My parents have provided me with the best possible education and 
much more. They are the anchor that enables me to seek independence and excellence. 
My brother and his wife, Amit and Janaina Lala, have been constant believers and silent 
pillars of support. My friends, who are the sole reason I have survived life away from 
home over these five years. My most heart-felt thanks goes to Raunak, who has 
incessantly been there by my side through all experiences that came my way, good and 
bad. He has helped me sail through this journey being my stressbuster and technological 
guide.☺ Priyanka and Parinaz have filled in the shoes for family and given me the love, 
backing and nurture that never let real home-sickness kick in. Raunaq has been my go-to 
person when I’ve needed any counseling and an unfailing support system. Avinash, who 
although joined me towards the end of this journey, has been the prime source of comfort 
and encouragement that saw me through the most difficult and trying last sprint. All of 
my friends back home in Bombay have been well-wishers and believers in my potential.  
 
I’m elated and grateful to have finally reached here. Thank you everyone! 
 
 
 
v
Table of Contents 
Acknowledgement ............................................................................................................. iv 
List of Tables ...................................................................................................................... x 
List of Figures .................................................................................................................... xi 
List of Abbreviations ........................................................................................................ xii 
Abstract ............................................................................................................................ xiv 
 
CHAPTER 1: 
Pharmacometrics: Concepts and Applications to Drug Development................................ 1 
Abstract ............................................................................................................................... 1 
What is Pharmacometrics?.................................................................................................. 2 
Disease models.................................................................................................................. 11 
Population analysis ........................................................................................................... 16 
Types of data and trial designs.......................................................................................... 22 
Case studies....................................................................................................................... 25 
Perspective ........................................................................................................................ 39 
Reference List ................................................................................................................... 42 
 
CHAPTER 2: 
Pharmacometric Analyses Impact Pediatric Drug Approval and Dosing......................... 47 
Abstract ............................................................................................................................. 47 
 
vi
Introduction....................................................................................................................... 48 
Applications of pharmacometric analyses ........................................................................ 51 
Future Perspective............................................................................................................. 58 
Conclusion ........................................................................................................................ 59 
Reference List ................................................................................................................... 59 
 
CHAPTER 3: 
Simulation-based Methodology for using PK Quality Standard to Design Pediatric Trials 
in the Population Analysis setting..................................................................................... 63 
Abstract ............................................................................................................................. 63 
Introduction....................................................................................................................... 65 
Methods............................................................................................................................. 69 
Results............................................................................................................................... 81 
Discussion......................................................................................................................... 88 
Reference List ................................................................................................................... 96 
 
CHAPTER 4: 
Covariate models – do not center at values outside the data range .................................. 98 
Abstract ............................................................................................................................. 98 
Introduction....................................................................................................................... 99 
Methods............................................................................................................................. 99 
Results............................................................................................................................. 105 
 
vii
Discussion....................................................................................................................... 107 
Reference List ................................................................................................................. 112 
 
CHAPTER 5: 
A Genetics-based Pediatric Warfarin Dosing Regimen derived using Pharmacometric 
Bridging .......................................................................................................................... 114 
Abstract ........................................................................................................................... 114 
Introduction..................................................................................................................... 116 
Methods........................................................................................................................... 120 
Results............................................................................................................................. 135 
Discussion....................................................................................................................... 147 
Reference List ................................................................................................................. 155 
 
CHAPTER 6: 
Conclusions and Future Research................................................................................... 159 
 
APPENDICES 
 
APPENDIX A: 
R script, NONMEM model and SAS program files used to run simulation-estimation for 
pediatric PK quality standard evaluation (Chapter 3)..................................................... 164 
APPENDIX B: 
NONMEM model file used for simulations for warfarin pediatric model qualification 
(Chapter 5) ...................................................................................................................... 189 
 
viii
APPENDIX C: 
Drug Model set-up in Trial Simulator for optimizing pediatric warfarin dosing regimen 
(Chapter 5) ...................................................................................................................... 192 
APPENDIX D: 
Target INR Outcomes for all genotypes (Chapter 5)…………………………………...193 
 
APPENDIX E: 
Population Pharmacokinetic-Pharmacogenetic Analysis of Nevirapine in HIV-infected 
Populations in Uganda and the U.S. – A Covariate Exploration .................................... 197 
 
VITA............................................................................................................................... 219 
 
ix
List of Tables 
CHAPTER 1 
Table 1: Summary of the types of regulatory decisions influenced by pharmacometric 
analyses ........................................................................................................................10 
Table 2: Comparison of systems biology, semi-mechanistic and empirical approaches to 
disease models .............................................................................................................15 
Table 3: Main features of the common population analysis methods .................................20 
Table 4: Summary of case studies, where pharmacometric analysis had an impact on 
decision making, during different stages of drug development...................................31 
CHAPTER 2 
Table 1: Pharmacometric analyses to design pediatric trials using existing data in 
pediatrics and/or adults ................................................................................................53 
Table 2: Pharmacometric analyses to provide primary or supportive evidence of 
effectiveness.................................................................................................................55 
Table 3: Pharmacometric analyses to derive pediatric dosing recommendations for 
labeling.........................................................................................................................57 
CHAPTER 3 
Table 1: Values of the one-compartment model parameters used for the simulations........75 
Table 2: Trial design scenarios explored during simulations ..............................................80 
CHAPTER 4 
Table 1: The one-compartment model parameters used for simulations...........................103 
Table 2: Mean and power for precision on clearance and volume estimates in absence and 
presence of appropriate centering. .............................................................................107 
CHAPTER 5 
Table 1: Description of cohort of pediatric subjects from CHLA .....................................136 
Table 2: Parameters of the warfarin pediatric population PKPD model used to predict 
CHLA data and to optimize dosing. ..........................................................................138 
Table 3: Final proposed pediatric warfarin dosing regimen – starting dose and titration 
scheme........................................................................................................................142 
 
 
x
List of Figures 
CHAPTER 1 
Figure 1: Potential applications of pharmacometrics throughout drug development ............4 
Figure 2: Conceptual framework for nonlinear mixed effects modeling.............................17 
CHAPTER 2 
Figure 1: Sample size vs. %CV in 8 pediatric PK studies chosen randomly from the 
literature and submissions to FDA...............................................................................68 
Figure 2: Flow chart of computations carried out by the simulation-estimation tool..........70 
Figure 3: Impact of all trial scenario elements explored on sample size adequacy to meet 
PK quality standard......................................................................................................82 
Figure 4: Power to achieve target precision standard (on mean clearance) at all sample 
sizes explored, by age bin, for a sample scenario. .......................................................83 
Figure 5: Mean bias (in mean clearance) at all sample sizes explored, by age bin, for a 
sample scenario............................................................................................................84 
CHAPTER 5 
Figure 1: PK-PD of S-warfarin ..........................................................................................119 
Figure 2: Outline of research approach employed.............................................................122 
Figure 3: Clinical trial simulations schematic ...................................................................130 
Figure 4: INR target outcomes for pediatric dose optimization ........................................133 
Figure 5: Model qualification outcomes: predicted and observed INR over time.............140 
Figure 6: INR vs. time profiles by genotype for mean simulations – initial dosing scheme 
for typical subjects. ....................................................................................................141 
Figure 7: Comparison of genotype-based and genotype-independent dosing on patient 
INR outcomes across time. ........................................................................................143 
Figure 8: Target INR outcomes across time with CHLA standard of care dosing and 
proposed dosing regimen. ..........................................................................................145 
Figure 9: INR outcomes across time with proposed warfarin dosing and formulation 
restrictions..................................................................................................................146 
 
xi
List of Abbreviations 
Abbreviation Interpretation 
ADAS-COG Alzheimer’s disease assessment scale – cognitive score 
BOV between-occasion variability 
BSV between-subject variability 
BLA Biologic License Application 
BPCA Best Pharmaceuticals for Children Act 
BSA body surface area 
CDC Center for Disease Control and prevention 
CHLA Children’s Hospital Los Angeles 
CL clearance 
Cmax maximum plasma drug concentration 
CROWN Creating an Optimal Warfarin dosing Nomogram 
CTS clinical trial simulation 
CV co-efficient of variation 
CYP2C9 cytochrome P450 2c9 
DDI drug-drug interactions 
EOP2A End-of-Phase-IIA 
ER exposure-response 
FDA Food and Drug Administration 
FDAMA Food and Drug Administration Modernization Act 
FOCEI first-order conditional estimation with interaction 
FPG fasting plasma glucose 
HAMD-17 Hamilton depression rating scale 
HbA1c hemoglobin A1c 
HVOD hepatic veno-occlusive disease 
EC50 concentration of drug to elicit half maximal response 
IND Investigational New Drug 
INR international normalized ratio 
IV intravenous 
 
xii
KA first-order absorption rate constant  
LOQ limit of quantitation 
NCA non-compartmental analysis 
NDA New Drug Application 
NM non-linear mixed-effects 
OFV objective function value 
PCA pro-coagulant complex activity  
PD pharmacodynamics 
PK pharmacokinetics 
PREA Pediatric Research Equity Act 
RCCT randomized concentration-controlled trial 
RDCT randomized dose-controlled trial 
RECT randomized effect-controlled trial 
RSE relative standard error 
SD standard deviation 
SE standard error 
t1/2 half-life 
TDM therapeutic drug monitoring 
Tmax time for maximum plasma concentration 
TS two-stage 
UCI upper limit of 95% confidence interval 
UPDRS unified Parkinson disease rating scale 
V volume of distribution 
VKORC1 vitamin K epoxide reductase sub-unit c1 
WSV within-subject variability 
 
xiii
Abstract 
 
APPLICATION OF PHARMACOMETRIC METHODS TO IMPROVE PEDIATRIC DRUG 
DEVELOPMENT  
By Mallika A. Lala, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2011 
 
Major Co-advisors:  Jogarao V.S. Gobburu and F. Douglas Boudinot  
 
 
 
Pharmacometrics is a quantitative science that is rapidly changing the landscape 
of drug development, and particularly so for the pediatric population. The motivation 
behind the research underlying this dissertation is to contribute towards the improvement 
of pediatric drug development by the astute application of pharmacometric methods. Two 
distinct research areas have been focused upon: 1- improving pediatric pharmacokinetic 
(PK) trial design and 2- improving pediatric dosing of warfarin by using a genetics-based 
dosing regimen. 
 
 
xiv
The first project examined in detail the feasibility of and simulation-based 
methodology for implementing a recent regulatory PK quality standard. The focus was on 
designing pediatric PK trials that employ sparse sampling and population analysis 
methods, using a simulation-estimation platform. The research provided clarity on the 
impact of various trial design elements, such as PK sampling, adult data inclusion, PK 
variability and analysis method on sample size adequacy to honor the standard. 
The PK quality standard was found to be practically feasible in terms of sample 
size adequacy. Informative sampling schedule for a given number of PK samples per 
subject is assumed during trial design. Recommendations are made to: 1- use prior adult 
or pediatric data for trial design and analysis, wherever possible and 2 - use one-stage 
population analysis methods and biologically feasible covariate models for designing 
pediatric PK studies. 
 
The second project involved derivation of the first ever pediatric warfarin dosing 
regimen, including starting dose and titration scheme, based on pharmacogenetics 
(Cyp2c9 *1/*2/*3 and VKORc1 -1629 G>A polymorphisms). While extensive research 
and several dosing models for warfarin use in adults exist, there is paucity of data in 
pediatrics. A validated adult warfarin population PKPD model was bridged using 
physiological principles and limited pediatric data to arrive at a pediatric PKPD model 
and dosing regimen. Pediatric data (n=26) from an observational study conducted at the 
Children’s Hospital Los Angeles (CHLA) was used to qualify the pediatric model.  
A 2-step pediatric starting dose based on body weight (<20 kg and ≥20 kg) for 
each of 18 (6 Cyp2c9 x 3 VKORC1) genotype categories is proposed. The titration 
 
xv
 
xvi
scheme involves percentage changes relative to previous dose, based on latest patient 
INR. The dosing regimen targets a major (≥ 60%) proportion of INRs within therapeutic 
range of 2.0-3.0, by the second week into warfarin therapy. Simulataneously, bleeding 
and thromboembolic risks are minimized via minimal proportions (≤ 10% and ≤ 20%) of 
INRs > 3.5  and INRs < 2.0, respectively. In simulations, the proposed dosing regimen 
performed better on target INR outcomes than the standard-of-care dosing used in the 
CHLA patients. Given the challeneges in and low likelihood of conducting pediatric 
warfarin clinical studies, the proposed dosing regimen is believed to be an important 
advance in pediatric warfarin therapy. Prospective warfarin studies in pediatrics using the 
proposed dosing regimen are recommended to refine and validate the suggested dosing 
strategy. 
 
 CHAPTER 1 
Pharmacometrics: Concepts and Applications to Drug 
Development 
 
ABSTRACT 
Pharmacometrics is the science of quantitaive clinical pharmacology that impacts 
decision-making throughouht the drug development and regulatory review process. It is 
based primarily on pharmacokinetic and pharmacodynamic modeling and simulation with 
applications including among others, clinical trial design and dose optimization. Through 
the channel of quantitiative drug, disease and trial models, pharmacometric methods have 
the unqiue ability to leverage all prior and current information from diverse sources 
including clinical pharmacology, pathophysiology and statistics.  
This chapter provides an introduction to the genral applications of 
pharmacometrics as well as concepts and methods employed, including non-linear mixed 
effects modeling and population analysis. Further, several case studies are cited, where 
pharmacometric analyses played a role in drug development and/or regulatory decision 
making. Finally, a future perspective on the field is provided with considerations for 
wider adoption of pharmacometrics to improve the efficiency of drug development 
programs. 
 
1
WHAT IS PHARMACOMETRICS? 
Introduction 
Pharmacometrics is the science of quantitaive clinical pharmacology that influences 
decision-making throughouht the drug development and regulatory review process. It is 
an amalgamation of several research areas, including among others, pharmacokinetics 
(PK), pharmacodynamics (PD), pathophysiology and statistics. Pharmacometrics 
comprises of an array of techniques that are primarily based on modeling and simulation 
of data, which include but are not limited to population pharmacokinetic (PPK) analysis, 
exposure-response (E-R, or PK-PD) determination for drug efficacy and safety, clinical 
trial simulations and disease progression modeling. 
 
Several organizations have discussed the increasing importance of modeling and 
simulation for enhancing drug development [1-4]. The pharmaceutical industry has 
conducted surveys to evaluate the role of pharmacometric analysis in their drug 
development process. A study at Parke-Davis [5] found that in almost half (5 of 12) of 
the cases reviewed, the population analysis provided information that influenced the 
direction of individual development programs and may have facilitated review and 
approval. A similar study at Hoffmann La Roche [6] found that a modeling and 
simulation guided approach contributed toward making clinical drug development more 
rational and efficient, by better dose selection for clinical trials and time savings up to 
several months. 
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The following sections of this chapter describe the general applications of 
pharmacometrics during drug development and regulatory review, as well as different 
concepts and methods employed.  Case studies, which bring out the role that 
pharmacometric analyses have played in various aspects of drug development, and a 
future perspective on the field, are also provided. 
 
Quantitative disease-drug-trial models 
Disease-drug-trial models may be considered mathematical expressions of the time 
course of biomarkers, clinical outcomes, placebo effects, drug effects, and trial execution 
characteristics [7]. Accrual of information from across drug development programs 
enables efficient future planning, for which quantified disease, drug, and trial information 
can serve as a helpful guide. 
 
Disease models quantify the relevant biological system in the absence of drug (detailed 
discussion in Section 2). Drug models characterize the exposure-response relationship for 
both efficacy and safety of drugs. Among other decisions, such models drive the 
determination of optimal dosing regimens. Using drug models early on can reduce 
unexpected safety/efficacy outcomes during the late clinical phase [8;9]. Trial models 
attempt to account for patient characteristics and behaviors such as eligibility criteria, 
baseline variables and their correlation, protocol adherence [10] and dropout rates, which 
may significantly influence outcomes in clinical trials. Trial models have great potential 
contribution towards more efficient and successful future clinical trials. 
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Applications 
Pharmacometrics can be applied at all stages of the drug lifecycle, right from the pre-
clinical phase through clinical development and regulatory review, as well as post-
marketing. Potential applications range from molecule screening and identification of 
biomarkers and surrogates, to dosing regimen and trial design selection and optimization, 
to prognostic factor and benefit/risk evaluation. These methods have the unique ability to 
leverage all prior and current information, providing a rational, scientifically sound 
framework to maximize knowledge and efficiency of drug development programs. The 
many and varied applications of pharmacometrics are illustrated in Figure 1. 
 
Figure 1: Potential applications of pharmacometrics throughout drug development 
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Clinical trial design 
It has been observed over time that registration trials fail to demonstrate effectiveness or 
safety, often due to ignorance of prior knowledge, both drug-specific and non-specific 
(placebo-effect or natural disease progression) and/or employment of one-size-fits-all 
dosing strategies [1;11]. Disease-drug-trial models and clinical trial simulations are 
useful tools that can help reduce such trial failures. Potential benefits include upfront 
comparison of candidate study designs, dose and safety outcomes selection, sample size 
and power determination, and evaluation of drug interactions and co-morbidities [12]. 
The resources needed to perform the pharmacometric analyses are negligible compared 
with the costs of unsuccessful trials.  
 
For instance, nesiritide, developed for the treatment of acute congestive heart failure, was 
initially not approved because the dosing regimen used in the first registration trial was 
sub-optimal. Modeling led to suggestion of a new, optimal dosing regimen, and results of 
simulated trials based on this regimen matched well with those of the second registration 
trial that led to eventual approval of the drug [13]. In retrospect it appears as though an 
early dose optimization could have saved three years of drug development time and one 
failed clinical trial.  
 
Another instance, is for a drug to treat type 2 diabetes mellitus [14], a semi-mechanistic 
model to describe the time course of FPG and HbA1c was developed and extensive 
simulations were performed to evaluate two different trial designs: genotype-stratified 
and biomarker enrichment designs. The biomarker-enrichment design with a bid dosing 
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regimen was proposed for future trials with an understanding that the trial results would 
be used to derive an optimal dosing strategy such as genotype-based dosing. An 
important resulting drug development decision was the need to develop a sustained 
release formulation of the drug. 
 
Dose optimization 
Exploring several dosing strategies in clinical trials is often impractical, costly, and in 
some cases, unethical. Under such circumstances, simulations can be used to explore all 
competing dosing schemes and select an optimal strategy. If no single dosing scheme is 
able to achieve target drug exposures in majority of patients, there may be need for dose 
individualization and therapeutic drug monitoring (TDM).  Modeling and simulation can 
help forecast this need and provide a TDM strategy [1]. This was observed in case of an 
oral suspension product for prophylaxis of invasive fungal infections in high-risk patients 
[15]. E-R analysis revealed very high variability in exposures across patients and the need 
for TDM to maximize effectiveness for all patients, and supported conducting a post-
marketing study to evaluate benefit of proposed TDM. The analysis also supported 
inclusion of administration conditions to optimize drug absorption, emphasizing the 
importance of adequate plasma concentrations, in the drug label.  
 
Usually, only dosing regimens ‘directly’ studied in clinical trials are proposed in drug 
labels. However, a drug model may effectively be used to explore the suitability of 
intermediate doses that are not directly studied but could potentially offer similar 
effectiveness as studied dosing regimens [16;17]. But extrapolating outside the studied 
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dose range may not be feasible. The ability of a well-developed exposure-response 
relationship to support approval of a dosing regimen not directly studied in clinical trials 
is in fact one of the strongest merits of modeling and simulation. Unfortunately, this tool 
is not being fully exploited currently. 
 
Covariate / Prognostic factor determination 
Apart from dose-ranging studies, the clinical pharmacology characterization of a new 
drug involves a number of bridging studies to identify influential covariates or prognostic 
factors such as body size, age, gender, food intake, co-morbidities, co-medications, and 
others. While effectiveness and safety data may not be collected in bridging studies, they 
could be simulated from a previously developed drug model. 
 
For instance, Sular is a once-a-day controlled release formulation of the drug Nisoldipine, 
which is approved in the United States for the treatment of hypertension. Food was found 
to increase the bioavailability (Cmax increases up to 245%) of the controlled release 
product. The influence of these higher drug concentrations on lowering of blood pressure 
was evaluated using simulation of the drug effect under fed condition from a previously 
developed exposure-response model [18]. Even though the Sular label recommends 
administration on an empty stomach for optimal bioavailability, these simulations 
alleviated the safety concern of a large drop in blood pressure, should the drug be 
administered with food. Hence, there is no safety warning in the label for the drug to not 
be administered in a fed condition. 
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Special populations 
Pharmacometric analyses enable the understanding of unique clinical pharmacology 
features in special populations such as pediatrics, geriatrics, renal/hepatic impairment, 
and others. A case in point is docetaxel, where the exposure-response relationship in 
patients with cancer was successful in identifying a sub-population, patients with liver 
impairment, to be more prone to grade 4 neutropenia [19]. This important finding 
improved the safety profile of the drug and was the basis of the dosing recommendation 
for patients with hepatic insufficiency in the label. The drug development program of 
docetaxel exemplifies the value added by prospective modeling and simulation while 
planning clinical trials. 
 
The FDA offers a six month extension on the marketing exclusivity for a new drug, 
should the sponsor fulfill the requirement of a written request to characterize the 
exposure-response relationship of the drug in pediatrics. Hence, one of the most sought 
out special populations to study for labeling changes is pediatrics. A well-defined 
exposure-response relationship of a drug in adults, be it for a biomarker, surrogate or 
clinical endpoint, can facilitate development of the same drug for use in pediatrics. 
Modeling and simulation is a powerful tool that can be used to provide plausible trial 
design, rational dosing recommendations and useful labeling information in pediatrics 
when sufficient understanding of adult and pediatric pharmacology is available [20].  
 
For instance, a pediatric population analysis [21], and further modeling and simulation 
[22], provided the labeled dosing recommendations for the anti-arrhythmic agent sotalol 
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in pediatrics aged 1 month to 12 years. The E-R analysis found drug effects in pediatrics to 
be consistent with adults. In this case, dosing for patients < 2 years of age was selected 
specifically based on modeling, and not studied directly in trials. 
 
Regulatory considerations  
The United States Food and Drug Administration (FDA) routinely utilizes 
pharmacometric methods as an aid in making regulatory decisions during the 
investigational new drug (IND), biologics license application (BLA) and new drug 
application (NDA) review processes. The role of pharmacometric analyses in various 
regulatory decisions are summarized in Table 1. 
 
A survey of 42 NDAs submitted between 2000 and 2004, which included a 
pharmacometric component, revealed that pharmacometric analyses were pivotal in 
regulatory decision making in more than half of the cases. Of the 14 reviews where such 
analyses were key to approval related decisions, 5 identified the need for additional trials, 
while 6 identified reduction in the burden of conducting additional trials [1]. 
 
The proceedings of an advisory committee meeting for cardio-renal (CR) drug products 
are noteworthy [23]. The meeting devoted 50% of the total time to discuss the role of 
exposure-response in CR drug development. The advisory committee concluded that 
model-dependent analysis to learn about the shape of the exposure-response curve and 
more innovative designs to potentially allow both, frequentist and Bayesian types of data 
analysis were needed. 
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Table 1: Summary of the types of regulatory decisions influenced by 
pharmacometric analyses 
 
Regulatory 
Decision 
Role of Pharmacometric Analyses 
 
Trial design 
guidance 
 
• Selection of dose or exposure range for registration trials 
• Derivation of optimal sampling schemes (PK and PD) 
  
Approval • Development of approval criteria 
• Evaluation of: 
o evidence of effectiveness 
o benefit-risk 
o targeted safety studies (ex: QT evaluation) 
o clinical implications of failed bioequivalence studies 
 
Labeling • Recommendation of dosing strategy: 
o dose and regimen 
o individualized doses, where required 
o therapeutic drug monitoring, where required 
o dosing in special populations (ex: pediatrics) 
o drug interactions 
• Evidence for warnings and precautions 
 
Policy • Evaluation of: 
o alternative primary analysis methods 
o competing recommendations for guidances 
o bioequivalence criteria 
 
 
10
The FDA issues guidance to industry to facilitate a smoother drug development and 
approval process. The guidance to industry on population pharmacokinetics [16] 
emphasizes the role of modeling and simulation in designing and analyzing trials. The 
FDA Modernization Act (FDAMA) [17] has a section for “extrapolation from existing 
studies” which emphasizes the ability to use knowledge from previous clinical trials for 
approval of the same drug product for pediatric use, or for establishing equivalence of 
alternative formulations, provided the original trial yielded well-defined exposure-
response relationships. The FDA has also implemented End-of-Phase-IIA (EOP2A) 
meetings with sponsors [24] and published the Critical Path Initiative [25], which again 
emphasize the usefulness of pharmacometrics in enhancing drug development. The 
premise for all these regulatory initiatives is that with efficient planning, sponsors can 
economize valuable drug development time and resources, which is in public health 
interest,  as well as reap full advantage of the resulting incentives. 
 
DISEASE MODELS 
A disease model is a mathematical representation of a given biological (or pathological) 
system in the absence of drug that attempts to quantify the time course of the disease [7]. 
There are three major sub-models that capture the relevant aspects of disease modeling, 
namely, the relationship between biomarkers and clinical outcomes, the natural disease 
progression, and the placebo effect. In addition, there are three general approaches to 
building any disease model: systems biology, semi-mechanistic, and empirical modeling. 
The main features of the three approaches are summarized in Table 2. 
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Biomarkers and clinical outcomes 
In several cases, particularly when clinical endpoints occur after prolonged periods of 
time, biomarkers are used as outcomes in clinical trials rather than the actual clinical 
endpoints. Characterization of the relationship between biomarkers and clinical outcomes 
for both efficacy and safety for a particular disease condition, is thus a very important 
aspect of disease modeling, and can help develop surrogate endpoints. Such models can 
then aid in trial design optimization and risk projection based on biomarker data. Systems 
biology models, although complex, are very useful for this purpose [26]. They are based 
on an understanding of the underlying biological system, much like physiologically-
based models. They represent the system at the molecular level, with an ability to account 
for pathological disturbances. The model parameters are estimated from multiple, 
detailed in-vitro and ex-vivo experiments [7].  
 
On the other hand, semi-mechanistic and empirical models are predominantly data driven 
and tend to disregard details of related diseases [27]. Semi-mechanistic models 
sufficiently simplify the biological system to be able to describe the available data well, 
and could be the first step toward a systems biology model. Empirical disease models are 
essentially mathematical expressions used to interpolate between observed data, and 
seldom relate to the underlying biology. Even so, such models are useful, depending on 
the problem at hand. Empirical models are simple and frequently all that is available, and 
are often invaluable in making go/no-go decisions and designing pivotal trials. The 
empirical parametric hazard model [28] that describes the relationship between the 
change in tumor size and survival is one such example.  
 
12
 It may be correct to say that every model will include some empirical component. For 
instance, in the case of diabetes, a detailed systems biology model with more than 50 
parameters [29], as well as a semi-mechanistic model [30] have been proposed. While the 
systems biology model takes into account glucose and HbA1c data, as well as other 
related information such as blood pressure, cardiac output, family history, cholesterol, 
and smoking status, the semi-mechanistic model focuses on just the glucose and HbA1c 
information. Similarly, the outputs of the systems biology model include risks of 
retinopathy, nephropathy, and neuropathy, while the semi-mechanistic model is restricted 
to prediction of changes in glucose and HbA1c. Having said that, the systems biology 
model will still need to establish a relationship between change in blood pressure and/or 
glucose and a binary event such as myocardial infarction, thus incorporating an empirical 
component [7].  
 
Natural disease progression 
The natural disease progression aspect of disease modeling aims at describing the time 
course of changes observed in the clinical outcome. Drug therapy may alter natural 
progression of the disease, and such models can then provide insights into the 
management of several diseases [31]. For this purpose, empirical models have been used 
most commonly. The natural progression of Alzheimer’s disease as measured by the 
Alzheimer’s Disease Assessment Scale – Cognitive score (ADAS-COG) and that of 
Parkinson’s disease using total Unified Parkinson Disease Rating Scale (UPDRS) have 
been described using empirical models [32-34]. However mechanistic models, which are 
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more generalizable, are also being studied. A mechanistic disease progression model for 
arthritis in rats has been proposed [35].  
 
Placebo effect 
The effect in a placebo group refers to the psycho-socially induced biochemical changes 
in a patient’s brain and body that in turn may affect both, the natural course of a disease, 
and response to therapy [36]. Thus, even though the placebo-effect is not directly related 
to the disease, it can significantly impact outcomes. This is particularly true for disease 
conditions that are measured symptomatically, such as pain and depression. Therefore, 
modeling the magnitude and time course of placebo effect has value in discerning true 
drug effects and also aids in estimating sample size during trial design. Recently, a 
Bayesian model that describes the time course of the Hamilton Depression Rating scale 
(HAMD-17) clinical score in the placebo arms of antidepressant trials, combined with a 
dropout mechanism, has been developed [37]. This model provides new insights on the 
validity of the results of several longitudinal registration trials currently used for new 
drug products. A placebo model for Crohn’s disease trials [38] is also available. 
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Table 2: Comparison of systems biology, semi-mechanistic and empirical 
approaches to disease models 
 
      Feature 
 
Approach 
Data source Validation Complexity 
& 
Resources 
Application 
Systems 
biology 
models 
Wide range – 
underlying biology, 
inter-relationships with 
related systems, 
multiple detailed 
experiments etc. 
Extremely 
challenging 
High – 
Diverse 
expertise 
involved. 
• target 
identification 
• dose selection 
• trial design 
optimization 
• risk projection 
based on 
biomarker data 
Semi-
mechanistic 
models 
Limited range – 
one or more 
experiments; related 
systems not considered
Empirical 
models 
Limited range – 
one or more 
experiments; may not 
accommodate  design 
variations and related 
systems not considered
Relatively 
simple 
Low – 
Lesser 
expertise 
involved. 
• go/no-go 
decisions  
• dose selection 
• trial design 
optimization 
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POPULATION ANALYSIS 
Conceptual framework 
A population model typically comprises structural and statistical model components. 
Structural models are deterministic in nature, and account for population or ‘fixed 
effects’ (primary model parameters), but do not account for variability. The typical value 
of systemic clearance (CL) for a 70 kg individual and the mean potency (EC50) of a drug 
are examples of fixed effects. A population model suite would include four structural 
models: PK model, PD model, covariate (or prognostic factor) model and disease 
progression model.  
 
Statistical models are stochastic in nature, and account for the variability or ‘random 
effects’ seen at both, the individual and the observational levels. A population model 
suite would include three statistical models: between-subject variability (BSV) model, 
between-occasion variability (BOV) model, and within-subject variability (WSV) model. 
Random effects models usually assume that the between-subject and between-occasion 
errors (η) are normally distributed with mean zero and variance Ω2, and that the within-
subject or residual errors (ε) are normally distributed with mean zero and variance σ2. 
BSV signifies deviations among different subjects and BOV signifies deviations among 
different occasions. WSV signifies deviation between predicted and observed values for 
each subject, and may be the result of measurement error or even model-misspecification. 
 
Nonlinear mixed effects models are called so because they attempt to account for both, 
fixed and random effects together. The “mixed effects” concept is depicted in Figure 2. 
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Consider a one-compartment PK model where the drug is given as an intravenous bolus 
and the volume of distribution (V) is identical in every individual (no BSV for V). Then, 
the concentration in the ‘ith’ subject at the ‘jth’ time point (Cij) can be described using the 
following equations: 
ij
t
V
CL
ij
i
e
V
DoseC ε+⋅=
⋅−
  Eqn. (i) 
 
iCLPOPi CLCL ,η+=    Eqn. (ii) 
 
where; CLi is the estimated clearance of the ‘ith’ subject, CLPOP is the estimated 
population mean clearance, ηCL,i is the difference between the population mean and 
individual clearances and εij is the residual error of the ‘jth’ sample of the ‘ith’ subject.  
 
Figure 2: Conceptual framework for nonlinear mixed effects modeling 
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Analysis methods 
A primary goal of population analysis is to estimate the mean value of relevant 
parameters (such as CL, V and EC50) in the population of interest, the variances in these 
parameters as well as residual variability of observations. Another goal is to explain the 
observed BSV using patient covariates such as body size, age, genotype etc. In addition, 
estimating individual PK parameters (such as CLi and Vi) is required to impute 
concentrations for performing E-R analysis and any other simulations at a later stage.  
 
The known methods for performing a population analysis are: naïve pooled, naïve 
averaged, two-stage (TS), and nonlinear mixed effects (NM) or one-stage analysis. The 
main features of these analysis methods are summarized in Table 3. 
 
In naïve pooled analysis, individual observations from all subjects are pooled (as though 
all data came from a single, giant subject) to obtain average PK parameters. A minor 
variation of this method is the naïve averaged analysis which involves determination of 
the mean of the data at each time point. Both these methods provide only the central 
tendency of the model parameters and no random effects are estimated. These methods 
are used more often for pre-clinical data and are appealing because of their simplicity. 
However, since between-subject variability is not estimated and cannot be accounted for 
using covariates, the potential applications of naïve pooled or naïve averaged analyses are 
very limited. 
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In two-stage analysis, the first stage involves estimation of the average parameters for 
each subject from their individual observations, while the second stage involves the 
estimation of the population mean and variance of the parameters, after adjusting for 
covariates, if necessary. Estimates of both, the central tendency and the inter-individual 
variability can be obtained reasonably well. The TS method requires collection of rich 
data to have sufficient samples per subject (greater than the number of model parameters 
to be estimated), which is the usual requirement with experimental data. One concern is 
this method assumes that the individual parameters, estimated in stage one, are known 
without any uncertainty. More serious drawbacks include the inability to model sparse 
data and concentration (or dose) dependent nonlinear processes. The conventional PK 
non-compartmental analysis (NCA) is a type of two-stage population analysis approach. 
 
In non-linear mixed effects analysis, data from all subjects are simultaneously modeled to 
yield estimates of both, population mean parameters as well as variance. Since both 
stages of the TS method are performed in one step, the NM technique is also known as 
the ‘one-stage’ method. Individual parameters are calculated post-hoc, subsequent to this 
one-stage optimization. Nonlinear mixed effects modeling is perhaps the most powerful 
technique for analyzing both rich and sparse data, and does not share the drawbacks of 
the other methods discussed earlier. One of the main advantages of the NM method is its 
ability to conduct meta-analyses which enables incorporating all data across a drug 
development program. The primary disadvantage of this method is that sophisticated 
software are required for the analysis, which mandates special training for its use, while 
learning resources are limited. In addition, these analyses can be highly time-consuming. 
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Table 3: Main features of the common population analysis methods 
    Feature 
 
 
Method 
Covariate 
exploration 
Uncertainty at 
observational 
level  
Uncertainty at 
subject level 
Relative 
Complexity 
& Time 
involved 
Naïve 
Pooled 
Indirect – 
A model with known 
relevant covariates 
can be imposed. 
Naïve 
Averaged 
Indirect – 
Subjects can be 
divided into groups 
based on relevant 
covariates. 
Ignored – 
Mean estimates 
will be unduly 
closer to outliers 
(extreme 
observations). 
Two-Stage Convenient – 
A covariate model 
can be estimated in 
stage 2. 
Ignored – 
All subjects are 
weighted 
equally, 
regardless of 
number of 
observations per 
subject. 
Low 
 
One-stage Convenient – 
A covariate model 
can be included in 
the optimization step. 
Accounted – 
Models will not 
be unduly 
influenced by 
extreme 
observations. 
Accounted – 
Subjects with 
more data are 
also weighted 
more. 
High - 
Special 
training is 
required. 
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Model qualification  
All models are required to be qualified and credible for their wider adoption. Validation 
implies a procedure of utmost robustness. However, the fact that the true model and its 
parameters are not known discourages the use of the term ‘validation’ for population PK-
PD models. Hence, qualification may be a better suited term.  
 
The purpose for which the model is being developed should be clearly specified as a pre-
requisite before undertaking any model building. Based on the purpose of the model, 
qualification methods can test either the descriptive capacity or the extrapolation capacity 
of a given model. Developing an acceptable descriptive model is critical for making 
labeling recommendations. However, drug labels, usually, do not extrapolate results 
beyond the range of data observed. 
 
Adequate description of the data at hand will ensure that the proposed model and its 
parameters are qualified to make reliable inferences, within the range of the data studied. 
This can be assessed using the routine diagnostic tests such as goodness-of-fit plots 
(independent variable versus observed and individual/population model predictions), 
summary statistics, and precision of the parameter estimates. A model and its parameters 
may be deemed ‘qualified’ to perform the particular task(s) if they satisfy certain pre-
specified criteria. Application of a predictive check to a model and its parameters along 
with Monte-Carlo simulations [39;40] is an effective method used for qualification of 
population models. 
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Physiological interpretation of model parameters is one of the most important aspects of 
model qualification. A model and its parameters may be deemed ‘credible’ to perform a 
particular task(s) if the conceptual foundation on which the model was proposed is 
satisfactory to a panel of experts. It is important to note that there is no formal means to 
assess whether a model can be used for extrapolation. Hence the credibility of the model 
i.e. whether the model was derived from sound mechanistic principles, which appear 
reasonable to subject matter experts, is important. Thus, a model (and its parameters) may 
be considered qualified to predict beyond the range of the data used for building the 
model if the descriptive capacity of the model is acceptable and the model is credible. 
 
TYPES OF DATA AND TRIAL DESIGNS 
Data 
Pharmacometrics data (referring to PK/PD measurements) that may be collected during 
clinical trials, in general, are of two types – rich data and sparse data. Typically, rich data, 
which refers to several (10-20) samples from each subject, is collected under controlled 
conditions in trials conducted in a small number of patients over a short duration of time. 
Data from each subject can be analyzed independent of the others, in most cases, and 
then summarized. Such kind of data is the best for building structural models. Dose-
escalation studies, bioequivalence studies, and bridging (for prognostic factor effects) 
studies are examples of trials where rich data are collected. 
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On the other hand, late phase clinical trials that are conducted in a large number of 
patients and for relatively longer durations, typically collect sparse data. Few (1-5) 
samples are taken from each individual due to practical limitations, which makes it 
challenging to analyze the data from each subject separately. Sparse data are most suited 
to build statistical models. Pivotal or registration safety-efficacy trials are examples of 
studies that tend to collect sparse data. 
 
Trial Designs 
Broadly, three of the most commonly used trial designs that employ population analyses 
are: parallel, cross-over, and titration. In a parallel study design, subjects are randomized 
to one of several treatment options, for instance, control, dose1, dose2 or dose3. Such a 
design supports the estimation of population exposure-response characteristics well, but 
not that of individual characteristics. In a cross-over design, each subject receives all the 
treatment options. This is the most powerful study design for estimating the individual 
exposure-response relationships. However, such trials are longer in duration and may 
experience carry-over effects from previous treatments. The titration design is one where 
patients are usually initiated at a low dose, which is then gradually increased either until 
no additional benefit is observed, or until dose-limiting toxicity occurs. This design 
resembles clinical practice most closely and individual exposure-response determination 
is possible. However, it may so happen that patients who are less sensitive to the drug 
need higher doses, making it (falsely) appear as though the response decreases after a 
certain dose. In several cases, particularly for the cross-over and titration designs, 
sophisticated data analysis such as mixed-effects modeling is required. 
 
23
Further, based on the assignment of randomized groups in the trial, there are different 
designs possible. Subjects may be randomized to receive a particular dose or 
concentration of the test drug or to a particular effect elicited by the drug. Accordingly, 
such trials are referred to as Randomized Dose Controlled (RDCT), Randomized 
Concentration Controlled (RCCT), or Randomized Effect Controlled (RECT) trials. An 
active control group is used where a placebo control is considered unethical. 
 
In an RDCT, the different doses of the drug to be tested are randomly administered to the 
subjects. Data are then collected throughout the trial and analyzed using an appropriate 
method. Such trials are the most commonly seen design due to the relatively simple 
execution and analysis involved.  
 
In an RCCT, a set of target drug concentration levels are selected based on the exposure-
response relationship established from previous studies. Subjects are then randomized to 
one of these pre-specified target concentrations [41]. Such a design obviates a dose-
titration period during which the dose that ensures achieving concentrations within the 
selected target range (ex.: 5 ± 0.5 μg/L) is identified. A variation of the RCCT design is 
when doses are pre-specified based on a certain demographic variable. For instance, body 
weight adjusted doses are routinely administered in pediatric studies. Similarly, in an 
RECT, subjects are randomly assigned to a pre-specified target effect level. Again, the 
target effects are chosen based on prior knowledge of the drug’s exposure-response, and 
the dose is titrated accordingly. 
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RCCT and RECT designs have similar requirements such as prior exposure-response 
relationship to select the appropriate target concentration or effect ranges, an efficient and 
sensitive analytical assay method with a short turn-around time, and sufficient strengths 
of the formulation to allow for any required dose adjustments. Candidate drugs for such 
trial designs are those where the PK has a large unexplained variability (RCCT) and those 
where the PD has a large unexplained variability (RECT). In addition, when the 
measured effect (desired/undesired) is symptomatic, for instance, effects such as pain or 
nausea that are ‘felt’ by patients, the RECT could be applicable. When the symptoms are 
not obvious, the RCCT may be a better choice. Unfortunately, very few drug 
development programs utilize RCCT or RECT designs, perhaps due to their complicated 
execution and data analysis, relative to the RDCT design, as well as the cost of 
implementing TDM if the drug is approved [42;43]. Notably, trials for 
immunosuppressant drugs used in transplantation generally employ the RCCT design. 
 
CASE STUDIES 
Pharmacometric analyses have been employed at various stages of the drug development 
process. Several case studies where such analyses have had pragmatic value in decision 
making are discussed. Table 4 summarizes all presented cases while a few selected cases 
have been discussed in detail. 
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Tacrolimus – liver, kidney, heart transplantation 
Background: 
Tacrolimus is an immunosuppressive agent indicated for the prophylaxis of organ 
rejection in allogeneic liver, kidney, or heart transplants. A large amount of variability 
has been observed in the PK and PD of this drug. Pharmacometric methods have been 
employed throughout the drug development stages of tacrolimus, to select rational dosing 
regimens and optimize therapy [44]. 
Key questions: 
1. What is a safe and effective dosing regimen for first-time-in-man clinical studies? 
2. What is a rational target therapeutic concentration range for tacrolimus? 
3. What is an optimal initial dose of tacrolimus for late phase clinical trials? 
4. What is an optimal TDM strategy for managing patients on tacrolimus therapy? 
Role of Pharmacometrics: 
The starting dose of tacrolimus (0.15 mg/kg/day IV) used in early phase clinical trials 
was extrapolated from a synthesis of safe doses in two animal models (rat and dog). The 
target concentration range for monitoring the drug therapy during these trials was also 
based on the same animal models, augmented with in vitro PD modeling using the IC50 
values from mixed lymphocyte reactions. Collectively, all the animal models studied 
were also highly predictive of the systemic toxicities observed with tacrolimus in 
humans. A pilot compassionate-use early clinical study in patients with refractory liver 
rejection suggested that the 0.15 mg/kg starting dose was clinically effective, but toxic in 
some patients, and doses had to be individualized to the patient. A reduced starting dose 
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(0.05 mg/kg/day IV) was predicted by simulations before onset of the pivotal trial, and 
the need for this dose reduction was dramatically confirmed during the U.S. and 
European multicenter registration trials. In addition, an Artificial Intelligent Modeling 
System (AIMS) was developed to efficiently guide dosing and monitoring of patients on 
tacrolimus. The AIMS-based TDM led to clinical and pharmacoeconomic benefits in a 
subsequent prospective pilot clinical study. 
Impact: 
Pre-clinical models proved to be a reliable guide for identifying a safe and effective dose 
and a therapeutic concentration range for tacrolimus. Implementation of the AIMS 
improved the TDM strategy by 3-4 fold reduction in number of blood samples drawn and 
a reduction in length of hospitalization after liver transplantation. Thus, modeling and 
simulation enabled more efficient trial design and data analysis of the RCCTs conducted 
during development of tacrolimus and improved the cost-effectiveness of therapy. 
 
Degarelix – prostate cancer 
Background: 
Degarelix is indicated for the treatment of advanced prostate cancer patients. During its 
clinical development, the primary end-point used in trials was suppression of testosterone 
levels (< 0.5 ng/ml) from day 28 of treatment initiation through 1 year of therapy in 90% 
patients. The dosing goals were to achieve this challenging end-point. The sponsor 
conducted five early and late phase dose-finding clinical studies but was unable to derive 
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an optimal dosing regimen. An end-of-phase 2a meeting was arranged between the FDA 
and the sponsor to discuss a better drug development plan for degarelix. 
Key question: 
What is a rational dosing regimen that would maximize the effectiveness of degarelix in 
advanced prostate cancer patients? 
Role of Pharmacometrics: 
Population analysis was conducted to develop an exposure-response model for degarelix 
based on the five dose finding studies conducted by the sponsor [45;46]. The FDA 
suggested alternative dosing strategies and clarified the regulatory expectations of the 
NDA. For initial suppression of testosterone levels by day 28, a higher loading dose 
requirement was explored. A lower maintenance dose was derived to sustain the 
testosterone suppression through 1 year of drug therapy. Using a mechanistic E-R model 
and extensive clinical trial simulations an optimal dosing regimen was derived. All 
pharmacometric analyses were conducted by the sponsor, under the guidance of the FDA. 
The model-based regimen was used in a registration trial that resulted in positive 
outcomes and led to approval of degarelix for this indication.  
Impact: 
Degarelix was approved for use in advanced prostate cancer based on a registration trial 
that employed a modeling and simulation derived dosing regimen, which several prior 
clinical studies failed to derive. Trials in prostate cancer patients are challenging and 
costly and early interaction between the sponsor and the FDA enabled more cost-efficient 
drug development and a smoother review process.  
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Busulfan – bone marrow transplantation 
Background:  
Busulfex, an intravenous formulation of the drug busulfan, is used in combination with 
cyclophosphamide as an immunosuppressive conditioning regimen for bone marrow 
ablation prior to hematopoietic stem cell transplantation. The drug was initially approved 
for use in adults with chronic myelogenous leukemia. The dose-limiting toxicity 
associated with busulfan is potentially fatal hepatic venoocclusive disease (HVOD). 
Clinical studies suggested that a therapeutic window of 900-1500 umol/L/min in adults 
was appropriate to balance safety (occurrence of HVOD and leukemic relapse) and 
efficacy (successful engraftment). The FDA issued a written request (WR) to the sponsor 
to determine the PK of busulfan in pediatrics (aged 4-17 years) and the optimal dosing 
regimen for this population that would achieve target exposures. 
Key question:  
What is the appropriate dosing strategy for busulfex in pediatric patients? 
Role of Pharmacometrics:  
A population PK study was conducted to characterize the PK of intravenous busulfan in 
pediatrics and provide dosing recommendations [47]. Clinical studies indicated that the 
therapeutic window was similar for pediatric and adult patients. However, this was 
confounded by the increased variability in the PK of oral busulfan seen in pediatric 
patients compared with adults. Hence a target therapeutic window with a lower, more 
conservative threshold for toxicity, than in adults, was used for pediatric patients (900-
1350 umol/L/min). Body weight, body surface area, age and gender were explored for 
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their impact on pediatric dosing. Simulations suggested that the mg/kg and mg/m2 based 
dosing regimens were similar in their efficiency. Exposures obtained by different dosing 
regimens, with 1 to 7 dosing steps including various combinations of weights and doses, 
were evaluated. All the dosing regimens explored had, at best, 60% patients achieving 
target exposures after the first dose. Notably, the model revealed that the unexplained 
between-subject variability (25%) was larger than the within-subject variability (6%), 
indicating that BSV is the key determinant of therapeutic success. This finding coupled 
with the narrow therapeutic window for busulfan, supported implementation of 
therapeutic drug monitoring for optimizing drug therapy. 
Impact: 
Based on the modeling and simulation, and practical considerations, a 2-step dosing 
regimen was proposed from this study: 1.1 mg/kg for patients weighing ≤ 12 kg and 0.8 
mg/kg (adult dose) for patients weighing > 12 kg. In addition, considering that about 40% 
patients may not achieve target exposures after the first dose, even with the optimized 
regimen, a TDM strategy was proposed to enhance therapeutic targeting. These dosing 
recommendations, which had not been directly tested in clinical trials, were incorporated 
into the drug label. 
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Table 4: Summary of case studies, where pharmacometric analysis had an impact 
on decision making, during different stages of drug development. 
 
Drug Stage Key Questions Decision 
Impacted 
Comments 
 
5c8, mAb 
[48] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
Perceived impact of model 
developed: 
• optimize sample 
collection in 
experiments 
• anticipate exposure-
response in humans 
• quantify other antigen-
provoked responses 
• project utility of 5c8 in 
treatment of antibody-
mediated autoimmune 
disease 
rPSGL-Ig 
[49] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• developed allometric 
models across animal 
species to predict PK 
and dose range for first-
time-in-man clinical 
trial 
Tacrolimus 
[44] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 
 
 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• derived early phase 
trials starting dose using 
two animal models 
• derived target conc. 
range for RCCT trials 
and TDM using animal 
and in-vitro PD models 
• derived final starting 
dose for pivotal trial 
using simulations 
• improved TDM strategy 
and cost-efficiency 
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Rivoglitazone 
[50] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection
• developed a ‘best-in-
class’ compound using 
modeling and simulation 
• selected biomarker/end-
point, dose, sampling, 
washout, eligibility & 
discontinuation criteria, 
and forecasted trials for 
late clinical phase 
• built disease model from 
related drug information 
Mycophenolate 
mofetil 
[51;52] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• derived dosing regimen 
for a late phase clinical 
trial (RCCT) using E-R 
model based on a pilot 
study 
Degarelix 
[45;46] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation  
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• explored alternative 
dosing strategies based 
on five phase 1/ 2 
studies 
• selected final dosing 
regimen for registration 
trial that eventually led 
to drug approval 
 
Piperacillin/ 
Tazobactam 
[53] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• recommended 2-step 
weight-based PIP/TAZ 
pediatric dosing regimen 
in drug label for patients 
aged ≥ 2 months  
• verified no new safety 
concerns than those in 
adults 
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 Benefit/ 
risk evaluation 
Busulfan 
[1;47] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• recommended 2-step 
weight-based pediatric 
dosing regimen in drug 
label 
• proposed TDM strategy 
in label to enhance 
therapeutic targeting 
Everolimus/ 
Cyclosporine 
[15] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• projected likely 
outcomes of altered 
dosing schemes 
• proposed new dosing 
regimen that reduced 
renal toxicity while 
maintaining efficacy 
thus improving 
benefit/risk profile than 
seen in registration trial 
• cardio-renal advisory 
committee 
recommended new 
regimen to be evaluated 
in future trial  
Apomorphine 
[1] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 
 
 
 
 
 
 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• demonstrated a 50% 
increase in exposure in 
renal impairment 
• derived maximum 
recommended dose and 
titration strategy and 
dose adjustment in renal 
impairment in drug label 
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Zoledronic acid 
[1] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• suggested a correlation 
between risk of renal 
deterioration and drug 
exposure 
• recommended dose 
adjustments in mild and 
moderate renal 
impairment patients in 
drug label 
Oxcarbeazepine 
[1;54] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation  
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• found no important 
differences in placebo 
and drug effects 
between adults and 
pediatrics 
• supported evidence for 
approving drug as 
monotherpay in 
pediatric patients with 
partial seizures 
• derived dosing 
instructions in drug label
• saved additional 
controlled trials 
Micafungin 
[15] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 
 
 
 
 
 
 
 
 
 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• derived dosing 
recommendation and 
supported approval of 
drug for esophageal 
candidiasis 
• provided evidence for 
label to indicate greater 
potential for liver 
toxicity at approved 
dose 
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Varenicline 
[15] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• showed much higher 
drug exposures in renal 
impairment 
• found baseline smoking 
status and age to be 
prognostic of abstinence 
from smoking 
• found marginal dose 
increase to increase 
effectiveness but also 
significantly increase 
toxicity (nausea) 
• recommended lowering 
dose in case of 
intolerance to adverse 
effects in drug label 
Docetaxel 
[19] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• identified a sub-
population (liver 
impairment patients) 
more prone to grade 4 
and febrile neutropenia 
• recommended reduced 
dose in label for patients 
with liver insufficiency 
to improve safety profile 
of drug 
Nesiritide 
[1;13] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation  
 
 
 
 
 
 
 
 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• explored alternative 
dosing regimens for 
reasonable benefit-risk 
profile 
• proposed dosing 
regimen for use in 
subsequent registration 
VMAC (Vasodilation in 
the Management of 
Acute CHF) trial that 
led to drug approval 
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Sotalol 
[1;21;22] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• found drug effects in 
pediatrics to be 
consistent with adults 
• found sponsor’s dosing 
recommendations to be 
acceptable for patients 
aged ≥ 2 years 
• derived more specific 
dosing for neonates and 
infants aged < 2 years in 
drug label 
Nisoldipine 
[18] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• alleviated safety concern 
of large drop in blood 
pressure upon 
administration of drug in 
fed condition, given 
significant food effect 
on increasing 
bioavailability of 
controlled-release 
product 
Oral suspension 
product for 
prophylaxis of 
invasive fungal 
infections in 
high-risk 
patients 
[15] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 
 
 
 
 
 
 
 
 
 
 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• revealed need for TDM 
to maximize effect for 
all patients 
• supported inclusion of 
conditions to optimize 
drug absorption and 
importance of ensuring 
adequate plasma 
concentrations in label 
• supported need for post-
marketing study to 
evaluate benefit of 
proposed TDM 
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Drug to treat 
type 2 diabetes 
mellitus 
[14] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• evaluated 2 trial designs: 
genotype-stratified and 
biomarker enrichment 
designs, using semi-
mechanistic model for 
FPG and HbA1c 
• proposed biomarker-
enrichment design for 
future trials that would 
help derive optimal 
genotype-based dosing  
• revealed need to develop 
sustained release drug 
formulation 
Drug to treat a 
life-threatening 
rheumatologic 
disorder 
[1] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• showed that biomarker 
was predictive of 
clinical outcome but a 
65% reduction would 
achieve significance, 
after two failed 
registration trials 
• recommended exploring 
doses that achieve 
greater reduction in the 
biomarker or maximal 
tolerated dose for future 
trials 
Drug to treat a 
debilitating 
neurological 
disorder 
[15] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 
 
 
 
 
 
 
 
 
  
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• showed that reduction in 
symptoms was related 
with drug dose while 
withdrawal effects were 
significant and 
consistent, after 1 failed 
and 1 successful 
registration trial 
• supported evidence of 
effectiveness for drug 
approval 
• saved additional clinical 
trial 
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Drug to treat a 
mild, moderate, 
or severe life-
threatening 
disease 
[15] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• identified non-responder 
sub-group: patients with 
mild disease 
• showed consistent 
effectiveness in patients 
with moderate and 
severe disease 
• elucidated inconsistent 
results from previous 
trials 
• recommended future 
study in only moderate 
and severe disease 
patients 
New class of 
antivirals 
[14] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation  
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• distinguished QD and 
BID dosing regimens 
using a mechanistic 
viral-dynamic model 
that previous models 
could not achieve 
• allowed assessment of 
impact of variability, 
dosing regimen, patient 
compliance and dropout 
on trial outcomes 
• proposed a lower dose 
BID regimen for future 
trials 
Drug to treat 
insomnia 
[14] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 
 
 
 
 
 
 
 
 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• recommended healthy 
subject studies for 
selecting doses for sleep 
onset but not for sleep 
maintenance evaluation 
• recommended patient 
trial durations of more 
than 30 days for reliable 
identification of doses 
and persistent sleep 
maintenance 
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Pro-drug to 
treat a life-
threatening 
disease 
[14] 
 Pre-
clinical 
 Early 
Clinical 
 Late 
Clinical 
EOP2A 
 Post-
marketing 
 
 Molecule 
screening 
 Trial / 
experimental 
design 
 Dose 
selection 
 Covariate 
determination 
 Evidence of 
effectiveness 
 Benefit/ 
risk evaluation 
 Go/no-go 
 Dose 
optimization 
 Improved 
trial design 
 Approval 
 Labeling 
 Special 
population – 
dose selection 
 
• revealed body weight to 
be prognostic for 
toxicity and 
effectiveness and that 
per kg dosing of both 
test and reference drugs 
would allow more 
appropriate investigation 
of non-inferiority 
• indirectly, also derived 
optimal dosing of 
reference drug for wider 
application across other 
development programs 
 
PERSPECTIVE 
Learn-Apply paradigm 
The strongest merit of model-based drug development lies in its ability to incorporate the 
entire base of relevant prior knowledge into decision-focused recommendations for the 
future. A Learn-Apply paradigm is being proposed as an effective means to leverage 
pharmacometric methods and enhance drug development [55]. Accordingly, learning 
refers to transforming information (such as clinical trial data) into knowledge while 
applying refers to utilizing this knowledge to make informed decisions (such as 
confirmation of effectiveness, dose selection etc). This is an extension to the learn-and-
confirm philosophy in modeling that has been promoted by Lewis Sheiner [56]. 
 
Currently, pharmacometric models are typically developed at the end of phase 3. A more 
prudent way to economize time and costs to develop models is by maintaining a 
progressive model building philosophy. The essence of progressive model building is to 
continuously update the current model as new knowledge is accrued. The advantages are 
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at least two-fold: the ability to ‘carry-forward’ knowledge all along the development of a 
given drug product, and the ability to divide a big problem into several small components 
that are easier to solve. For instance, in the case of developing a "best-in-class" 
compound, model-based drug development can use the wealth of knowledge from 
predecessor drugs with a similar mechanism of action [50]. Right from the phase 1 stage, 
efficacy and safety drug models can be developed based on preclinical data of the new 
drug, as well as clinical experience with predecessors. As the clinical development 
advances, the models can be continually updated, and thus the characteristics of the new 
drug would become increasingly well defined. However, implementation of such a 
paradigm calls for more open collaboration of scientists from all disciplines and an 
institutional commitment to use the ‘current’ model while designing the next trial. 
 
Future considerations 
The late-phase attrition rates in drug development are alarmingly high at both, the 
registration trial and the regulatory review stages, and it is believed that timely 
application of pharmacometric methods can enhance future development plans and 
reduce these attrition rates [1-7;11;57].  
 
Quantitative disease-drug-trial model suites can serve as a valuable tool for improving 
future drug development and should be increasingly employed to design trials using 
clinical trial simulations. The FDA has set a target to design 50% of all pediatric trials 
using simulations by 2015 and 100% by 2020. Upon development of and experience with 
a particular disease-drug-trial model suite, a standardized template can be created for the 
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trial design, data analysis and review for all drugs under that indication. Consortia on 
specific topics are perhaps effective means for developing such model suites. 
 
Early-on interaction between the FDA and drug sponsors may help in more efficient 
planning. The End-of-Phase 2A (EOP2A) meetings are a good platform to facilitate this 
goal via more rational dose selection and trial design and reduction in number of cycles 
involved in the NDA review [24].  
 
However, modeling and simulation must not be viewed as a substitute for clinical trials 
altogether, nor seen as a tool to salvage failed trials, which were poorly-designed, for 
regulatory approval. The aim is simply to employ these techniques into a continuous 
learn-apply paradigm, capitalize on prior knowledge, improve trial design, and support 
evidence for approval and labeling of drugs.  
 
Increased collaboration between the industry, academia and the FDA is essential for the 
growth and wider application of pharmacometrics. In addition, increased interaction 
across the board between experts, such as clinicians, pharmacometricians and statisticians 
is a must for better appreciation of this field. Finally, training in this area is currently not 
offered by many academic institutions, and this may be an important step forward in the 
future.  
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 CHAPTER 2 
Pharmacometric Analyses Impact Pediatric Drug Approval 
and Dosing 
 
 
ABSTRACT 
The purpose of this article is to review case studies where pharmacometric analyses, also 
known as PK/PD modeling and simulation, have contributed to decision making in 
pediatric drug development and regulatory reviews. Most prominently, pharmacometric 
analyses support dose selection for clinical trials, evidence of effectiveness for regulatory 
approval and dosing recommendations for pediatric labeling. In addition, the article 
provides a future perspective on adopting pharmacometric analyses to improve pediatric 
pharmacotherapy and drug development. 
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INTRODUCTION 
The need to improve pediatric pharmacotherapy and drug development has a long history 
with regulators and public health professionals. As the potential harm of extensive off-
label drug use in pediatrics began to surface, several legislative initiatives were 
undertaken to generate pediatric-specific data. The aim was to ensure that the pediatric 
patient population no longer remained a therapeutic orphan [1]. In the U.S., the Food and 
Drug Administration Modernization Act (FDAMA) in 1997, the Best Pharmaceuticals for 
Children Act (BPCA) in 2002 and the Pediatric Research Equity Act (PREA) in 2003, 
have jointly provided an impetus to pediatric clinical studies and useful pediatric 
prescribing information in drug labels [2;3]. The European Council (EC) and the 
European Parliament have also promoted major regulatory changes in the way pediatric 
studies are planned and conducted in Europe. The regulation provides financial 
incentives, and requires a Pediatric Investigation Plan (PIP) for all new products and 
some existing products (new indication, new formulation, new dosage form, etc.), similar 
to the pediatric Written Request (WR) in the U.S. [4]. 
 
These initiatives have been largely successful in stimulating pediatric investigations. The 
desire to generate prospectively planned data for pediatrics is now being realized. As of a 
recent update, FDA has issued 386 pediatric written requests for several important 
diseases. Thus far, 173 approved drugs have obtained pediatric exclusivity by fulfilling 
the elements of written requests, as agreed upon by the FDA and sponsors. FDA has 
made labeling changes for many drug products (n>160) and the majority of these changes 
resulted in new pediatric safety and effectiveness information [5]. 
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 In the early 1990s, it was accepted that pediatric-specific data were either impossible or 
difficult to generate. In recent times, while financial incentives have led to an increase in 
the amount of information available to treat the pediatric population, there still remains a 
concern regarding the generation of good quality data to guide pediatric 
pharmacotherapy.  
• Off-label use of medication continues to be a major concern in pediatrics 
[6;7]. According to a 2005 study (677 patients), prescribing information in all 
age categories was available for less than 35% of commonly prescribed 
medications [7]. There are data from a 2004 survey (7901 patients) to 
indicate that 96% of cardiovascular-renal, 86% of pain, 80% of 
gastrointestinal, and 67% of pulmonary and dermatologic medication 
prescriptions either did not follow the prescribing recommendations or such 
information was not available [6]. Additionally, younger children were more 
likely to be treated with off-label strategies.  For example, 92% (out of 238 
patients) received one or more courses of an unapproved drug [8]. 
• Many pediatric investigations fail to generate useful data due to challenges 
unique to pediatric drug development. A recent study found that about half of 
the pediatric antihypertensive pivotal dose-response trials failed [9]. A 
retrospective analysis of such trials revealed that poor dose selection, lack of 
acknowledgement of differences between adult and pediatric populations and 
lack of pediatric formulations were associated with trial failures [9].  
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These concerns point to the unique nature of pediatric drug development. Such drug 
development programs are typically short (one or two clinical trials) and generally do not 
involve mortality/morbidity end-points. Drug approval is often based on matching 
systemic exposures or effect on pharmacodynamic biomarkers, to those in adults. 
Another major challenge is our understanding of and ability to account for the impact of 
growth and maturation on clinical pharmacology. It is expected that different drug 
exposures and/or altered response to the drug would be achieved in pediatric patients as 
compared with adults [10]. Altered clinical pharmacology along with ethical and 
logistical constraints together pose challenges to the design and analysis of pediatric trials 
as well as to pediatric therapeutics.  
 
Towards that end, there has been a growing interest in exploring means to enhance 
pediatric drug development [4;11]. Pharmacometric analysis methods are an important 
tool to improve the success of pediatric clinical trials and, therefore, pediatric 
pharmacotherapy. As summarized by Manolis and Pons, pharmacometric analyses 
consist of characterization and prediction of pharmacokinetics/pharmacodynamics 
(PK/PD), extrapolation from adults to children, interpolation between pediatric age 
subsets and optimal use of scientific literature and in vitro/preclinical data. 
Pharmacometric analyses can be employed to design informative studies using 
knowledge about disease pathophysiology, drug pharmacology (from adults and/or 
pediatrics), and organ maturation in pediatrics.  
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The focus of the present article is to review case studies where pharmacometric analyses 
have influenced three major areas: pediatric trial design and therapeutics guidelines, 
evidence of effectiveness, and dosing recommendations for pediatric labeling. For each 
of these areas, case studies are grouped according to a best fit scenario and one of the 
case studies is discussed in detail. In addition, the article also provides future perspectives 
for the application of modeling and simulation to improve pediatric trial design and 
therapeutics.  
 
APPLICATIONS OF PHARMACOMETRIC ANALYSES 
Trial Design and Therapeutics Guidelines 
A prospective clinical trial is one of the best ways to generate information to derive 
useful prescribing guidelines for pediatric drug use. For several drugs, however, there are 
either no data from prospectively planned clinical trials or pediatric trials have failed to 
achieve their primary objective. While it is possible that some drugs approved for adults 
may not be effective in the pediatric population, it is important to derive evidence-based 
support. Table provides examples where pharmacometric analyses were used to design 
future pediatric studies based on adult data or studies for drugs where there had been a 
failed pediatric trial for the same drug. 
 
A case in point is the antihypertensive drug esmolol. The pediatric registration trial failed 
to demonstrate effectiveness of the drug [12]. However, an external clinical study of the 
same drug and indication in pediatrics, that was conducted even before the registration 
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trial commenced, found the drug to be effective and reported a distinct exposure-response 
(E-R) relationship for reduction in blood pressure [13]. The registration trial investigated 
125-500 ug/kg/min esmolol doses in spite of the external clinical study showing 700 
ug/kg/min of esmolol to be effective in reducing blood pressure in pediatric patients with 
acute hypertension after cardiac operations. The results of these studies clearly 
demonstrate that the choice of doses studied in the registration trial was a key 
determinant of trial failure. It is unlikely that a pediatric trial of esmolol will be repeated. 
Thus, inefficient trial design led to a potentially effective treatment not being approved 
for use in pediatrics, a common theme among antihypertensive trials conducted in the 
early 2000s.  
 
Pharmacometric analyses can provide a rational basis for making important choices while 
designing pediatric trials using available information. Important trial design aspects such 
as dose range to be studied, sample size and PK sampling, trial duration, and analysis 
methods should be carefully selected [9;14]. A case study to systematically design a 
pediatric clinical trial based on adult data (without pediatric data) for anti-hypertensive 
drugs is available [14]. Presumably, such systematic use of available information may 
have helped appropriate dose selection for a registration trial of esmolol (discussed 
above). 
 
On the other hand, there are several instances of drugs that have been in clinical use for 
years in pediatrics, but optimal dosing strategies were unknown. In many such cases, 
pharmacometric analyses have provided insights to retrospectively derive dosing 
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information or to design subsequent trials to further optimize dosing strategies and 
perhaps guide therapeutic decisions. Such examples are also cited in Table 1.  
 
Table 1: Pharmacometric analyses to design pediatric trials using existing data in 
pediatrics and/or adults 
 
Drug Problem Statement Pharmacometric Analyses 
Contributions 
Topotecan[15], 
Furosemide[16], 
Vancomycin[17], 
Ondansetron [18] 
• Explored competing dosing 
regimens  
• Recommended optimal dosing 
strategy for use in future trials 
and/or clinical practice 
Fluconazole[11;19], 
Actinomycin-D 
(AMD) [20] 
 
Lack of clear guidelines 
for pediatric use despite 
years of clinical 
experience 
• Developed dosing guidelines that 
were successfully employed in 
subsequent trials 
• Examined the success (in terms 
of efficacy and safety) of dosing 
strategies and designed a 
prospective efficacy trial 
Carvedilol[21-23], 
Esmolol [12] 
Failure of pediatric trial 
for drug approved in 
adults 
• Provided insights into failed trial 
• Recommended optimal dosing 
strategy for use in future trials 
• Recommended appropriate end-
point for future trials 
Famciclovir[24], 
Teduglutide[25] 
Prospective clinical 
trial design 
• Recommended prospective study 
design including elements such 
as dose selection, sample size and 
PK sampling 
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Evidence of effectiveness 
The primary analysis methods for drug approval (treatment vs placebo comparison using 
standard hypothesis testing) and some endpoints (mortality/morbidity) used in adult trials 
may not be feasible or practical in pediatrics. Occasionally, a pivotal trial may fail to 
meet its primary endpoint due to avoidable reasons. Model-based endpoints may then be 
used in select instances, along with prior knowledge from adults and related pediatric 
data, to provide primary or supportive evidence of effectiveness for approval in 
pediatrics. Model-based endpoints are expected to be more powerful than standard 
hypothesis testing and hold unique value in pediatric trials due to challenges identified 
above. Table 2 provides a summary of case studies where pharmacometric analyses were 
considered suitable to support evidence of effectiveness for pediatric drug approval. 
 
Under certain circumstances, regulations allow the use of well established exposure-
response knowledge from one population for the approval in another [26]. 
Pharmacometric analysis was useful in bridging consistent drug effect of d,l sotalol 
hydrochloride on a surrogate (heart rate) in pediatrics and adults. Sotalol was originally 
approved in adults to treat life-threatening ventricular fibrillation and tachycardia, and for 
maintenance of sinus rhythm in patients with symptomatic atrial fibrillation and flutter. A 
clinical study assessing the antiarrhythmic and beta blocking effects of sotalol on QTc 
and heart rate in pediatrics ranging from neonates to 12-year-old children formed the 
basis of approval for sotalol’s use in pediatric patients. A biomarker study and ensuing 
pharmacometric analyses led to the judicious dosing recommendation in pediatrics [27].  
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Table 2: Pharmacometric analyses to provide primary or supportive evidence of 
effectiveness 
 
Drug Problem Statement Pharmacometric Analyses Contributions
Oxcarbazepine 
(Trileptal) [28] 
 
• Unethical to conduct a 
monotherapy trial in 
pediatrics 
 
• Provided evidence for approving the 
drug (first ever) as monotherpay in 
pediatric patients with partial seizures 
• Drug approved without additional 
controlled trials and model-derived 
dosing instructions included in label 
Candesartan 
Cilexitil 
(Atacand) [29] 
• Trial in patients aged 
6 to <17 yrs failed 
potentially due to 
poor dose selection 
and primary analysis 
method 
• No other approved 
ARB for patients 
aged <6 yrs and no 
new pediatric trial 
expected 
• Supported evidence of effectiveness in 
patients aged 6 to <17 yrs  
• Provided rational dosing 
recommendations in drug label 
Sotalol 
(Betapace) [27] 
• Impractical to 
conduct a mortality 
trial in pediatrics 
 
• Demonstrated consistent drug effect on 
surrogate (heart rate) in pediatrics and 
adults 
• Proposed dosing for patients aged ≥ 2 
years 
• Derived dosing recommendations for 
neonates and infants in drug label. 
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Dosing Recommendation  
The most successful application of pharmacometric analyses to pediatric drug 
development has been deriving dosing recommendations [30]. In several instances these 
recommendations have been successfully incorporated into the drug label (Table 3). In 
others, such as voriconazole [31] and leflunomide [32], dosing strategies have been 
proposed to guide therapeutic decisions. Occasionally, pediatric doses not directly studied 
in trials have been approved and included in the drug labels (see Table 3 for specific 
examples). In fact, in some therapeutic areas such as anti-virals and anti-infectives, drugs 
are frequently approved for pediatric use by extrapolating effectiveness from adult data. 
Drug exposures that are shown to be safe and effective in adults are typically considered 
target exposures for pediatrics. Suitable pediatric dosing regimens are then derived based 
on matching exposures between pediatrics and adults. In addition, as described 
previously (Table 1) there are several cases of drugs that have already been in clinical use 
for pediatrics where pharmacometric analyses have been used after-the-fact to 
recommend dosing strategies in order to improve therapeutics. 
 
Pharmacometric analyses have been used to optimize dosing recommendations after trial 
results are obtained based on the therapeutic goal. According to the FDA’s pediatric 
study decision tree [33] there are three broad approaches to conduct pediatric studies to 
seek drug approval and dosing recommendations: the PK-Only approach, the PK-
Biomarker approach, and the PK-Efficacy approach. Depending upon the disease, 
expected response to intervention, and prior information available (from adult or related 
pediatric data), one of the three approaches is selected for the pediatric drug development 
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program. Table 3 below provides a summary of case studies, categorized by approach 
used, where pharmacometric analyses were employed to derive pediatric dosing 
recommendations for labeling.  
 
Table 3: Pharmacometric analyses to derive pediatric dosing recommendations for 
labeling 
Drug Pharmacometric Analyses Contributions 
PK-Only Approach 
Piperacillin/ 
Tazobactam 
(Zosyn) [34] 
• Derived a 2-step body weight based dosing regimen to include 
in the label 
 
Busulfan 
(Busulfex) [35] 
• Derived a 2-step, body weight based dosing regimen to include 
in the label  
• Derived therapeutic drug monitoring strategy to enhance 
therapeutic efficiency 
Levofloxacin 
(Levaquin) [36] 
• Recommended dosing regimen to balance efficacy and safety 
that was not directly studied in a pediatric trial 
PK-Biomarker Approach 
Argatroban [37] • Provided dosing strategy for pediatrics that matched therapeutic 
response and risk with adults 
Levetiracetam 
(Keppra) [38] 
• Demonstrated that a higher dose (3 mg/kg) that was not directly 
studied may offer better effectiveness than the lower dose (2 
mg/kg) that was studied in the pivotal trial; Both doses 
incorporated into the label 
Tipranavir 
(Aptivus) [39] 
• Recommended higher dose (of two doses) studied in the trial 
based on benefit/risk evaluation 
• Explored different dosing strategies and recommended a body 
weight-based dosing regimen along with original BSA-based 
dosing 
PK-Efficacy Approach 
Fenoldopam 
(Corlopam) [40] 
• Recommended capping the pediatric dose (at 0.8 mcg/kg/min) 
based on benefit/risk evaluation 
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FUTURE PERSPECTIVE 
There are several areas within the realm of pediatric drug development that could highly 
benefit from future research [41]. Pharmacometric analyses have the potential to 
contribute towards many of these areas. 
• Pediatric dosing decisions will gain much higher success if developmental 
ontogeny is well understood and routinely incorporated. This is particularly true 
for disposition pathways such as non-renal elimination pathways and transport 
systems where effect of maturation is not well established.  
• Pediatric clinical trials will be much more informative with new biomarkers 
(surrogates) that are well suited to the pediatric population and powerful analysis 
methods (such as model based endpoints).  
• Pediatric clinical trials also need a sound rationale for sample size selection. 
Established methods to derive sample size are missing for typical PK and PKPD 
studies because these studies are not designed with a goal to derive statistical 
significance. We are exploring methods such as defining an acceptable precision 
standard to derive an objective basis for sample size selection.  
• Pediatric pharmacotherapy also needs powerful quantitative techniques to identify 
safety signals to optimize treatment strategies. This may involve identification of 
useful biomarkers that are predictive of adverse drug events. It is important to 
enable detection of safety signals even with data from a small number of subjects. 
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CONCLUSION 
In summary, the case studies presented in this article exemplify that pharmacometric 
analyses have had a significant impact on improving pediatric pharmacotherapy. Wider 
adoption of these methods will bring objectivity to decision making during pediatric drug 
development, improve trial success rates, and provide a more rational basis for decisions 
in pediatric therapeutics. 
 
 
REFERENCE LIST 
 (1)  Shirkey H. Therapeutic orphans. J Pediatr 1968 Jan;72(1):119-20. 
 (2)  Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, et al. 
Improving pediatric dosing through pediatric initiatives: What we have learned. 
Pediatrics 2008 Mar;121(3):530-9. 
 (3)  Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of 
BPCA and PREA. Clin Pharmacol Ther 2007 Apr;81(4):477-9. 
 (4)  Manolis E, Pons G. Proposals for model-based paediatric medicinal development 
within the current European Union regulatory framework. Br J Clin Pharmacol 
2009 Oct;68(4):493-501. 
 (5)  FDA. Pediatric Drug Development. http://www fda 
gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867 
htm 2010 [cited 2010 Jun 12]; 
 (6)  Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label 
prescribing to children in the United States outpatient setting. Acad Pediatr 2009 
Mar;9(2):81-8. 
 (7)  Hsu B, Brazelton T. Off-label medication use in an academic hospital pediatric 
critical care unit. WMJ 2009 Oct;108(7):343-8. 
 (8)  't Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. 
Unapproved and off-label use of drugs in a children's hospital. N Engl J Med 
2000 Oct 12;343(15):1125. 
 
59
 (9)  Benjamin DK, Jr., Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, 
et al. Pediatric antihypertensive trial failures: analysis of end points and dose 
range. Hypertension 2008 Apr;51(4):834-40. 
 (10)  Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman 
RE. Developmental pharmacology--drug disposition, action, and therapy in 
infants and children. N Engl J Med 2003 Sep 18;349(12):1157-67. 
 (11)  Laer S, Barrett JS, Meibohm B. The In Silico Child: Using Simulation to Guide 
Pediatric Drug Development and Manage Pediatric Pharmacotherapy. Journal of 
Clinical Pharmacology 2009 Aug;49(8):889-904. 
 (12)  FDA. Esmolol Review. http://www fda 
gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UC
M162702 pdf 2003 
 (13)  Wiest DB, Garner SS, Uber WE, Sade RM. Esmolol for the management of 
pediatric hypertension after cardiac operations. J Thorac Cardiovasc Surg 1998 
Apr;115(4):890-7. 
 (14)  Jadhav PR, Zhang J, Gobburu JV. Leveraging prior quantitative knowledge in 
guiding pediatric drug development: a case study. Pharm Stat 2009 Jul;8(3):216-
24. 
 (15)  Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using pharmacokinetic and 
pharmacodynamic modeling and simulation to evaluate importance of schedule in 
topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 2008 Jan 
1;14(1):318-25. 
 (16)  Schoemaker RC, dDer Vorst MM, van Heel IR, Cohen AF, Burggraaf J. 
Development of an optimal furosemide infusion strategy in infants with modeling 
and simulation. Clin Pharmacol Ther 2002 Oct;72(4):383-90. 
 (17)  Mehrotra M, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing 
regimens in preterm and term neonates using Monte-Carlo simulations. Journal of 
Clinical Pharmacology 2007 Sep;47(9):1206. 
 (18)  Mondick JT, Johnson BM, Haberer LJ, Sale ME, Adamson PC, Cote CJ, et al. 
Population pharmacokinetics of intravenous ondansetron in oncology and surgical 
patients aged 1-48 months. European Journal of Clinical Pharmacology 2010 
Jan;66(1):77-86. 
 (19)  Wade KC, Benjamin DK, Kaufman DA, Ward RM, Smith PB, Jayaraman B, et al. 
Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in 
Young Infants. Pediatric Infectious Disease Journal 2009 Aug;28(8):717-23. 
 
60
 (20)  Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, et al. 
Population pharmacokinetic investigation of actinomycin-D in children and young 
adults. Journal of Clinical Pharmacology 2008 Jan;48(1):35-42. 
 (21)  Albers S, Meibohm B, Mir TS, Laer S. Population pharmacokinetics and dose 
simulation of carvedilol in paediatric patients with congestive heart failure. 
British journal of clinical pharmacology 2008 Apr;65(4):511-22. 
 (22)  Laer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, et al. Carvedilol therapy 
in pediatric patients with congestive heart failure: A study investigating clinical 
and pharmacokinetic parameters. American Heart Journal 2002 May;143(5):916-
22. 
 (23)  Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. 
Carvedilol for children and adolescents with heart failure - A Randomized 
controlled trial. Jama-Journal of the American Medical Association 2007 Sep 
12;298(10):1171-9. 
 (24)  Ogungbenro K, Matthews I, Looby M, Kaiser G, Graham G, Aarons L. 
Population pharmacokinetics and optimal design of paediatric studies for 
famciclovir. British journal of clinical pharmacology 2009 Oct;68(4):546-60. 
 (25)  Mouksassi MS, Marier JF, Cyran J, Vinks AA. Clinical Trial Simulations in 
Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a 
Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel 
Syndrome. Clinical Pharmacology & Therapeutics 2009 Dec;86(6):667-71. 
 (26)  FDA. Guidance for Industry Providing Clinical Evidence of Effectiveness for 
Human Drug and Biological Products. http://www fda 
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/uc
m078749 pdf 2010 [cited 2010 Dec 26]; 
 (27)  FDA. Sotalol Review. http://www accessdata fda 
gov/drugsatfda_docs/nda/2001/19-865S010_Betapace_biopharmr pdf 2001 [cited 
2010 Jun 12]; 
 (28)  Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang YN, Tandon V, 
et al. Impact of pharmacometrics on drug approval and labeling decisions: A 
survey of 42 new drug applications. Aaps Journal 2005;7(3):E503-E512. 
 (29)  FDA. Candesartan Review. http://www fda 
gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UC
M189128 pdf 2009 [cited 2010 Jun 12]; 
 (30)  Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther 2010 
Mar;87(3):270-1. 
 
61
 (31)  Karlsson MO, Lutsar I, Milligan PA. Population Pharmacokinetic Analysis of 
Voriconazole Plasma Concentration Data from Pediatric Studies. Antimicrobial 
agents and chemotherapy 2009 Mar;53(3):935-44. 
 (32)  Shi J, Kovacs SJ, Wang YN, Ludden TM, Bhargava VO. Population 
pharmacokinetics of the active metabolite of leflunomide in pediatric subjects 
with polyarticular course juvenile rheumatoid arthritis. Journal of 
Pharmacokinetics and Pharmacodynamics 2005 Aug;32(3-4):419-39. 
 (33)  Exposure-Response Guidance to Industry. http://www fda 
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/uc
m072109 pdf 2010Available from: URL: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformatio
n/Guidances/ucm072109.pdf 
 (34)  Tornoe CW, Tworzyanski JJ, Imoisili MA, Alexander JJ, Korth-Bradley JM, 
Gobburu JVS. Optimising piperacillin/tazobactam dosing in paediatrics. 
International journal of antimicrobial agents 2007 Oct;30(4):320-4. 
 (35)  Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, et al. Population 
pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. 
Journal of Clinical Pharmacology 2007 Jan;47(1):101-11. 
 (36)  Li F, Nandy P, Chien S, Noel GJ, Tornoe CW. Pharmacometrics-Based Dose 
Selection of Levofloxacin as a Treatment for Postexposure Inhalational Anthrax 
in Children. Antimicrobial agents and chemotherapy 2010 Jan;54(1):375-9. 
 (37)  FDA. Argatroban Review. http://www fda 
gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/uc
m071734 pdf 2008 [cited 2010 Jun 12]; 
 (38)  FDA. Levetiracetam Review. http://www fda 
gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/uc
m072477 pdf 2008 [cited 2010 Jun 12]; 
 (39)  FDA. Tipranavir Review. http://www fda 
gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/uc
m072836 pdf 2008 [cited 2010 Jun 12]; 
 (40)  FDA. Fenoldopam Review. http://www fda 
gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/uc
m162711 pdf 2004 [cited 2010 Jun 12]; 
 (41)  Jadhav P, Burckart G, Lesko L, Gobburu J. Pediatric Drug Development and 
Clinical Pharmacology. Drug Development 2009 Sep;4:80-3. 
 
 
62
 
63
 
 
CHAPTER 3  
Simulation-based Methodology for using PK Quality Standard 
to Design Pediatric Trials in the Population Analysis setting 
 
 
ABSTRACT 
The objective of this research is to evaluate the feasibility and methodological 
challenges while implementing a pharmacokinetic (PK) quality standard, in the 
population analysis setting. It is important for pediatric trials to yield good quality PK 
data to enable making reliable dosing decisions. The quality standard aims to ensure both, 
rational pediatric PK trial design and consistency in regulatory review. A simulation-
based method for designing pediatric trials to be prospectively powered to meet the 
quality standard is proposed.  
A simulation-estimation platform, aiming to optimize the pediatric sample size 
that met the PK quality standard under different scenarios, was used to explore the impact 
of several trial design elements. In general, reasonable sample sizes (range: 16 - 64 
pediatric subjects) were required to meet the quality standard even with sparse sampling 
schedules (2-3 samples per subject). Increasing sample size and PK samples per subject 
increased the precision of parameter estimates. Sample size requirements to achieve 
target precision progressively increase with increasing between-subject PK variability 
(low-30%, medium-50% and high-70%). Inclusion of rich adult data, in general, reduced 
required pediatric sample sizes (eg. from N=64 to N=48 for 70% variability). However, a 
ceiling effect is observed in the extent adult data can inform the model and reduce 
pediatric sample size adequacy (no additional benefit of 24 vs. 12 adults). A comparison 
of population mean analysis and individual post-hoc analysis methods found the former 
to be more powerful and less biased. Finally, all trends were moreover the same for i.v. 
and oral administration models. 
In conclusion, the PK quality standard is practically feasible in terms of sample 
size adequacy. A simulation-based approach to design pediatric PK trials using the 
standard is described. Informative sampling schedule for a given number of PK samples 
per subject is assumed during trial design. The recommendations are: 1- to use prior adult 
or pediatric data for trial design and analysis, wherever possible and 2- to use one-stage 
population analysis methods with biologically plausible covariate models for designing 
pediatric PK studies. 
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INTRODUCTION 
The pediatric population has been described as a therapeutic orphan [1] because 
historically, pediatric drug development was deprived of the patronage given to drug 
development programs in adults [2;3]. However, over the past decade, concerns and 
actions of health care professionals, researchers and regulators have together led to an 
impetus in pediatric clinical research [4;5]. Recent legislative initiatives in combination 
have dramatically stimulated changes in pediatric drug labeling [6]. The aim is to provide 
useful prescribing information for pediatric pharmacotherapy, such as rational dosing and 
identification of risks of therapies. Eventually, the hope is to amend the long drawn 
deficit in pediatric drug development.  
 
Under any pediatric drug development program, pharmacokinetic (PK) information is a 
key driver of decisions including but not limited to dosing, approval or labeling. 
According to the FDA’s pediatric study decision tree [7], a PK trial, where suitable, may 
serve as the basis for drug approval in pediatrics. In fact in some therapeutic areas, such 
as anti-virals and anti-infectives, regulatory approval of drugs for use in pediatrics is 
primarily based on PK studies. In other areas, PK data from pediatric studies may have a 
crucial role to play in determining the doses to be tested in pivotal safety and 
effectiveness trials. Occasionally, drug doses not directly studied in pediatric trials are 
approved and included in the label for pediatric use based on prior exposure-response 
characterization from adults or pediatrics. PK data is also useful in supporting evidence 
of effectiveness and safety related labeling decisions. Hence it is important that all 
pediatric drug development programs, typically comprising only few (1-2) trials, yield 
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good quality PK data. Trial design elements, particularly sample size and PK sampling 
schedule, have a significant impact on the quality of the resulting PK data. Making 
rational choices during the study design stages itself can save time and costs, ensure good 
quality PK data and safeguard the interpretability of study results as well as pediatric 
exclusivity granted to sponsors. 
 
Despite the recent progress in pediatric drug development, there have been multiple 
unexpected and disappointing results, particularly for pediatric PK studies.  One case in 
point is for the drug metoprolol, where data collected in pediatric trials could not be used 
efficiently. Three pediatric dose levels (0.2, 1 and 2 mg/kg) were studied in the trial with 
single trough PK sampling. However, 60% of the samples for dose group 0.2 mg/kg were 
below LOQ. Firstly, this raised a scientific/regulatory concern due to the (avoidable) 
complexity involved in the exposure-response analysis, which served as the basis for 
approval of the drug. Secondly, collecting unusable data from pediatrics raises ethical 
questions in its own standing.  
 
Another, and perhaps the most important, aspect of pediatric trial design that warrants 
attention is sample size selection. The pediatric PK studies submitted to the FDA have 
vastly variable sample sizes. Often a clear rationale is not provided, which leads to 
inconsistency and introduces subjectivity during regulatory review. There was an 
instance where a pediatric written request stipulated a sample size of 24 pediatric subjects 
to be studied, based on no scientific rationale. But due to challenging recruitment rate, 
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that sample size requirement could not be met, adversely affecting the pediatric 
exclusivity determination.  
 
Heretofore, the choice of sample size for pediatric PK studies seems to have been a 
logistic decision rather than a scientific one. Figure 1 presents the sample sizes used vs. 
variability (%CV) reported on clearance, in eight randomly selected pediatric PK trials, 
for illustration. One can observe that there is no correlation between sample size and 
%CV, which brings out the lack of rationale behind sample size selection. Typically, 
these studies have included a small number of patients, particularly in the lower age 
range, which is inadequate for estimating PK parameters with good precision.  
 
These instances draw attention to the need for rational pediatric trial design. In case of 
pediatric PK studies, there is lack of objective criteria to design a trial, which are 
available for mainstream efficacy trials. The consequences may be detrimental as is 
apparent from the cases cited above. In recognition of need for a uniform criterion to 
define PK data quality, a regulatory requirement has been recently initiated as part of the 
pediatric written request [8]. The FDA recommends using a pre-defined target on the 
precision of primary PK parameter estimates, such as mean clearance and volume of 
distribution, as a quality standard for PK data. The requirement is to prospectively power 
(at least 80%) a pediatric trial to target a 95% confidence interval within 60% and 140% 
of the geometric mean estimate of primary PK parameters, for each pediatric age group 
studied. The aim is to provide guidelines for bringing objectivity into pediatric PK trial 
design. 
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 Figure 1: Sample size vs. %CV in 8 pediatric PK studies chosen randomly from the 
literature and submissions to FDA.  
1Studies cover different age groups ranging from 2 days – 18 years.  
2Vertical dashed lines represent different variability levels  
 
 
 
 
An objective criterion, such as the proposed PK quality standard, is one way of ensuring 
more rational pediatric trial design. Implementation of the standard will lead to greater 
consistency and efficiency in analysis of pediatric studies and their regulatory review. 
However, there remain methodological research questions on how to select the optimal 
sample size while designing pediatric trials, so as to prospectively power the study to 
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meet the precision standard. Frequently, pediatric studies collect sparse PK data (1-3 
samples per subject) and population analysis techniques are used for the design and data 
analysis of such trials. Methods on optimizing the PK sampling schedule for population 
analyses have been published previously [9-11]. The current study focuses on simulation-
based methodology to derive sample size, and assess the impact of different elements, 
while designing pediatric studies to meet the proposed PK quality standard, in the 
population PK setting.  
 
METHODS 
A simulation-estimation method was developed for the current study. A pediatric 
population was simulated in terms of demographics and PK observations under different 
trial design scenarios with increasing sample sizes. The parameters of the PK model were 
then estimated using the simulated data and relevant metrics for the estimates of mean 
systemic clearance and central volume of distribution were determined. Figure 2 is a flow 
chart describing all the computations carried out by the tool. The following sections detail 
the steps involved during the simulation-estimation for a base case trial design scenario 
with n=16 pediatric subjects, 2 PK samples per subject (1 and 3 hours), 30% between-
subject variability in clearance and volume, no adult data included, oral drug 
administration, and using population mean estimates for analysis. 250 replicate datasets 
were simulated for the analysis. 
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Figure 2: Flow chart of computations carried out by the simulation-estimation tool 
 
 
 
 
Answers to the following six research questions were sought through the current study: 
1. What are the typical sample sizes for different trial design scenarios that achieve 
80% power for target (60-140%) precision and acceptable bias? 
2. What is the impact of varying the number of samples per subject? 
3. What is the impact of low, medium or high PK between-subject variability? 
4. What is the impact of including adult data for estimation? 
5. What is the impact of the analysis method used? 
6. What is the impact of i.v. vs. oral administration models? 
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Nominal design 
For the present study, the PK model developed previously in pediatrics for Zosyn 
(piperacillin/tazobactam) [12] was adopted. The model drug used follows one-
compartment, dose-proportional PK and has 100% bioavailability with fast absorption 
(Tmax about 2 hrs) and a half-life (t1/2) of 1.5 hrs. A single 100 mg/kg dose was 
administered orally to the simulated pediatric subjects.  
 
Demographics 
A CDC (Center for Disease Control and prevention) database was used for the simulation 
of pediatric demographics that included age, gender and weight. The database contained 
ages from birth-20 yrs, in increments of 1 month, yielding n=240 unique ages. For each 
unique combination of age and each gender (n=480) there are parameters, including a 
variability component, to determine the distribution of body weight. Thus, 100 
individuals of different body weight for each combination of age and gender were 
simulated resulting in a virtual bank of n=48000 unique pediatric subjects.  
 
For this study, the pediatric subjects were divided into four age bins as is commonly done 
during recruitment in pediatric clinical trials. The age bins used were 1 mo to 2 yrs, >2 to 
6 yrs, >6 to 12 yrs and >12 to 17 yrs. Subjects were randomly sampled from this bank of 
pediatrics and evenly distributed into each age bin. All replicate datasets maintained the 
same set of subjects in terms of covariates. 
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The bank was also used to determine the “true” mean clearance and volume for each 
pediatric age bin. Using the covariate model employed for the simulations, the “true” 
individual clearances and volumes for each virtual subject in the bank were determined 
and subsequently the geometric mean (non-parametric) of these parameters for each age 
bin was arrived at. In addition, we also determined the mean (parametric) clearance and 
volume predicted by the model at the median age and weight for each age bin. 
 
Simulation-estimation models 
The one-compartment model used in the present study was parameterized in terms of 
total systemic clearance (CL) and volume of distribution for central compartment (Vc), 
and in case of oral administration scenarios, the first-order absorption rate constant (KA). 
The between-subject variability (BSV) of the model parameters was described using a 
lognormal distribution. 
 
An allometric scaling model was used for body weight effect on clearance and volume 
whereas an Emax-type model was used for age effect on clearance. The covariate models 
were employed for simulation and estimation as well as to determine the true individual 
clearance and volume for each subject in the pediatrics bank. 
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iVceTVKAKAi
η•=
        
…. Eqn. 3
  
 where; ηCLi is the difference between individual (CLi) and population mean (TVCL) 
clearance on log scale, ηVci is the difference between individual (Vci) and population 
mean (TVVc) volume of distribution on log scale, ηKAi is the difference between 
individual (KAi) and population mean (TVKA) absorption rate constant on log scale, 
alloCL and alloVc are the allometirc exponents that account for the effect of body weight 
(WT) on clearance and volume respectively, A50 is the covariate parameter that accounts 
for the effect of maturation on clearance and reflects the age at which clearance is half of 
its maximal (or adult) value. ηCLi, ηVci and ηKAi were all assumed to follow a normal 
distribution, independent of each other, with mean of zero and variances of Ω2CL, Ω2Vc 
and Ω2KA respectively. 
        
The residual error or within-subject variability (WSV) was described using a proportional 
error model as shown below: 
 ( )Cppredi CpCp ε+•= 1       …. Eqn. 4 
 
where; εCp is the difference between the individual observed plasma concentration (Cpi) 
and the individual model prediction (Cppred) and is assumed to follow a normal 
distribution with mean of zero and variance of σ2Cp. 
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Truncated simulations were performed in order to contain the simulated parameter values 
within reasonable limits. The distributions of clearance, volume, t1/2 and KA were 
truncated using the generic expression shown below, for each of these parameters: 
( SDLnMeanLOLIM •−= 3exp )
)
      …. Eqn. 5 
( SDLnMeanHILIM •+= 3exp       …. Eqn. 6 
where; LOLIM and HILIM are the lower and upper limits desired for the simulated 
parameters, LnMean is the mean parameter on the log scale and SD is the standard 
deviation of the parameter on the log scale. For clearance, volume and KA the variances 
used for simulations (Table 1) determined SD and for t1/2 the variances of clearance and 
volume were added to determine SD. 
 
The parameter values for the “true” one-compartment model used for simulations, with 
associated covariate effects, are listed in Table 1. During estimation the oral absorption 
parameters, TVKA and Ω2KA, were fixed, while all remaining model parameters were 
estimated. For the population mean analysis, model predictions of mean clearance and 
volume at the median age and weight, for each of the four age bins, were determined as 
mean parameter estimates.  
 
 
 
 
 
 
 
 
74
Table 1: Values of the one-compartment model parameters used for the simulations 
Parameter Value Units 
TVCL 3.2 L/h /20kg 
TVVc 6.2 L /20kg 
TVKA 2 (fix) /h 
Ω2CL (CV) 30, 50, 70 % 
Ω2Vc (CV) 30, 50, 70 % 
Ω2KA (CV) 50 (fix) % 
σ2CP (CV) 10 % 
ALLO_CL 0.75  
ALLO_Vc 1  
A50 0.18 years 
 
TVCL, TVVc, TVKA: typical values of systemic clearance, central volume of distribution and 
first-order absorption rate constant 
Ω2CL, Ω2Vc, Ω2KA: variance in CL, Vc and KA respectively; CV: coefficient of variation 
σ2CP: variance in individual plasma concentrations 
ALLO_CL, ALLO_Vc: allometric exponent for weight effect on CL and Vc respectively 
A50: covariate parameter for effect of maturation on CL, defined as the age at which clearance is 
half of the adult value 
 
Data analysis 
For each replicate, the precision and bias in the mean clearance and volume parameter 
estimates were computed. The mean bias and power to achieve target precision standard 
were then determined, based on all replicates. 
Precision metrics 
In accordance with the recent regulatory requirement, we assessed precision as a %CV-
like metric but in terms of upper bound of the 95% confidence interval (UCI) rather than 
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standard error (SE). Thus, precision was defined as the ratio of the upper limit of the 95% 
confidence interval to the mean parameter estimate, or relative UCI (RUCI). Values close 
to 1 for this ratio imply high precision (or small standard errors) while higher values 
imply more imprecision (or large standard errors). Then as per the PK quality standard 
defined previously, the target is for this ratio to be ≤ 140%. Given the lognormal 
distribution of the parameters (CL and Vc), it is assumed that if the UCI is within 140% 
of the mean, then the LCI will be within 60% of the mean. Hence we focused only on the 
UCI for assessing precision.  
 
A percentage expression was used to determine precision on clearance and volume 
parameters for every replicate and the mean of this metric for all replicates was the ‘mean 
imprecision’. Thus a value of 100 for the metric represents no imprecision (or a 0 
standard error) and higher the value of the metric, deviant from 100, lower is the 
parameter precision. 
100•⎟⎠
⎞⎜⎝
⎛=
Mean
UCIRUCI        …. Eqn. 7 
The proportion of replicates where RUCI met the target was determined to be the power 
to achieve the precision standard.  A trial design was considered successful if it achieved 
80% power for target precision (i.e. RUCI ≤ 140 for ≥80% replicates). 
 
In order to construct the 95%CI, for each age bin, model estimated mean parameters and 
standard errors were used. Then the 2-sided tdf,α statistic corresponding to the total 
pediatric sample size for estimating eight model parameters (see Table 1) was used (α 
=0.025, n=16, df=8, t= 2.306). 
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Bias metrics  
For the purpose of computing bias on the parameter estimates, reference values that may 
be considered “true” estimates were used. The mean parameter estimates for each age bin 
obtained from the virtual pediatrics bank, as described above were considered as the 
reference values. 
 
The metric used to compute bias in the parameter estimates was the percent deviation 
from the reference value, calculated as follows: 
100% •⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
true
trueest
P
PP
Deviation       …. Eqn. 8 
where; Pest is the estimated value of the parameter by fitting the model to the simulated 
data and Ptrue is the reference value for the model parameter. The mean bias for all 
replicates was determined. A deviation within 20% of the reference value was regarded 
as acceptable bias. A trial design was evaluated not only in terms of precision but also 
acceptable bias, for research purposes. 
 
We also considered the bias in the covariate parameter estimates and variance estimates 
(both BSV and WSV) as well as shrinkage in post-hoc estimates to assess their 
reasonable estimation (results not shown). However these metrics were excluded from the 
power analysis for the trial design. 
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Scenarios explored 
We were interested in exploring the impact of varying different trial design elements on 
meeting the requirements of the PK quality standard. Table 2 provides a summary of the 
different scenarios explored in our simulations. There were 756 unique scenarios 
explored. Different combinations of all the following key design elements were 
evaluated: 
 
1. Between-subject variability (3 scenarios): The base case trial design was with low 
(30%) between-subject variability. Scenarios with medium (50%) and high (70%) 
between-subject variability were also simulated. 
2. Samples per subject (3 scenarios): Three sparse sampling schedules, in terms of 
number of PK samples (1, 2, or 3) per subject, were explored. 
While it is recognized that single trough sampling may be irrelevant for 
population PK analysis and using such sparse sampling schedules is discouarged, 
this scenario has been included for research completion purposes. For the single 
trough sampling scenarios the estimation was carried out differently, based on 
previous recommendations [13]. Accordingly, only the TVCL, alloCL, Ω2CL and 
σ2Cp parameters were estimated, when rich adult data was included. In absence of 
adult data, even the residual variability parameter (σ2Cp) was not estimated. 
3. Adult data inclusion (3 scenarios): The designs were varied in terms of inclusion 
of rich adult data (10 samples per subject) in the estimation, exploring three 
scenarios: pediatric data alone, or with additional rich PK data from 12 or 24 
adults.  
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4. Analysis method (2 scenarios): Two different analysis methods were assessed. 
Thus all metrics were determined on both, population mean estimates (a one-stage 
approach) as well as individual post-hoc estimates (similar to a two-stage 
approach). For the latter analysis method, the geometric means of individual post-
hoc estimates of clearance and volume were empirically determined, for each age 
bin. In order to construct the 95%CI, for each age bin, we used standard errors of 
age- and weight-normalized post-hoc individual estimates and a 2-sided tdf,α 
statistic corresponding to the pediatric sample size for that particular age bin (α = 
0.025, df = n-1) . 
5. Drug administration (2 scenarios): Scenarios were simulated using both i.v. as 
well as oral administration models, for comparison.  
6. Sample size (7 scenarios): For each scenario, trial designs with increasing 
pediatric sample sizes (n = 16, 24, 32, 40, 48, 64 and 80) were simulated, to 
determine the design that met the quality standard.  
 
79
Table 2: Trial design scenarios explored during simulations  
Design element ORAL I.V. 
SAMPLING 
 
• 2 per subject (1, 3 h) 
• 3 per subject (1, 3, 4 h) 
• Single trough (4 h) 
Rich sampling used for adult 
data: 10 per subject  (0.25, 0.5, 
1, 1.5, 2, 2.5, 3, 4, 6, 8 h) 
 
• 2 per subject (0.1, 2h) 
• 3 per subject (0.1, 2, 3 h) 
• Single trough (3 h) 
Rich sampling used for adult 
data: 10 per subject  (0.1, 0.5, 1, 
1.5, 2, 2.5, 3, 4, 6, 8 h) 
VARIABILITY 
 
For Cl and Vc: 
• Low (30%) 
• Medium (50%) 
• High (70%) 
For KA: 50% fixed for all cases 
 
For CL and Vc: 
• Low (30%) 
• Medium (50%) 
• High (70%) 
ADULT DATA 
 
• No adult data 
• Rich data from 12 adults 
• Rich data from 24 adults 
 
ANALYSIS 
METHOD 
 
• Population mean estimates, for each pediatric age bin 
• Individual post-hoc estimates, for each pediatric age bin 
SAMPLE SIZE 
 
• 16 
• 24 
• 32 
• 40 
• 48 
• 64 
• 80 
Distributed evenly across four age bins 
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Software 
An R environment was employed for the simulation-estimation procedure with system 
calls to NONMEM and SAS. For the simulations, random numbers were generated using 
a six digit seed. 250 replicates were simulated for each trial design. NONMEM version 
VI with Compaq Visual FORTRAN 6 compiler was used to conduct the simulations. 
SAS version 9.2. was used for the estimations. The estimation method used in SAS was 
QPOINTS=1 (equivalent to LaPlace in NONMEM). R version 2.9.1. was used to create 
the automated program script and carry out data manipulation, data analysis and graphics 
generation. 
  
RESULTS 
Figure 3 is a comparative display of the impact of all aspects of trial design explored on 
meeting the PK quality standard.  
 
What are the typical sample sizes for different trial design scenarios that achieve 
80% power for target (60-140%) precision and acceptable bias? 
As expected, power increases with increasing sample size. The trends remain similar for 
both clearance and volume estimates and for all scenarios tested. Figure 4 is a 
representation of the trend for power to achieve target precision against sample size, by 
age bin, for a sample scenario (oral, 50% variability, 2 PK samples, no adult data). 
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In general, the bias in the parameter estimates was acceptable - deviation within 20% of 
reference values. This result is expected [13]. The mean bias in most scenarios tended to 
be positive, and was generally higher for age bin 1 (1mo - 2yrs) than other age bins. In 
general, mean bias w.r.t. simulated data was higher (up to +40% for age bin 1) than that 
w.r.t. true data i.e. pediatrics bank. Figure 5 presents the mean bias, by age bin, for the 
same sample scenario (oral, 50% variability, 2 PK samples, no adult data). 
 
Figure 3 displays the smallest sample size that achieves 80% power for target precision 
and acceptable bias, for all age bins, across all trial scenarios. The sample size selected as 
a success for a trial design was one for which the criteria were met for all age bins.  
 
Figure 3: Impact of all trial scenario elements explored on sample size adequacy to 
meet PK quality standard.  
1 Results shown are for all oral administration scenarios; i.v. scenario results were similar. 
2 Where dotted lines are not visible on the graph, they overlap with solid lines. 
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Figure 4: Power to achieve target precision standard (on mean clearance) at all 
sample sizes explored, by age bin, for a sample scenario (oral, 50% variability, 2 PK 
samples per subject, no adult data). 
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Figure 5: Mean bias (in mean clearance) at all sample sizes explored, by age bin, for 
a sample scenario (oral, 50% variability, 2 PK samples per subject, no adult data). 
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What is the impact of varying the number of samples per subject? 
Scenarios with 3 PK samples per subject consistently achieved higher power than that 
achieved with 2 PK samples per subject. However, this translated into lower sample size 
requirements only in a few cases. This can be seen in Figure 3. Mean bias was not 
different for 2 vs. 3 samples per subject. Shrinkage was in general ≤ 20% and was 
consistently greater in cases of 2 samples per subject over 3 samples per subject, as 
expected. 
 
In this study, the results of single trough sampling scenarios are not directly comparable 
to those of scenarios with 2 or 3 samples per subject because the estimation was carried 
out differently for single trough sampling, as described in section 2.5. We assessed 
precision and bias for only the mean clearance estimates. The power trends however 
remain similar as for cases with 2-3 samples per subject. The bias was generally 
acceptable at lower variability scenarios but at high (70%) variability, the mean bias in 
clearance estimates was up to 30% deviation. However, post-hoc estimates are 
susceptible to high shrinkage in case of such sparse data, which was observed in our 
study for single trough sampling scenarios in absence of adult data (30-70% shrinkage).  
 
What is the impact of low, medium or high PK between-subject variability? 
Between-subject variability was the trial design element with maximum bearing on 
power and sample size requirements to meet the precision standard. As would be the case 
in conventional power analyses, higher PK variability resulted in lower power and higher 
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sample sizes, consistently in all scenarios. Variability did not have implications on bias 
estimates.  
 
The residual error estimation was dependent on variability. While a 10% proportional 
residual error was used for simulations, at low and medium variability scenarios (30%, 
50%) this estimate was 15-17% whereas at high (70%) variability scenarios the residual 
error estimates were higher, 20-30%. In addition, the A50 parameter estimate was more 
biased at higher variability.  
 
What is the impact of including adult data for estimation? 
In case of the population mean analysis method, inclusion of adult data (rich sampling) 
from 12 adults significantly improves the power to achieve target precision. This results 
in a smaller number of required pediatric subjects when adult data is included in the 
estimation. For instance, n=64 and n=48 met the precision standard for a 70% variability 
scenario without and with adult data, respectively. However, a ceiling effect was 
observed in the inclusion of adult data. In most cases, including rich data from 24 adults 
did not offer significant increase in power or reduction in sample sizes over including 
rich data from 12 adults.  
 
The inclusion of adult data does not significantly impact the outcomes of the individual 
post-hoc analysis method. The power/sample size to meet the precision standard, in 
general, remains unaffected whether adult data is included or not. Figure 3 presents the 
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impact of inclusion of adult data on minimum sample size requirements to achieve 
precision standard for all scenarios. 
 
Adult data inclusion had no significant impact on mean bias in clearance and volume 
estimates. However, it did significantly reduce the bias in estimation of the A50 
parameter. Shrinkage in single trough sampling scenarios was significantly lowered 
(≤20%) in presence of adult data. Adult data also significantly improved the estimation of 
BSV parameters, in all cases.  
 
What is the impact of the analysis method used? 
The population mean analysis method is a more powerful analysis approach than the 
individual post-hoc method i.e. allows use of smaller sample size to meet precision 
standard, consistently for all scenarios. This observation is clear in Figure 3. Population 
mean analysis also resulted in consistently lower mean bias in estimation, compared with 
individual post-hoc analysis.  
 
For population mean analysis, as far as the covariate parameter estimates, the alloCL and 
alloV were generally well estimated (≤ ±20% deviation), although the alloCL was 
generally under estimated. The A50 parameter was always significantly over predicted 
with 50-300% deviation from the reference value (0.18) used for simulations. As far as 
variance, these parameters were generally reasonably estimated (≤ ± 20% deviation) but 
the tendency was towards underprediction. This is expected, since we used truncated 
simulations to restrict the simulated clearance and volume estimates within reasonable 
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bounds. In case of single trough sampling, the BSV on clearance was considerably under-
estimated (-50 to -80% deviation). Adult data inclusion significantly reduced the bias in 
estimation of variance (-20 to -40% deviation).  
 
For individual post-hoc analysis, as far as shrinkage in parameter estimates, it was 
generally ≤ 20%. As expected, shrinkage was greater with lesser number of PK samples 
per subject and was significant (30-70%) for single trough sampling. However, this 
reduced (to ≤20%) in presence of adult data.  
 
What is the impact of i.v. vs. oral administration models? 
All trends in power, sample size, and bias remained moreover similar between i.v. and 
oral administration scenarios.  
 
DISCUSSION 
What are the typical sample sizes for different trial design scenarios that achieve 
80% power for target (60-140%) precision and acceptable bias? 
The study aimed to address the practical feasibility of implementing the precision 
standard, in terms of sample size.  Hence the inferences are focused on the estimates of 
sample size adequacy and trends across different scenarios explored, and not on the 
specific numbers arrived at for sample size. They are intended to serve as guidelines 
while designing pediatric trials in keeping with the quality standard. 
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In general, reasonable sample sizes were found to be adequate to meet the proposed 
quality standard, ranging from 16-64 subjects, even with sparse sampling and high 
between-subject variability. Hence we consider the proposed quality standard to be 
practically feasible. Further, the estimation bias with these sample sizes was also found to 
be acceptable (deviation from true values within 20%). While bias cannot be assessed in 
real trials, it is re-assuring that the simulations do not suggest major bias in the estimates.  
 
In absence of adult data, the sample size for trial design success was driven by both the 
extreme age bins, bin 1 (1mo-2yrs) and bin 4 (12-17yrs). In presence of adult data, the 
sample size was mainly driven by bin 1. Bins 2 (2-6 yrs) and 3 (6-12 yrs) invariably 
complied with the criteria, for a given sample size, as long as bins 1 and 4 did. This result 
is expected given the covariate model we have used, where body weight is the main 
driver for clearance and volume estimates. Estimation precision is always lower at the 
extreme ends of the data range. Hence precision on parameter estimates was consistently 
found to be poorest for age bin 1 (also lowest body weight group), and in absence of adult 
data, even for age bin 4 (also highest weight group). Thus, the total sample size that can 
be used in a pediatric trial in order to be powered to meet the quality standard may be 
lowered by recruiting fewer subjects in the middle age bins 2 and 3, and more subjects in 
age bins 1 and 4. However, this decision is more of a regulatory issue than a research 
focus of the current study.  
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What is the impact of varying the number of samples per subject? 
Sparse sampling schedules are most common in pediatric trials. While we explored 
scenarios with either 2-3 or single trough PK sample per subject, the results are 
generalizable. Increasing the number of PK samples per subject, even within the realm of 
sparse sampling schedules, adds information to the model to aid better precision. If rich 
pediatric PK data are available, non-compartmental analysis (NCA) may be considered, 
in which case the sample size determination is fairly straightforward using variability 
estimates from adult data or relevant prior pediatric data [8]. 
 
Of note is the fact that apart from number of samples, the sampling time schedule is of 
critical importance during study design and has bearing on parameter precision as well. 
However, several researchers have proposed methods to optimize PK sampling schedules 
while designing a population study [9-11], and a thorough account of this aspect of 
optimal trial design is beyond the scope of the present research. It is assumed that optimal 
sampling time points for a given number of samples are pre-determined based on a 
previous method.  
 
As mentioned previously, we do not encourage the use of single trough sampling for 
population PK studies, in recognition of its limitations. With only single trough data, 
estimating volume parameters at all, let alone with good precision, is an unreasonable 
expectation. Previous research has shown that the bias in estimation may be higher with 
single trough sampling and that both between-subject as well as residual variability 
parameters together may not be well estimated [13]. However, there still are cases where 
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pediatric PK studies collect only single trough samples. At times practical restrictions, for 
instance anemia or other health conditions in pediatric patients would only permit single 
trough data to be collected. Further, large registration trials frequently collect only single 
trough PK samples.  Hence we incorporated this scenario in our simulations. Only 
clearance parameters may be estimated within the precision standard with reasonable 
sample sizes, given the assumption that prior information on the structural model is 
available. 
 
What is the impact of low, medium or high PK between-subject variability? 
PK variability is the predominant determinant of sample size as would be expected in any 
power analysis. This parameter may differ considerably across drugs. We explored three 
levels of between-subject-variability in order to generalize the methods to a wide range of 
drugs. With sophisticated analytical methods and assays available today, we do not 
anticipate the residual variability to be significantly high. Also structural PK models are 
seldom severely mis-specified. Hence we did not explore the impact of varying this 
parameter.  
 
What is the impact of including adult data for estimation? 
While designing a pediatric study, it is important to leverage prior information that may 
be available in the form of either adult data for the same drug in question, or as relevant 
adult or pediatric data from related drugs or indications. Most pediatric drug development 
programs occur after the drug is approved in adults. Hence during pediatric trial design, it 
is likely that a population PK model of the drug based on adult data would be available.  
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For the analysis, sparse pediatric PK data may then be combined with the rich adult data 
in order to estimate the relevant PK parameters in pediatrics. Hence inclusion of rich 
adult data is also an important consideration while designing pediatric studies.  
 
Rich adult data would additionally inform the structural model, leading to improved 
estimation precision. Accordingly, we did observe an increase in precision and lowering 
of pediatric sample size requirements, upon inclusion of adult data in the simulations. 
However, the concern with including rich adult data in design or analysis of pediatric 
trials would be the undue influence of the adult data on estimation, leading to perhaps 
falsely high precision, simply by virtue of the large possible adult sample size. This 
concern was addressed in our simulations. Importantly, we used a tdf,α statistic 
corresponding to only total pediatric sample size while constructing the 95% CI on 
parameter estimates, avoiding an undue impact of adult sample size on precision. We 
found a ceiling effect in terms of amount of adult data included. In most cases, rich data 
from 24 adults did not offer a pediatric sample size advantage over using rich data from 
12 adults. In the few cases this did happen, the gradient was reduced, and with more adult 
data (48 adults) there was no added benefit (results not shown).  
 
Both observations made with regard to adult data inclusion are useful. The first one re-
iterates the importance of using prior information where available, while the latter 
alleviates the concern of adult data driving the parameter precision and leading to 
unrealistically low pediatric sample size requirements.  
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What is the impact of the analysis method used? 
There could be different ways to assess whether the precision standard is met. For 
instance, in the case of clearance, one option is to estimate the population mean clearance 
for each pediatric age group to be studied while the other option could be to use the 
geometric mean of individual post-hoc clearance estimates, for each pediatric age group. 
Hence both analysis methods were explored. Given rich PK sampling, conventional 
NCA, which is a two-stage analysis method, is comparable with the post-hoc analysis 
approach used in our study. However, the body weight and age effect on post-hoc 
individual estimates were normalized while determining precision so as to make the 
precision assessment comparable with the population mean method. NCA and post-hoc 
methods yield similar sample size outcomes at equivalent variability levels. The 
population mean analysis was more precise and less biased than post-hoc analysis, which 
is in fact a merit of mixed-effects modeling. Thus, the population-mean or one-stage 
approach is the most powerful analysis method for pediatric data. 
 
What is the impact of i.v. vs. oral administration models? 
While an i.v. administration model is the simplest simulation template in terms of 
parameters, most pediatric drugs are oral formulations. Hence both scenarios were 
evaluated. However, since PK samples during the absorption phase would rarely be 
available in pediatrics we chose to fix the absorption parameters (KA and BSV_KA) 
based on adult values. Thus in terms of parameters estimated, the i.v. and oral scenarios 
were the same. The only difference was additional variability (50%) contributed to the 
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model by the KA parameter in the oral scenarios. As expected then, the outcomes and 
trends were similar for both i.v. and oral cases. 
 
Metrics used 
The quality standard specifies the 95% confidence interval (CI) rather than standard error 
(SE) for the precision standard. Using CI takes the combined effects of both SE and tdf,α 
into consideration for calculating precision. In case of small sample sizes (<30), which 
are commonly used for pediatric studies, this is an important consideration for precision, 
rather than using SE alone. Under an asymptotic normal distribution assumption, the 
precision standard specified would be equivalent to achieving a relative standard error 
(RSE) on the mean parameter estimate within 20%. In our study, we empirically 
constructed the 95% CI using model-generated SE estimates and tdf,α values 
corresponding to the pediatric sample size used, avoiding undue influence of adult data 
on precision. A non-parametric bootstrap would be the alternative way to construct the 
required 95% CI, but this technique would be computationally very intensive and was not 
considered justified for the scope of this study. 
 
The bank of virtual pediatric subjects generated may be considered the true population of 
interest for this study. Hence the non-parametric mean clearance and volume parameters, 
for each age group, derived from the bank were used as reference values or true mean 
estimates. These estimates matched well with the parametric mean estimates derived 
using the covariate models for clearance and volume with median demographic values, 
for each age group. Hence, we elected to use the same approach to determine the 
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population mean parameter estimates, for each age group, under the population mean 
analysis scenarios.  
 
Scenarios 
The aims of the study were to address the simulation methodology to design a pediatric 
trial, along with the impact of different trial design elements, while targeting the 
precision quality standard.  Hence a simple one-compartment PK model was used in the 
simulations. However, the methods used can also be applied for scenarios that differ 
based on the underlying PK model, the covariate model used, the dose administered or 
the number of and division into age bins, even though such scenarios were not explored 
in this study. Scenarios were chosen to assess the impact of what we believe are the key 
pediatric trial design elements. 
 
Conclusions 
The following are the salient findings of this research: 
1. Plan well at the design stage to ensure an informative pediatric trial.  
2. The PK quality standard of 60-140% precision with 80% power is practically 
feasible. Reasonable sample sizes are adequate to comply with the standard and it 
may be implemented using a simulation-based approach. 
3. Pre-determined optimal sampling times for a given number of PK samples per 
subject is important during trial design. 
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4. Use prior adult data or pediatric data for trial design and analysis, wherever 
possible. Inclusion of adult data will not unduly drive precision and sample size to 
achieve the quality standard.  
5. Use one-stage population mean analysis methods, with biologically plausible 
covariate models, for pediatric PK studies.  
6. Allometric and Emax-type age-effect covariate models are feasible to use in 
simulations, while designing pediatric trials to achieve the PK quality standard. 
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 CHAPTER 4  
Covariate models – do not center at values outside the data 
range 
 
 
ABSTRACT 
The purpose of this paper is to draw attention to a seemingly obvious concept during 
centering of covariate effects in a population analysis. A simulation-estimation platform 
with pediatric data was used to assess the impact of the choice of reference body weight 
value at which the body weight effect on clearance and volume parameters is centered. It 
was found that the reference value chosen for centering had implications for not only 
parameter interpretation but also their precision.  Absence of centering or in effect using 
1 kg as a reference value led to 20-30% lower mean precision than centering at the 
median of body weight range. In addition, centering at the upper end of the body weight 
range led to 5-10% lower mean precision than centering at the median. The results can be 
generally applied to all covariates underlining the recommendation that covariate effects 
should be centered at an appropriate value of the covariate. Usually, using the median of 
the covariate data range as the reference value will lead to most relevant interpretation of 
model parameters and highest possible precision. 
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INTRODUCTION 
While developing covariate models in population analyses, it is good practice to center 
the effect of a covariate on a model parameter at a particular reference value of the 
covariate in order to make the parameter interpretable.  It is perhaps a known issue, at 
least among modelers, that when centering is done at a value outside the present data 
range there could be instability in estimation and poor parameter precision. However, a 
systematic study that accounts this phenomenon has not been published previously and 
we believe it is of value to modelers in general. We used covariate models with body 
weight effect centered at different reference values to demonstrate two key implications 
of centering on: 1- parameter precision and 2- parameter interpretation. 
 
METHODS 
As part of a larger project, we conducted extensive simulation-estimation of pediatric 
data. A pediatric population was simulated in terms of demographics and 
pharmacokinetic (PK) observations under scenarios with increasing sample sizes. The 
parameters of the PK model were then estimated using the simulated data and precision 
and bias metrics for the estimates of mean systemic clearance and central volume of 
distribution were determined. For each sample size scenario, 250 replicate simulation-
estimations were carried out. 
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Nominal Design 
A single 100 mg/kg dose of a hypothetical drug was administered intravenously (bolus) 
to the simulated pediatric subjects. The drug follows one-compartment, dose-proportional 
PK and has a half-life of about 1.5 hrs. A sparse sampling schedule design with 3 samples 
per subject (0.1, 2 and 4 hrs) was employed. The different sample size scenarios used 
were 16, 24, 32, 48 and 72 pediatric subjects. 
 
Demographics 
We used a CDC database for the simulation of pediatric demographics that included age, 
gender and a relationship to determine body weight. Using this information we generated 
a bank of n=48000 unique virtual pediatric subjects. The subjects were divided into four 
age bins (1 mo to 2 yrs, >2 to 6 yrs, >6 to 12 yrs and >12 to 17 yrs) as is commonly done 
during recruitment in most pediatric clinical trials. The weight range of simulated 
subjects was 5 kg - 80 kg (median = 20 kg). For each scenario, the desired total number 
of subjects was randomly sampled from this bank of pediatrics, with equal number of 
subjects into each age bin. 
 
Simulation Models 
The one-compartment model used in the present study was parameterized in terms of 
total systemic clearance (CL) and volume of distribution for central compartment (Vc). 
The between-subject variability (BSV) of the model parameters was described using a 
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lognormal variance model. The allometric exponential covariate model was used to 
account for effect of body weight on both clearance and volume. 
iCLCL eWTTVCLCL alloii
η••=       … Eq. 1 
iVcVc eWTTVVcVc alloii
η••=        … Eq. 2 
where; ηCLi is the difference between individual (CLi) and typical value or population 
mean (TVCL) clearance on log scale, ηVci is the difference between individual (Vci) and 
typical value or population mean (TVVc) volume of distribution on log scale, alloCL and 
alloVc are the allometric exponents for the effect of individual body weight (WTi) on 
clearance and volume respectively. ηCLi and ηVci were both assumed to follow a normal 
distribution independent of each other, with mean of zero and variances of ω2CL and ω2Vc 
respectively. The residual error or within-subject variability (WSV) was described using 
a proportional error model as shown below: 
( )Cppredi CpCp ε+•= 1        … Eq. 3 
where; Cpi is the individual observed plasma concentration, Cppred is the individual 
model prediction and εCp is the residual error assumed to follow a normal distribution 
with mean of zero and variance of σ2Cp. 
 
The parameter values for the “true” one-compartment model and associated covariate 
effects used for simulations are listed in Table 1. 
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Table 1: The one-compartment model parameters used for simulations 
Parameter Value Units 
Mean Clearance 3.2 L/h/20kg 
Mean Volume 6.2 L/20kg 
BSV_Clearance  30 % CV 
BSV_Volume 30 % CV 
Residual error 10 % CV 
alloCL 0.75  
alloV 1  
 
BSV: between-subject variability; CV: coefficient of variation 
alloCL, alloV: allometric exponent for weight effect on clearance and volume respectively 
 
Estimation models 
For the current study, for every simulated replicate, three estimation cases were carried 
out, based on the centering of the body weight effect in the covariate model: 
• Case 1: Covariate effect not centered (effective reference value = 1 kg) 
• Case 2: Covariate effect centered at upper end of data range (reference value = 70 kg) 
• Case 3: Covariate effect centered at median of data range (reference value = 20 kg) 
Accordingly, one of the following three covariate models was employed: 
( ) CLalloCL iWTTHETATVCL •=       … Eq. 4 
CLallo
iCL WTTHETATVCL ⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛
•=
70
      … Eq. 5 
CLallo
iCL WTTHETATVCL ⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛
•=
20
      … Eq. 6 
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Correspondingly, covariate models were also applied for TVVc, using the alloVc 
parameter. All model parameters were estimated. 
 
Metrics 
We assessed the resulting precision and bias of mean parameter estimates (clearance and 
volume) for each replicate. The mean precision, power to achieve a target precision and 
mean bias, based on all replicates, were then computed for each sample size scenario.  
 
In accordance with a recent regulatory requirement of a precision standard on primary PK 
parameter estimates [1], we assessed precision as a %CV-like metric but in terms of 
upper bound of the 95% confidence interval (UCI) rather than standard error (SE). Using 
CI takes the combined effects of both SE and tdf,α into consideration which is important 
in case of small sample sizes (<30) that are commonly used for pediatric studies rather 
than considering SE alone. Thus, precision was defined as follows: 
100•⎟⎠
⎞⎜⎝
⎛=
Mean
UCIprecision        …. Eq. 7 
Values close to 100 for this ratio represent high precision (or small standard errors) while 
higher values, deviant from 100, represent more imprecision (or large standard errors). 
We determined precision on clearance and volume parameters for every replicate and the 
mean of this metric for all replicates was the “Mean Imprecision” for a particular sample 
size scenario.  
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In order to assess power, we used a pre-determined target on parameter precision, again 
based on the regulatory requirement [1], defined as precision ≤ 140%. Under an 
asymptotic normal distribution assumption, the precision target specified would be 
equivalent to achieving a relative standard error (RSE) on the mean parameter estimate 
within 20%. The proportion of replicates where the mean precision met the target was 
determined to be the power to achieve target precision for that sample size scenario. In 
order to construct the 95%CI, we used model estimated mean parameters and standard 
errors and a tdf,α statistic corresponding to the total pediatric sample size used at a 2-sided 
α =0.05.  
 
For the purpose of computing bias on the parameter estimates, the model parameters used 
for simulation (Table 1) were considered to be the “true” estimates. The percent deviation 
from the true value was the metric used, calculated as follows: 
100•⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
true
trueest
P
PP
bias        …. Eq. 8 
where; Pest is the estimated value of the parameter by fitting the model to the simulated 
data and Ptrue is the true value for the model parameter. 
 
Software 
We employed an R environment for the simulation-estimation platform with system calls 
to NONMEM. For the simulations, random numbers were generated using a six digit 
seed. The estimation method used was FOCEI. NONMEM version VI with Compaq 
Visual FORTRAN 6 compiler was used to conduct the simulations and estimations. R 
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version 2.9.1. was used to create the automated program script and carry out data 
manipulation and analysis.  
 
RESULTS 
Precision and bias of mean parameter estimates 
We found a dramatic improvement in the precision of the estimates of primary model 
parameters (mean clearance and volume) when the body weight effect in the covariate 
model was centered at the median (Case 3, reference value = 20 kg) as compared to at an 
extreme value outside the data range (Case 1, reference value = 1 kg). Absence of 
centering, or in effect using a 1 kg reference value, led to 20-30% lower mean precision 
and up to 85% lower power, than centering at the median of body weight range. The 
outcomes are less dramatic for centering at the upper end of the body weight range (Case 
2, reference value = 70 kg), which led to 5-10% lower mean precision and up to 6% 
lower power than centering at the median (refer Table 2). 
 
As we can see in Table 2, when body weight effect is centered at the median of the 
simulated data the precision on clearance and volume is high (100% power) at all sample 
sizes. However, when 1 kg is used for centering the mean precision is poor (<50%) at 
lower sample sizes and reasonable precision is obtained only at much higher sample sizes 
(n>50) than would be expected.  
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The bias in parameter estimates was unaltered by the choice of reference value used for 
centering body weight effect on clearance and volume. 
 
Table 2: Mean and power for precision on clearance and volume estimates in 
absence and presence of appropriate centering. 
 
       Reference Value = 1 kg Reference Value = 20 kg Reference Value = 70 kg 
Sample Size Mean Imprecision  Power Mean Imprecision  Power Mean Imprecision  Power 
  (%) (%) (%) (%) (%) (%) 
Clearance          
16 156 15 114 100 125 94 
24 149 22 112 100 122 98 
32 142 46 110 100 120 100 
48 136 78 108 100 116 100 
72 131 98 107 100 114 100 
           
Volume          
16 157 15 116 100 126 94 
24 150 15 115 100 122 96 
32 143 42 111 100 120 100 
48 137 74 109 100 117 100 
72 132 98 107 100 114 100 
 
Age range: 1 month – 16 years;   Body weight range: 5 – 80 kg 
Mean imprecision = (95% UCI/Mean parameter)•100;    
Power=% replicates where mean imprecision ≤ 140  
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DISCUSSION  
Impact of centering on parameter precision 
In most population analyses, the precision of model parameters, usually in the form of 
standard error (SE), is used as a diagnostic tool for the model. A lower SE indicates 
higher precision on parameter estimates, which is desirable and reflects well on the model 
itself.  
 
However, caution must be exerted while making this interpretation. The precision on a 
parameter estimate is sensitive to both, sample size and the available data range, and in 
turn to the reference value that a covariate effect is centered at. It is expected that any 
software will run into difficulties while estimating a parameter in a data range where little 
or no information is available. Hence, for instance, if a reference value of 1kg is used to 
model the body weight effect on primary parameters then the parameter estimate may be 
very imprecise because it will require the model to extrapolate to an extreme covariate 
range relative to the data present. However, if the sample size is sufficiently large, the 
imprecision may not be significant. Similarly, if centering at 70 kg (commonly used in 
adult population analyses) is applied while modeling pediatric data [2-4], then the mean 
parameter estimates could again have misleadingly lower precision because the observed 
data would be concentrated at a lower weight range than the reference value. 
 
Accordingly, as we found in Case 1, the precision on population mean clearance and 
volume estimates was unexpectedly poor (refer Table 2) for a population analysis given 
low between-subject-variability (30%) and residual variability (10%). We can attribute 
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the poor precision to inappropriate choice of centering at 1 kg, which is an extreme low 
value outside of the available of body weight range. In Cases 2 and 3 the parameter 
precision was as expected for a population analysis. However, Case 3 (centering at the 
median of the body weight range) had higher mean precision relative to Case 2 (centering 
at the upper end of the weight range). 
 
Thus, if a poor choice of reference value is made for centering a covariate effect, it may 
adversely affect the parameter precision. In turn, dosing decisions can potentially be 
affected - either if the parameter precision is subsequently used in simulations to derive 
dosing regimens, or by erroneously rejecting reasonable model parameter estimates based 
on precision. Some researchers use both mean parameter point estimate as well as 
precision to conduct simulations to derive dosing recommendations, and caution must be 
exerted while selecting reference values for centering covariate effects in such cases. 
However, the choice of centering is irrelevant when the allometric exponent is fixed to a 
constant during modeling or when sampling covariance between parameter estimates is 
ignored during simulation. 
 
We also found in our study that the choice of centering does not affect the overall model 
significance (OFV) nor the precision or significance of other covariate effects. We 
simulated a categorical covariate (gender) effect on clearance using a proportional model, 
along with body weight effect, and then estimated the gender effect using the three 
different reference values for body weight effect. Reference value had no impact on the 
precision or statistical significance of the gender effect. This result is expected since in 
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this case the gender effect parameter is estimated for all levels of body weight. However, 
in a case where a different mean clearance parameter is estimated for each gender and the 
determination of a significant gender effect depends on the difference between mean 
clearance estimates, and their respective precision (95% CI), an erroneous decision about 
gender effect may be made if inappropriate centering of body weight effect is used.  
 
Interpretation of parameter estimates 
The primary reason for centering covariate effects used in a population PK model is to 
make the model parameters interpretable. In our study, in Case 1, absence of appropriate 
centering limited the interpretability of resulting mean parameter estimates because 
according to the models used (Eq. 4) the parameters represented the mean clearance and 
volume for a non-existing individual weighing 1 kg. On the other hand in Cases 2 and 3, 
when centering of the body weight effect was done at realistic body weight values (Eq. 5 
and 6), the resulting model parameters were interpretable.  
 
Further, if a proportional model is used to incorporate a covariate effect, for instance age 
[5], according to the model depicted below (Eq. 9) then Aeff is a parameter that represents 
the effect of age on clearance and TVCL would be interpreted as the typical value of 
clearance for an individual with age = 0 years. Again, this is an unrealistic population 
mean clearance estimate that is not interpretable. The interpretation of model parameters 
becomes even more complicated when multiple covariates are involved for a single 
model parameter.  
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)1( ieffCL AgeATHETATVCL •+= •      … Eq. 9 
Hence it is good practice to center the individual covariate effects at a reference covariate 
value that would make the model parameter interpretable and plausible. The proportional 
model for age effect (Eq. 9) used above can be modified as follows to make TVCL 
meaningful: 
))50(1( −+= •• ieffCL AgeATHETATVCL      … Eq. 10 
TVCL now represents the typical value of clearance for an individual aged 50 years, 
which is a useful interpretation of the parameter since 50 years is a plausible age for an 
adult.  
 
For most relevant interpretability of model parameter estimates, the choice of the 
reference value to be used for centering covariate effects should depend not only on the 
range of covariates present in the data being analyzed but also the population of interest.  
For instance, in Case 2 in this study, 70 kg is a reasonable reference value for centering 
body weight effect in an adult population model but, in terms of parameter interpretation, 
not so suitable for pediatrics [2-4] or an adult obese population. Therefore, typically the 
median or mean of the covariate range in the data available serves as a good choice for 
the reference value [6-9]. In Case 3, the mean parameter estimates were for a 20 kg 
pediatric subject making their interpretation most relevant for the population of interest to 
this study. However, we do recognize that the advantage of using a uniform centering 
reference value for all populations is the convenience of comparing mean parameter 
estimates across all studies, pediatric and adult. 
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In some population PK analyses, model parameters may be expressed per kg (e.g. 
clearance is reported as L/h/kg), even when a centered model is used and the allometric 
exponent is not 1 [10;11]. Per kg parameter expression is also implied when centering of 
body weight effect is omitted [5;12]. Both these approaches not only limit the 
interpretability of the clearance parameter but can also lead to erroneously determining 
clearance values at higher body weights.  
 
Other covariate effects 
The choice of reference value for centering body weight effect in a population model is 
perhaps most critical since it is the most commonly used covariate. However, the same 
rationale applies to any continuous covariate used in the model. For categorical 
covariates too, a similar rationale holds true. For instance, in case of a categorical 
covariate with multiple levels, such as genotype, a mean clearance parameter for a 
particular genotype category may be estimated, along with different effect parameters for 
the remaining genotype categories. In such cases, the choice of genotype category for 
which the mean clearance parameter (or intercept) is estimated will dictate its precision. 
This is similar to choice of reference value for a continuous covariate. The genotype 
category with highest number of subjects in the available data will have a mean clearance 
estimate with highest precision. However, the precision of the different genotype effect 
parameters (or slope) remains independent of the choice of reference genotype category.  
The interpretation of a model parameter is also based on defining the reference covariate 
category (or typical population) that it represents. In case of genotype, it would perhaps 
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be most advisable to use the genotype with highest prevalence in the population of 
interest as the reference category. 
 
Conclusion 
Centering covariate effects used in population models is important. While doing so the 
choice of the reference covariate value at which its effect is centered is critical for both, 
model parameter interpretation and precision. However, interpretation and presentation 
may always be altered by re-parameterizing the model in terms of covariate values, as 
applicable for the circumstance at hand. The model applied for estimation may not 
always directly produce the parameters desired for interpretation. A final 
recommendation would be to use model parameterization that yields stable and precise 
estimation, and also parameters with relevant interpretation, for which the median or 
mean of continuous covariate data is an ideal choice.  
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CHAPTER 5 
A Genetics-based Pediatric Warfarin Dosing Regimen derived 
using Pharmacometric Bridging 
 
 
ABSTRACT 
The objective of this research was to derive a genetics-based pediatric dosing 
regimen for warfarin, including starting dose and titration scheme, using modeling and 
simulation. 
Whilst several algorithms have been suggested for warfarin dosing in adults, 
pediatric specific dosing algortims are absent. Even so, warfarin continues to be 
extensively used as an anticoagulant in the pediatric population. A model-based approach 
was used to arrive at a proposed pediatric dosing regimen that was based on warfarin 
dosing in adults and pharmacokinetic/pharmacodynamic (PK/PD) principles. Pediatric data 
on warfarin dosing and INR came from a study conducted at the Children’s Hospital of 
Los Angeles (CHLA). The dosing regimen targeted a major (≥ 60%) proportion of INRs 
within therapeutic range of 2.0-3.0, by week two into warfarin therpay. Simulataneously, 
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the target was to minimize bleeding and thromboembolic risk by minimizing the 
proportions of INR > 3.5 (to ≤ 10%) as well as those of INR < 2 (to ≤ 20%). The targets 
were set as used in adults as well as in pediatric studies. 
A 2-step pediatric starting dose is proposed based on body weight (<20 kg and ≥20 
kg) for each of 18 genotype categories, using differet possible combinations of individual 
CYP2C9 (*1/*2/*3) and VKORC1 (-1639 G>A) genotypes. The titration scheme involves 
percentage changes relative to previous dose, based on the latest patient INR. In 
simulations, the propsed dosing regimen performed better than the empricial dosing used 
in the CHLA patients, based on consistently maintaining target INR outcomes. To our 
knowledge, this is the first ever proposed dosing regimen for using warfarin in pediatric 
patients. However, the research is limited by the small sample size of available pediatric 
PK/PD data and absence of prospective validation of the dosing regimen. Hence 
prospective clinical studies with warfarin in pediatrics using the proposed dosing regimen 
are recommended. 
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INTRODUCTION 
Warfarin is the most widely used oral anticoagulant. It has been used for over 50 years in 
adults for the treatment and prevention of venous thromboembolism, pulmonary embolism, 
and thromboembolic events associated with atrial fibrillation, myocardial infarction, 
cardiac valve replacement and stroke [1;3;4]. The drug is currently not approved for 
pediatric indications [1]. Management of warfarin therapy is complicated owing primarily 
to two reasons – its narrow therapeutic index and high inter- and intra- individual 
variability in drug response. The individualized treatment goal is to maintain patient INR 
(international normalized ratio) within a therapeutic range, usually 2.0-3.0. Therapy 
involves potentially fatal thromboembolic risk at lower INRs and hemorrhagic risk at 
higher INRs [2-5].  
 
Various known warfarin pharmacokinetics (PK) and pharmacodynamics (PD) factors 
contribute to the observed INR variability. Figure 1 is a schematic of the PK-PD of S-
warfarin, the potent enantiomer in the raceimic warfarin product administered. Most 
importantly, polymorphisms in two genes – cytochrome p450 2c9 (CYP2C9) and vitamin 
K epoxide reductase c1 (VKORC1), which are involved in the PK and PD of warfarin 
respectively, have been shown to result in increased INRs and reduced warfarin dose 
requirements [3-10]. The variant alleles *2 and *3 in the CYP2C9 gene reportedly reduce 
warfarin clearance to about 30% and 15% respectively [4;8]. Patients with these variant 
alleles also require a longer time to achieve stable dosing, and are at a significantly 
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increased bleeding risk when compared with patients with the CYP2C9*1*1 (homozygous 
wild-type) genotype [6;11-13]. Multiple polymorphisms (such as -1639 G>A and 1173 
C>T) in the VKORC1 gene, which occur in linkage disequilibrium, have been shown to 
increase warfarin sensitivity by about 30-50% [13;14], reducing warfarin dose 
requirements. Collectively, the CYP2C9 and VKORC1 genotypes have been shown to 
account for approximately 45% of the variability in warfarin dose requirements 
[7;9;10;15;16]. At a clinical pharmacology advisory committee meeting of the U.S. Food 
and Drug Administration (FDA) in 2005, there was consensus on existence of sufficient 
mechanistic and clinical evidence to support lower doses of warfarin for patients with 
certain polymorphisms in CYP2C9 and VKORC1 genes [17]. Subsequently, the warfarin 
label was updated in 2007 to include recommendations to genotype subjects for CYP2C9 
and VKORC1 before initiating warfarin therapy and use lower doses accordingly [1]. 
Notably, the prevalence of the CYP2C9 polymorphisms in Caucasians is about 35% [18] 
and that of VKORC1 polymorphisms is about 40% in Caucasians and very high, i.e. about 
85%, in Asians [5]. Therefore, testing for these polymorphisms is being performed to 
guide dosing in adults, which may improve the clinical safety and efficacy of warfarin 
[11]. Additional influential factors for warfarin dosing include but are not limited to body 
weight, age, co-morbidities, drug-drug interactions (DDI) and diet. Extensive research has 
been undertaken in order to account for the impact of all these factors on warfarin therapy 
and several algorithms for dosing warfarin in adults have been proposed [7-
10;12;15;16;19]. 
 
Figure 1: PK-PD of S-warfarin 
 
PK: two-compartment model dose-proportional PK, metabolic clearance via CYP2C9 only 
PD: inhibition of synthesis of components of pro-coagulant complex activity (PCA) characterized using 
inhibitory Emax model; response measured as INR, a derivative of prothrombin time 
CL- clearance; V- volume of distribution; ka- first-order absorption rate constant; Cfree- free/unbound  
plasma drug concentration; EC50- drug concentration to elicit half maximal inhibitory response; ksyth- zero-
order rate constant for PCA production; kout- first-order rate constant for PCA degradation [42]. 
 
 
As far as pediatrics, even though not approved, warfarin remains the mainstay of oral 
anticoagulant therapy for patients with cardiovascular indications for prevention of 
thromboembolism [20-23]. Two distinct pediatric patient populations receive warfarin 
frequently; one are infants and young children with congenital heart defects who have 
undergone Fontan or other surgery, and second are the adolescent patients who have valve 
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replacement. Some other common pediatric indications requiring warfarin therapy include 
presence of central venous lines, congenital antithrombin deficiency, and cerebral 
thromboembolism. As in adults, the management of warfarin therapy is difficult in 
pediatrics and adverse effects are common [20;24;25]. The bleeding rate in pediatric 
patients on warfarin has been reported to be about 0.5% per patient year for major bleeding 
events and to range from 1.9-2.3% per patient year for minor bleeding events [25;26]. 
While major bleeding may occur even at warfarin doses considered therapeutic, serious 
hemorrhage risk has been shown to increase with increasing intensity of anticoagulation 
[27]. The occurrence of recurrent thromboembolic events in pediatric patients while still on 
warfarin therapy has been reported to range from 1.3-2.3% per patient year [25;26].  
 
Limited clinical studies of warfarin in the pediatric population have been conducted 
[26;28;29]. Body size and age have been suggested to have an influence on warfarin dose. 
Some researchers also propose a maturation effect on the fundamental activity of the 
human coagulation system [30;31]. In addition, the polymorphisms in CYP2C9 and 
VKORC1 genes have been shown to be associated with lower pediatric warfarin dose 
requirements [32-34]. It is intuitive that these genetic effects seen in adults would be 
similar in pediatrics given that the mechanism of action of warfarin, and the coagulation 
and drug elimination pathways, are the same in pediatrics and adults. 
However, all clinically available computer-based pharmacogenetic dosing algorithms for 
warfarin ignore considerations for pediatrics. In order to provide pediatric patients on 
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warfarin therapy with the pharmacogenetic advances that are now being integrated into 
adult care, it is important to develop and validate a pediatric warfarin dosing algorithm. 
Such an algorithm should integrate the impact of CYP2C9 and VKORC1 genotype with 
other factors (such as body size, ontogeny of PK-PD determinants, concomitant drugs) on 
warfarin disposition and effect in pediatrics.  A recent study reported enthusiasm among 
pediatric hematologists for trials to develop a pediatric warfarin dosing algorithm, 
incorporating pharmacogenetic effects [35]. However, patient recruitment problems have 
been a severe limitation to such trials [36]. The need for efficient, novel approaches to 
enable addressing pediatric warfarin dosing has been highlighted [35].  
 
The objective of the current study is to develop a genetics-based pediatric warfarin dosing 
regimen, including both starting doses and a titration scheme, which can be validated 
prospectively for pediatric patients. A pharmacometric bridging approach, using modeling 
and simulation along with limited available pediatric data have been used to assess the 
potential usefulness of the dosing regimen. The eventual goal is to establish a new standard 
of care for pediatric patients who require warfarin therapy via an optimal, validated dosing 
regimen that will guide clinicians for safer and more effective warfarin use in pediatrics. 
 
METHODS 
An attempt has been made to leverage all the information previosuly available for the data 
anlysis in this study, using efficient modeling and simulation methods. Prior information 
was available in the form of an accepted adult warfarin PKPD model [14] and warfarin 
dosing and INR information was available from a limited number of pediatric subjects 
from Children’s Hospital, Los Angeles (CHLA). Our research approach is outlined in 
Figure 2. Briefly, we derived a pediatric PKPD model using the prior adult PKPD model 
and knowledge of physiology. By physiology we refer to PKPD principles such as the 
relation between drug clearance and body size, the maturation pattern of drug metabolizing 
enzymes and the mechanism of action of warfarin. We then qualified the pediatric model 
using the CHLA data, which were not used for model derivation. Initial pediatric warfarin 
doses were estimated by matching target INRs for typical pediatric subjects with adults. 
The pediatric dosing regimen - starting dose and titration scheme - were then optimized 
using simulations of several thousand pediatric subjects. 
 
Figure 2: Outline of research approach employed 
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CHLA data 
Patients 
Data for the current study came from pediatric patients ≤ 18 years of age who were 
followed previously (within the last 1 year) and currently (during the study period) in the 
warfarin clinic of the Division of Cardiology, CHLA. Patients who had received warfarin 
for less than 7 days were excluded. This was an observational study with patients receiving 
standard of care warfarin therapy. The clinicians dosed and monitored patients as per their 
clinical expertise, with each patient treated on a case to case basis, depending on their 
condition and target INR. Warfarin dosing and INR logs (INR measurements across time) 
were recorded during regular scheduled visits to monitor warfarin therapy. Informed 
consent for study participation was obtained at one such routine visit along with a sample 
of 1.0 ml blood in addition to the routine blood draw. The blood sample was transported to 
the USC (University of Southern California) pharmacogenetics laboratory where genetic 
testing was done. A vitamin K dietary intake estimate was performed from a 1-3 day food 
diary. In addition to genotype and diet, data items collected were age, weight, height, 
gender, warfarin dose, INR, other medical illness or medications and adverse events. The 
information was obtained from the existing nurse coordinator's database and documented 
under the study ID number. 
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Genetic analysis 
Genomic DNA samples were extracted from blood samples using a genomic DNA 
extraction kit (QIAmp DNA Blood Mini kit, Qiagen, Mississauga, Ontario, Canada). The 
genotypes for the CYP2C9 *2 (rs1799853) and *3 (rs1057910) and the VKORC1 -1639 
G>A (rs9923231) SNPs were determined using real-time quantitative polymerase chain 
reaction assay based on the 5’ nuclease allelic discrimination assay (ABI PRISM 7900 
Sequence Detection System, Applied Biosystems, Foster City, California). Genomic DNA 
(10 ng) was mixed with 2.5 µL of gene specific primers and probes (10X concentrated) 
and 12.5 µL of polymerase chain reaction universal master mix (Applied Biosystems) to a 
final volume of 25 µL. Thermal cycler parameters included 10 minutes at 95oC and 50 
cycles involving denaturation at 95oC for 15 seconds and annealing/extension at 60oC for 1 
minutes. For quality control of genotyping, negative and positive controls were used 
whenever genotyping was performed. Distributions of the CYP2C9 and the VKORC1 
genotypes were compared to the Hardy-Weinberg theoretical distribution using the chi 
square test. A p-value less than 0.05 was considered statistically significant. 
 
Pediatric warfarin model: derivation & qualification 
Prior adult model 
Previosuly, a group at the FDA in collaboration with Harvard Partners, Boston MA has 
developed a warfarin population PKPD model and dosing scheme in adults [14]. The adult 
model was based on published research on the concentration-effect relationship for 
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warfarin [8;42] as well as data from an adult warfarin trial, CROWN (creating an optimal 
warfarin dosing nomogram). The model was built using data from an initial 271 subjects 
and subsequently validated in the same trial by using model-derived dosing in 117 subjects 
(unpublished results). In the current study, a pediatric warfarin population PKPD model 
was derived using the adult model and mechanistic reasoning.  
 
Pediatric PK model 
The adult PK parameters were first scaled to account for body size effects in pediatrics. A 
covariate effect for body weight was included in the pediatric model, using previously 
published and widely accepted allometric scaling principles [37;38]. A body weight effect 
with allometric exponent of 0.75 was included on systemic and inter-compartmental free 
clearances while that with an exponent of 1 was included for the central and peripheral free 
volumes of distribution. Next, the impact of maturation on free warfarin clearance was 
accounted for, using age as a covariate. The age effect on free clearance in the model is 
based on a relationship previously developed for the maturation of CYP2C9 using warfarin 
pediatric data [39]. According to the model used, CYP2C9 enzyme activity increases with 
age and attains maturity by the age of 2-3 months. Finally, effects of the CYP2C9 
genotype (variants *2 and *3) on clearance were included in the model as estimated for 
adults [8]. These values came from a clinical PKPD study in 150 adult patients on warfarin 
that included subjects of all relevant polymorphic CYP2C9 genotypes. 
 
Between-subject variability in our pediatric PK model was described for three model 
parameters - clearance, central volume, and peripheral volume, using a lognormal 
distribution. The total plasma drug concentrations were corrected for plasma protein 
binding, which is reported to be 99% [1], in order to achieve free plasma drug levels. The 
following equations describe the PK model we used: 
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where; ηCLi is the difference between individual (CLi) and population mean (TVCL) 
clearance on log scale, ηVci is the difference between individual (Vci) and population mean 
(TVVc) central volume of distribution on log scale, ηVpi is the difference between 
individual (Vpi) and population mean (TVVp) peripheral volume of distribution on log 
scale, Qi and TVQ are the individual and population mean inter-compartmental clearance, 
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ely. 
CYPeff is the covariate parameter that accounts for the effect of CYP2C9 genotype on 
clearance, WTi and Agei are individual body weight and age and Cp, Cpfree and fu are 
total, free and fraction unbound plasma drug concentrations of S-warfarin. ηCLi, ηVci and 
ηVpi were all assumed to follow a normal distribution, independent of each other, with 
mean of zero and variances of Ω2CL, Ω2Vc and Ω2Vp respectiv
 
The pediatric model assumes that immature CYP2C9 clearance is not saturable at 
therapeutic warfarin concentrations. Plasma protein binding was assumed to be unaffected 
by maturation. The model does not account for the impact of drug-drug interactions and 
dietary vitamin K on warfarin PK. 
 
Pediatric PD model 
There is no published study that establishes the concentration/dose-response relationship 
for warfarin in the pediatric population. This relationship is assumed to be similar in 
pediatrics and adults for pediatric PD model derivation. The assumption is based on two 
reasons. First, the mechanism of action of warfarin is the same for pediatrics and adults, 
namely inhibition of synthesis of vitamin K dependent clotting factors in the liver, and 
drug response in both populations is measured clinically as INR. Second, the 
concentration-response relationship has been shown to be similar between pediatrics and 
adults for other anticoagulants, namely argatroban [40] and heparin and low molecular 
weight heparin [41]. While these drugs have a different mechanism of action than warfarin 
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and their response is measured in terms of aPTT, the net effect is on clotting factor activity, 
much as for warfarin. Hence, in absence of pediatric specific warfarin PD data, the adult 
PD model [14] for warfarin was used for pediatrics as well.  
 
Warfarin exerts anticoagulation by inhibiting synthesis of vitamin K dependent clotting 
facttos, which results in a decrease in total clotting factor complex activity (PCA). This 
effect is measured clinically as a subsequent increase in prothrombin time (PT). The INR is 
a standardized measurement of PT, accounting for variations in lab reagents. The PD 
model used describes an inhibitory effect of warfarin on INR degradation rather than on 
synthesis of PCA. Given the inverse relationship between PCA and INR, and the fact that 
the clinical response to warfarin therapy is measured as INR, such a representation of the 
effect of warfarin is both logical and intuitive.  
 
The PD effect in patients is driven by free drug levels and hence protein-binding corrected 
plasma drug concentrations are used in the model. According to the model (Eqn. 6), INR 
change is dependent on previous INR, free warfarin plasma concentration (Cpfree) and drug 
potency (EC50), which may be defined as the drug concentration required for half maximal 
inhibitory effect. Patient sensitivity to warfarin, which is dependent on VKORC1 
genotype, was captured as differing potency of the drug (EC50VKOR) to elicit the same 
response in subjects with different genotypes. 
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Between-subject variability in our pediatric PD model was described for three parameters - 
Kin, Kout, and EC50VKOR, using a lognormal distribution. The measurement error on INR 
was accounted for using an additive error model. The following equations describe the PD 
stochastic models used: 
iKini eTVKinKin
η•=        … Eqn. 7 
iKouti eTVKoutKout
η•=        … Eqn. 8 
iVKORECVKORiVKOR eTVECEC
505050
η•=     … Eqn. 9 
INRpredobs INRINR ε+=        … Eqn. 10 
where; ηKini is the difference between individual (Kini) and population mean (TVKin) 
synthesis rate constant for INR on log scale, ηKouti is the difference between individual 
(Kouti) and population mean (TVKout) degradation rate constant for INR on log scale, 
ηEC50VKORi is the difference between individual (EC50VKORi) and population mean 
(TVEC50VKOR) VKORC1 genotype-dependent warfarin potency on log scale and INRε  is 
the difference between observed (INRobs) and model-predicted (INRpred) INR. ηKini, ηKouti, 
ηEC50VKORi and INRε were all assumed to follow a normal distribution, independent of each 
other, with mean of zero and variances of Ω2Kout, Ω2Kin, Ω2EC50VKOR and σ2INR respectively. 
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Pediatric model qualification 
The prediction capability of the derived pediatric population PKPD model was qualified 
using CHLA pediatric data. Data were used from only those subjects whose CYP2C9 and 
VKORC1 genotypes and INR log information were available. We first predicted individual 
CHLA patient INRs using our model, based on only the demographic and warfarin dosing 
information from the CHLA data. 200 replicate simulations were performed for each 
CHLA subject’s set of demographic and dosing data, to generate a distribution of predicted 
INRs across time. For the validation simulations, INR distribution was truncated within 
values 1.0-6.0. Thus, we generated 5th, 50th and 95th INR prediction percentiles, for each 
CHLA subject over time. This step was blinded to the INR data from the CHLA study. 
Next, we overlaid the observed INR-time profiles for each subject from the CHLA trial 
onto the model INR prediction percentiles. If about 90% of a subject’s INR observations 
fell within the 5th and 95th percentiles, the model predictions were considered reasonable. 
The proportion of subjects where model predictions matched reasonably well with INR 
observations were determined to qualify the model’s prediction capability. 
 
Optimal pediatric dosing: clinical trial simulations 
The pediatric PKPD model was employed to investigate optimal warfarin dosing using 
clinical trial simulations. The aim was to optimize INR outcomes to clinically reasonable 
targets. Figure 3 is a schematic representation of the simulation process. For purposes of 
deriving starting dose, each genotype category was treated independently. Given all 
possible combinations of genotypes for CYP2C9 (*1*1, *1*2, *1*3, *2*2, *2*3 or *3*3) 
and VKORC1 (GG, GA or AA), we had 18 unique genotype categories. 
 
Broadly, a two-step approach was used for determining optimal dosing. In the first step we 
narrowed the starting dosing choices based on deterministic simulations in typical subjects 
within each genotype. The second step comprised of performing stochastic simulations to 
derive the best starting and titration dosing. 
 
Figure 3: Clinical trial simulations schematic 
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Demographics  
We used a CDC (center for disease control and prevention) database for the simulation of 
pediatric demographics that included age, gender and weight. The database contained ages 
from birth-20 yrs, in increments of 1 month, yielding 240 unique ages. For each unique 
combination of age and gender there is a parameter set, including a variability component, 
to determine the distribution of body weight. We simulated 100 individuals of different 
body weight for each combination of age (1 month - 17 years) and gender resulting in a 
virtual bank of about 48000 unique virtual pediatric subjects. For preliminary simulations 
we considered six typical pediatric subjects, covering the entire pediatric demographic 
range. The six typical subjects represent the mean body weight and age, obtained from the 
virtual bank, for five different body weight/age groups. The typical demographics were: 
5kg/1month; 8kg/6mo; 11kg/1.5yrs; 16kg/4yrs; 28kg/9yrs; 54kg/15yrs. For final 
simulations, subjects were randomly sampled from the virtual bank of pediatrics. 1000 
pediatric subjects for each genotype category were simulated.  
 
Initial pediatric dosing: mean simulations 
In the initial step, the target was to match warfarin INRs in typical pediatric subjects with 
adults. Body weight based dosing (mg/kg/day) was considered suitable for pediatrics. 
However, given the body-weight clearance relationship is not linear; the mg/kg dose is 
expected to be different across different body weight groups (lower for subjects with 
higher body weight). Thus one consideration was to arrive at a reasonable number of 
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dosing steps by body weight level. We also considered the need to adjust dosing steps 
based on age group. For the mean simulations all sources of variability in the pediatric 
model were disregarded. INR outcomes were simulated for the first 30 days of warfarin 
therapy. 
 
Initial estimates of starting dose (mg/kg/day) for each of the six typical pediatric subjects 
were derived for each genotype category. Adult starting doses and our pediatric covariate 
model for clearance [8;14] were used for this purpose. Then using the initial pediatric dose 
estimates we simulated INR outcomes for the average subject, within each genotype 
category. The starting dose was adjusted to target, on an average, an INR of 2.5 and/or to 
match the INR-time profile for typical subjects with that of adults. Doses that rendered 
mean INR-time profiles closest to the target were considered for the full-fledged stochastic 
simulations.   
 
Final pediatric dosing: stochastic simulations 
The next step was to perform stochastic simulations in order to optimize the pediatric 
dosing scheme for the entire population. For these simulations all sources of variability 
were included in the model, namely, demographic variability, between-subject PK and PD 
variability and INR measurement error. For each genotype category, the dosing aim was to 
target a high (≥ 60%) proportion of INRs within therapeutic range of 2.0-3.0, by week two 
into warfarin therpay. Simulataneously, the target was to minimize bleeding and 
thromboembolic risk by minimizing proportions of INR > 3.5 (to ≤ 10%) as well as 
proportions of INR < 2 (to ≤ 20%). While week 2 (14 days) into therapy was considred the 
primary time end-point, the INR outcomes through month 1 (30 days) were evaluated for 
all dosing regimens tested. The target clinical outcomes (depicted in Figure 4) are  based 
on those used commonly in pediatric patients on warfarin [20;24;26;28;29] as well as those 
desired in adults, as per the expertise of the CROWN trial clinicians [14]. 
 
The starting dose as well as titration scheme were optimized as an iterative process, 
assessing the target INR outcomes for all genotype groups. INR monitoring (and dose 
titration) in our simulations was performed twice a week, as is done in regular clinical 
practice. Simulations were performed for first 30 days of warfarin therapy. For the final 
propsed dosing regimen INR outcomes through 90 days of warfarin therapy were also 
simulated. 
 
Figure 4: INR target outcomes for pediatric dose optimization 
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Initially genotype-independent dosing was compared with genotype-based dosing. In the 
former case, all subjects were given the same body weight adjusted doses as determined 
for the CYP2C9*1*1 and VKORC1 GA genotype. In the latter case, dosing was as per our 
proposed regimen – subjects with different genotypes were given different body weight 
adjusted doses. Comparisons were made with regard to target INR outcomes for all 
genotype categories. 
 
The proposed dosing regimen was then compared with the empirical dosing as used in 
subjects in the CHLA study. For the proposed dosing target INR outcomes were as 
previously defined (Figure 4). However, for the CHLA dosing since the target INR varied 
across patients, outcomes were in accordance with individual patient target INR range. To 
maintain consistency with INR outcomes used for the proposed dosing, sub-therapeutic 
INRs for CHLA dosing were those below the lower limit of the patient’s target therapeutic 
INR range while supra-therapeutic INRs were considered at 0.5 value above the upper 
limit of the target range.   
 
Finally, we also evaluated the impact of restricting doses proposed by our regimen to 
available strengths of warfarin formulations, on the target INR outcomes. The lowest dose 
that is currently feasible to administer to pediatric patients in warfarin clinics is 0.5 mg.  
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Software 
Trial Simulator version 2.2.1 by Pharsight® was used for the mean and stochastic 
simulations, while determining pediatric doses. NONMEM version VI with Compaq 
Visual FORTRAN 6 compiler was used for simulations during model validation. For 
NONMEM simulations, random numbers were generated using a six digit seed. R version 
2.9.1 was used for data processing, data analysis and graphics generation. The NONMEM 
model used is given in Appendix B. The drug model set-up in clinical trial simulator is 
given in Appendix C. 
 
RESULTS 
CHLA Data 
A total of 36 pediatric subjects were included in the CHLA study. Of these, 10 subjects 
were missing genotype and/or INR log data. We were able to use data from 26 pediatric 
subjects for model qualification. Cohort demographics are provided in Table 1. The mean 
age of subjects was 4yrs 5mo (range 4 mo-18 yrs) and mean body weight was 23 kg (range 
6.9-84 kg). The cohort included a wide range of body weight but only one subject with age 
< 6 months. While there were a fair number of subjects with the VKORC1 polymorphisms 
in the study cohort, the CYP2C9*2 polymorphism was rare and the *3 polymorphism was 
absent. There were three sub-groups in terms of target INR range, which was dependent on 
indication for warfarin therapy. 
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 Table 1: Description of cohort of pediatric subjects from CHLA 
Characteristic Mean (range) or Number (%) 
Age (years) 4.4 (0.33-18) 
Body weight (kg) 23 (6.9-84.1) 
Height (cm) 107 (65-189) 
BSA 0.81 (0.36-2.1) 
Warfarin maintenance dose (mg/kg/day) 0.12 (0.04 - 0.3) 
Gender: 
Male 
Female 
 
16 (61%) 
10 (39%) 
Race: 
Hispanic 
Caucasian 
African American 
Mixed 
 
16 (61%) 
7 (27%) 
2 (8%) 
1 (4%) 
Target INR: 
1.5-2.5 
2.0-2.5 
2.5-3.5 
 
13 (50%) 
5 (19%) 
8 (31%) 
Indication: 
Valve replacement 
Fontan procedure 
Kawasaki 
Cardiomyopathy 
 
8 (31%) 
12 (46%) 
5 (19%) 
1 (4%) 
CYP2C9 genotype: 
*1*1 
*1*2 
*1*3 / *2*2 / *2*3 / *3*3 
 
22 (85%) 
4 (15%) 
0 
VKORC1 genotype: 
GG 
GA 
AA 
 
7 (27%) 
8 (31%) 
11 (42%) 
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A wide range of doses (0.5-6.5 mg/day) were used in the pediatric subjects by the 
clinicians in the CHLA study. Starting doses in particular ranged from 0.5-5 mg/day. The 
dosing and titration choices did not follow a specified algorithm. For instance, two 
comparable patients weighing 16 kg, with target INR 1.5-2.5, were started on doses of 0.5 
mg/day and 1.5 mg/day, respectively. Further, in case of two patients with target INR 2.5-
3.5, during monitoring at an INR of 1.4 on day 5, one patient was given a 20% increase in 
dose while the other didn’t receive any dose change.  
 
The patient charts reveal that adherence to dosing assigned was poor in 4 subjects and 
prolonged times (> 60 days) were needed to arrive at stable dose in 12 (46%) subjects. The 
median time to achieve stable INR was 137 days. There were 4 major bleeding and 6 
minor bleeding events during the study.  
 
Pediatric warfarin model 
The parameters of the pediatric model that we derived and used for clinical trial simulation 
are shown in Table 2.  
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Table 2: Parameters of the warfarin pediatric population PKPD model used to 
predict CHLA data and to optimize dosing. 
Parameter Value (*for a 20 kg subject) Variability 
PK: two-compartment model 
TVCL 0.1207 L/h* 30 %CV 
CYPeff 
*1*1 
*1*2 
*1*3 
*2*2 
*2*3 
*3*3 
 
100% 
68% 
55% 
28% 
31% 
15% 
 
TVVc 3.45 L* 24 %CV 
TVVp 1.65 L* 98 %CV 
TVQ 0.05 L/h*  
Allometric exponent 
for weight effect on: 
CL and Q 
Vc and Vp 
 
0.75 
1 
 
Ka 2 /h  
Bioavailability 50%  
Unbound fraction 1%  
PD: sigmoidal Emax indirect response model 
Kin 0.01953 /h SD = 0.005 
Kout 0.01698 /h SD = 0.005 
EC50VKOR 
GG 
GA 
AA 
 
3.953 μg/L 
3.075 μg/L 
2.547 μg/L 
SD = 0.783 
 
INR residual error  SD = 0.586 
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 The model qualification outcomes for all 26 subjects are presented in Figure 5. The 5th, 
50th and 95th perrcentiles of INR predictions by the model and observed INR values from 
the CHLA subjects are shown. In about 80% cases (20/26) the observations lay moreover 
within the 95% prediction intervals. No particular genotype, age or body weight group was 
associated with cases where the model did not predict the INR time profile well. However, 
in case of the only two African-American subjects present in the cohort, the model fails to 
capture the INR profile well. Based on these results, the model was considered reasonable 
for use in subsequent simulations to determine an optimal warfarin dosing regimen for 
pediatrics.  
 
 
 
 
Figure 5: Model qualification outcomes: predicted and observed INR over time 
P5, P50, P95 – 5th, 50th (median) and 95th percentile model predicted INR. 
OBS – CHLA subjects observed INR 
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Initial pediatric dosing – typical subjects 
The simulated INR-time profiles for the typical subjects for four representative genotype 
categories are presented in Figure 6. Based upon these profiles, as well as the clearance-
body weight relationship for warafrin as per our model, we found the need to use two 
different mg/kg doses for higher (≥ 20 kg) and lower (< 20 kg) body weight subjects, 
within each genotype category. We did not find the need to alter mg/kg dose based on an 
age cut-off. The selected initial dosing scheme allowed for targeting an INR of 2.0-2.5, 
on an average, for all genotypes and moreover matched the average adult INR profiles.   
 
Figure 6: INR vs. time profiles by genotype for mean simulations – initial dosing 
scheme for typical subjects. 
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Final pediatric dosing – population 
For the stochastic simulations, the results were evaluted in terms of the target INR 
outcomes across time. We refined the starting dose from the initial doses derived for 
typical subjects, as suitable for each genotype category. We also made minor 
modifications to the titration scheme from that suggested for adults [14]. Thus, we 
derived an optimal pediatric warfarin dosing regimen, inclusive of starting dose and 
titartion scheme to maximize desired INR outcomes. Our final proposed dosing regimen 
is given in Table 3. 
 
Table 3: Final proposed pediatric warfarin dosing regimen – starting dose and 
titration scheme 
 
 
The comparison of INR outcomes for genotype-independent and genotype-based dosing 
are displayed in Figure 7, for four representative genotypes. The genotype-independent 
dosing results in progressively worse outcomes (dramatic increase in proportions of 
INR>3.5) as the number of variant CYP2C9 or VKORC1 alleles increases. 
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Figure 7: Comparison of genotype-based and genotype-independent dosing on 
patient INR outcomes across time. 
 
 
 
 
The comparison of INR outcomes between CHLA dosing and our proposed genotype-
based dosing are displayed in Figure 8 for all (six) genotypes present in the CHLA data. 
There were vast differences in outcomes between genotype categories under CHLA 
dosing. 
 
In case of genotype *1*1-GG (homozygous wildtype for both genes) the proportions of 
INR within target therapeutic range were high (60%) at week 2, with the CHLA dosing. 
However, there is a decline in this proportion and an increase in proportions of supra-
therapeutic INR (to 20%) through month 1. In case of the other extreme end of genotype 
*1*2-AA (heterozygous variant for CYP2C9 and homozygous variant for VKORC1) 
while the proportions of INR within target therapeutic range were again high (60%) at 
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week 2, there is a sharp decline in this proportion (to 30%) and an increase in proportions 
of supra-therapeutic INR (to 50%) through month 1. In contrast, with the proposed 
dosing, both therapeutic and supra-therapeutic INRs are consistently around 60% and 
10% respectively through month 1.   
 
In case of the remaining, intermediate genotype categories, the proportions of INR within 
target therapeutic range were much lower (10-40%) at week 2 with CHLA dosing and 
remain lower (upto 45%) through month 1, relative to the proposed dosing (60%). As far 
as supra-therapeutic INR proportions, there is again an increase observed through month 
1 (up to 10- 30%), in all cases. Notably, the proportions of sub-therapuetic INR at week 2 
were much higher (40-90%) with CHLA dosing and remain considerably high (20-50%) 
through month 1, relative to the proposed dosing (< 20%). 
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Figure 8: Target INR outcomes across time with CHLA standard of care dosing and 
proposed dosing regimen. 
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Finally, we report the simulated INR outcomes for all genotype categories using our 
proposed dosing but having imposed restrictions of available warfarin formulation 
strengths. Here, the lowest dose administered and all dose changes (increase/decrease) 
during the titration were limited to a minimum of 0.5 mg. The INR outcomes for four 
representative genotypes are displayed in Figure 9. As expected, proportions of INR >3.5 
increase sharply as the number of variant CYP2C9 or VKORC1 alleles increases. This is 
because the doses administered tend to be higher than those proposed for certain 
genotypes owing to the formulation strength limitations for low dose requirements.   
 
Figure 9: INR outcomes across time with proposed warfarin dosing and formulation 
restrictions. 
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DISCUSSION 
There are two primary contributions of the current study:  
1- A proposed scientifically based pediatric warfarin dosing regimen that can be 
reproduced across clinical settings. 
2- A tool that can be used by clinicians/researchers to arrive at an optimal pediatric 
warfarin dosing regimen, should INR outcomes be targeted other than those used in the 
current study.  
The research, in a nutshell, involved leveraging prior information in the form of adult 
warfarin data, extensive research on warfarin pharmacokinetics and pharmacodynamics 
and physiology to meet a clinical need. Pharmacometric methods were employed to 
bridge an adult model and dosing regimen to develop a pediatric warfarin model and 
propose a dosing regimen. The most relevant aspects of the research are discussed 
further. 
 
Pediatric model qualification 
In perspective, a warfarin population PKPD model built with adult data was appropriately 
scaled for a pediatric population and used to predict INR outcomes over time for pediatric 
patients on warfarin. The INR outcomes were predicted well in about 80% of the patients, 
given limitations in sample size, covaraiate distributions and individual therapeutic INR 
targets. The mechanisms that the model represents are supported by 
pharmacological/physiological knowledge. The allometric and maturation models used 
for scaling PK parameters from adults to pediatrics are those proposed and/or widely 
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accepted in the literature. Thus, the pediatric model appears useful based on physiology, 
consistency with adult data, and predictive ability in limited pediatric data. 
 
Having said that, the available CHLA pediatric data represented limited CYP2C9 
genotypes. *1*2 was the only genetic polymorphism present in the subjects. In the 
general Caucasian population the prevelance of *1*2, *1*3, and *2*2/*2*3/*3*3 are 
20%, 10% and 5% respectively. In addition, there were no subjects aged < 2 months in 
order to assess the validity of the CYP2C9 maturation model used for pediatric clearance. 
 
The model makes predictions for the typical subject with a given set of covariates having 
fixed effects and assumes compliance with dosing regimen. However, an important 
concern that contributes to INR variability and is difficult to quantify is patient adherence 
to dosing regimen [2]. In fact, the INR logs of some of the patients where the model 
appeared unable to predict INR well did reveal poor protocol adherence and exceptional 
difficulty in achieving stable INR. In most cases, the model predictions follow the dosing 
patterns (constant or increasing dose) but INR outcomes are counter-intuitive (decreasing 
or steady). Such observations are classic cases of non-compliance with warfarin therapy.  
 
The model also tended to over predict the INR outcomes for both the African-American 
subjects present in the cohort. It is known that subjects of the black race have a lower 
sensitivity to warfarin, requiring higher doses, owing to certain genetic polymorphisms 
that were not included in the current model. Hence this observation is not surprising but 
may also be confounded by non-compliance. In addition, particularly in case of 
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pediatrics, diet can have an influence on INR to a greater extent than captured by the 
unexplained variability model parameter. These aspects may have led to subjects in the 
CHLA study straying from their predicted INR profile. 
 
Initial pediatric dosing 
The mean simulations led us to conclude that two weight bins with different mg/kg doses, 
for all genotypes, would result in desired INR profiles on an average. In addition, given 
that 18 different starting doses are already required based on genotype, we found it to be 
of practical convenience to have a 2-step dosing regimen based on body weight. There 
has been speculation about an impact of age in regard to the wide observation that 
younger children require higher mg/kg warfarin doses than older children and adults, and 
uncertainty has been expressed about the underlying mechanism [20;26;28;29]. However, 
we would like to point out that this is neither an unexpected observation nor a 
consequence of an age or maturation effect. It is an expected outcome based on the nature 
of the clearance-body weight relationship for the drug. The slope of the relationship is 
steeper at the lower weight range, which are mostly younger children, and gets shallower 
at the higher weight range, which are mostly older children. Hence per kg dose is higher 
for younger, or rather lighter weighing, pediatric subjects. Accordingly, for all genotypes 
we have proposed a smaller mg/kg dose for subjects weighing ≥ 20 kg and a higher dose 
for subjects < 20 kg. Notably, the absolute doses (in mg) administered to heavier children 
would still be higher than absolute doses given to lighter children.  
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Final pediatric dosing 
Based on our pediatric warfarin PKPD model, it is expected that genotype would have a 
significant effect on warfarin clearance and INR response, and thereby on required doses 
for target INR. In the simulations, assuming everyone to belong to the same genotype 
category (CYP2C9*1*1/VKORC1-GA) for dosing purposes resulted in adverse INR 
outcomes, particularly for the homozygous variant genotypes (*2/*3 and AA). Between 
the CYP2C9 (PK) and VKORC1 (PD) genetic effects, the polymorphisms altering PK 
had the most significant impact on dosing. There are two reasons for this; first, the 
homozygous variant CYP2C9 variant genotypes *2*2, *2*3 and *3*3 had a large 
magnitude of effect (-70 to -85% on clearance) relative to the VKORC1 homozygous 
variant genotype AA (-35% on potency). Second, warfarin dose is titrated by monitoring 
INR, the PD response, and not the drug concentrations which reflect PK. Hence adjusting 
starting dose based on genotypes relevant for PK is most crucial. Patients with the 
*2*2/*2*3/*3*3 genotypes have prolonged warfarin half-life (3-6 times longer than 
*1*1) and the starting dose needs to account for this effect. For patients with genetic 
polymorphisms, outcomes at week 3 or 4 into therapy are more clinically relevant than 
week 2. While all results have been presented for only four or six (of eighteen) genotype 
categories, the conclusions for all scenarios tested remain the same for all genotypes. 
 
In the CHLA study, the target INR range of 2.5-3.5 used for patients with valve 
replacement matches with that reported in the literature. However, the choice of target 
INR 1.5-2.5 and 2.0-2.5 for patients undergoing Fontan procedure or diagnosed with 
Kawasaki are different from that reported widely in the literature [20;24;26;28;29]. 
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Hence for the proposed dosing the commonly accepted and employed target INR range of 
2.0-3.0 was selected, to maintain consistency with the literature and to generalize the 
outomes to most settings. However, the modeling and simulation tool developed can be 
employed to derive rational pediatric warfarin dosing for optimizing clinical outcomes in 
terms of any other target INR range or even another INR end-point, if desired. 
Comparison of the CHLA warfarin dosing with our proposed genetics-based dosing 
regimen on individual target INR outcomes reflects the erratic nature of pediatric 
warfarin dosing practices, and the need for a uniform dosing regimen. The dose and 
titration choices used in the CHLA study were independent of patient genotype and did 
not follow a specific, reproducible algorithm. This is common practice for pediatric 
warfarin dosing. Granted the dosing decisions are based on clinical experience, but this 
would vary considerably across clinicians and institutions. The first clinical problem with 
current dosing practices, such as those used in the CHLA study, is that even if good INR 
control is obtained (which was not common in the study) the dosing employed cannot be 
reproduced in another setting. The second problem is their moreover empirical nature. 
Hence a rational, uniform dosing regimen that can be replicated across patients and 
clinics is required.  
 
While INR control was fairly good initially for the *1*1-GG and *1*2-AA genotype 
groups with the CHLA dosing, there was an increase in supra-therapeutic outcomes 
across time, and significantly so for *1*2-AA, which indicates sub-optimal starting dose 
and/or titration scheme. The INR control was poor for the remaining genotype groups. 
Their INR outcomes in general reflect clinician attitude to be conservative with warfarin 
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therapy. In several cases, the INRs tend to remain in the sub-therapeutic range through 
even a whole month into therapy. This is because there is grave concern, perhaps more so 
in pediatrics, of overdosing leading to bleeding events. As a result though, the 
proportions of INRs within the therapeutic window were lower than ought to be targeted. 
However, while supra-therapeutic INRs remain well below 10% initially, the trend was 
for these to increase significantly over time, more so in patients with genetic 
polymorphisms. Thus despite the general conservative dosing, lack of an appropriate 
starting dose and/or a rational and consistent dose titration scheme can lead to several 
cases with risky supra-therapeutic INRs after first couple weeks into warfarin therapy. 
 
Based on simulations, we consider our dosing regimen superior to that used in the CHLA 
study, which may be regarded as the current standard of care. Our regimen succeeded 
over empirical dosing in maximizing targeted INR outcomes consistently throughout the 
first month into warfarin therapy. We also expect to see similar results should these 
dosing regimens be compared in a clinical trial. 
 
Finally, we make a case for the need for a suitable pediatric warfarin formulation. From 
our simulations it is clear that limiting the lowest dose administered and smallest possible 
dose change to 0.5 mg is not advisable for pediatric subjects, particularly those with 
homozygous CYP2C9 and/or VKORC1 polymorphisms. In addition, the oral tablet is not 
a well-suited dosage form for pediatric patients. In several cases where patients are 
unable to swallow whole tablets, the tablets are crushed and administered with apple 
sauce. Such drug administration practices, along with a limitation on lowest dose strength 
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available, further contribute to the already high variabiltiy in INR outcomes. Hence a 
more pediatric-friendly warfarin formulation, in terms of both strength and dosage form, 
is a timely requirement. 
 
Scope of the study 
Currently there is no information available on altering warfarin dose in pediatrics based 
on influential factors. In particular, quantifying the impact of polymorphisms in the 
CYP2C9 and VKORC1 on pediatric warfarin dosing is of critical therapeutic relevance. 
To our knowledge, our research brings forth the first ever proposed dosing regimen for 
using warfarin in pediatric patients as well as a useful tool to derive such dosing. The 
pediatric PKPD model used complies with what is known of warfarin and general 
pharmacology, and is consistent with adult warfrain clinical data.   
 
However, we recognize the limitations of the current research. We believe that in general 
the limitations may be attributed to the paucity of available clinical data on warfarin use 
in pedtarics. Firstly, we were restricted to a small sample size of pediatric subjects 
(n=26), which we used to qualify the model. Hence the model was based on adult data 
and physiological principles rather than pediatric data, and the proposed dosing was 
based on simulations. Moreover, the available pediatric data was limited in terms of 
covariate distributions, particualrly CYP2C9 polymorphisms and youngest ages.Another 
limitation to our study is the absence of prospective validation of the dosing regimen. For 
any dosing regimen to be widely accepted it must first be shown to be superior on 
relevant clinical outcomes in a prospective controlled trial. Given the practical limitations 
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to conducting pediatric warfarin interventional trials, we recommend that more 
propspective observational studies and experiemntal studies be conducted in pediatrics to 
update the PKPD model and hence the proposed dosing strategy. However, despite the 
limitations, we believe we have made efficient use of available information and 
suggested an important first step towards improving pediatric warfarin dosing.   
 
The research was based on certain assumptions. First, that the concentration-INR 
response relationship for warfarin is similar between pediatrics and adults. Some 
researchers have suggested intrinsic developmental differences in the coagulation 
systems [30;31], precluding extrapolation of dose-response for antithrombotic therapy 
from adults to the youngest subset of the pediatric population (< 6 months). The second 
assumption is that the CYP2C9 polymorphisms reduce warfarin clearance to the same 
extent in pediatrics and adults. Last, we assumed no developmental changes in plasma 
protein binding and dose-proportional PK throughout the entire pediatric age range. 
However, again there is dearth of data regarding how ontogeny affects warfarin 
pharmacokinetics and pharmacodynamics to formally challenge our assumptions. This is 
particularly true for VKORC1 where the patterns of developmental expression are not yet 
known.  
 
The eventual goal of studies like ours is to establish a new standard of care for pediatric 
patients who require warfarin therapy. A genetics-based warfarin dosing nomogram that 
functions more efficiently than conventional arbitrary dosing at maximizing therapeutic 
INR outcomes will represent a major advance in pediatric pharmacotherapy.  Such a 
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nomogram could be made widely available to all clinicians, and would enhance the safety 
and effectiveness of warfarin therapy in pediatric patients. Hence, further research for 
refining and validating the proposed model and dosing regimen would be useful. Even so, 
the proposed regimen is based on rational sciene and is recommended for use in pediatric 
studies and practice.  
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 CHAPTER 6 
 Conclusions and Future Research 
 
 
CONCLUSIONS 
Over the past decade there has been significant interest and progress in conducting 
pediatric clinical research in order to directly generate information for the safe and 
effective use of drugs in this special population. However, pediatric drug development is 
challenging and fairly unique is several aspects. Most development programs have just 
one chance to perform an informative set of trials, generally few in number. In some 
cases, logistic and ethical constraints, and lack of financial incentives prevent conduct of 
trials and limit the data available on drug use in pediatrics. Hence novel, efficient 
approaches such as pharmacometric methods have and can be used to leverage prior and 
current information and make useful decisions during pediatric drug development. The 
research underlying this dissertation as well as the several case studies discussed in 
chapters 1 and 2 highlight the contribution of pharmacometrics in enhancing pediatric 
drug development. 
 
 
159
One aspect of the research undertaken provides evidence of the use of modeling and 
simulation in improving pediatric trial design. With objective criteria such as the PK 
quality standard in place, pharmacometric techniques can be successfully applied in 
better planning of pediatric PK trials, to ensure informative trial outcomes. The other 
aspect of the research undertaken represents the power of pharmacometric methods in 
maximizing on limited available information and generating useful dosing guidelines in 
pediatrics. A warfarin model and genetics-based dosing regimen that was originally built 
using adult data and validated in a clinical trial was successfully leveraged along with 
physiological principles to derive a pediatric warfarin model and dosing regimen. The 
work caters to a heretofore unmet clinical need for a rational, reproducible pediatric 
warfarin dosing strategy that may be applied across clinical settings.  
 
The broader implications of the current research include, in general, improved pediatric 
health care and quality of life. Parents of children requiring pharmacotherapy for various 
conditions as well as the clinicians treating these patients stand to benefit considerably 
from the wider adoption of such research, as described in this dissertation. The work also 
represents an advance for pharmacogenetics. For instance, adults are now able to avail of 
genetics-based warfarin dosing and the research aims at providing similar care for 
pediatric patients as well. While clinical research historically has been focused on the 
adult population, the work undertaken represents increased awareness and avenues for 
bridging the gap between adults and pediatrics. The research is encouargaing for future 
investments in enhancing pediatric drug development.  
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FUTURE RESEARCH 
The quality standard described currently applies only to pediatric PK trials. However, the 
likelihood is that future regulation will introduce such standards for exposure-response 
trials in pediatrics as well. Research on methodology and feasibility for pediatric trial 
design to achieve good target precision on the slope of the exposure-response relationship 
is a potential avenue for related future research. In general, all future clinical trials ought 
to be designed rationally, using modeling and simulation.  
 
Future clnical studies with warfarin in pediatrics would serve as a bonus to our current 
research. Controlled interventional clinical trials of warfarin in pediatric patients are an 
unrealistic expectation, given the age of this drug and lack of financial incentive for 
future trials. However, experimental PKPD studies can help update the model and 
prospective observational studies may help improve the dosing regimen. Refining and 
prospectively validating the proposed dosing regimen could lead to wider adoption of 
rational and standardized dosing for warfarin use in pediatrics, rather than the current 
empirical standard of care dosing practices. The current research is a step forward in 
enhancing the safety and effectiveness profile of the most widely used anticoagulant that 
stands to benefit from future research. 
 
Further, there are several reserach areas within pediatrics that can benefit from modeling 
and simulation such as quantifying effects of ontogeny and identifying pediatric-specific 
biomarkers and trial end-points. Moreover, the applications of pharmacometrics go 
beyond pediatrics to all populations and to all aspects of drug development. Identification 
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of risk factors for new and existing drug therapies and quantifying pharmacogenetic 
information is an important research area. Pharmacometric analysis has been used for this 
purpose for the anti-viral drug nevirapine. The report is presented in Appendix D of this 
dissertation. In summary, a continuous Learn-Apply paradigm, if adopted, can 
significantly improve pediatric and overall drug development and therapeutics. Timely 
application of pharmacometric methods would be an integral part of such a paradigm.
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APPENDIX A 
R script, NONMEM model and SAS program files used to run 
simulation-estimation for pediatric PK quality standard 
evaluation (Chapter 3) 
 
R script 
 
#### EXECUTING SIMULATIONS IN NONMEM AND ESTIMATIONS IN SAS THROUGH R ### 
### VARYING BOTH SAMPLE SIZE AND NUMBER OF SAMPLES ### 
 
 
library(Hmisc) 
library(grid) 
library(lattice) 
 
setwd("/home/lalam/Peds_Sim") 
#setwd("W:/Peds_Sim") 
 
## INPUT SIMULATION SCENARIO: ONE COMP. ORAL FIRST ORDER ABSORPTION ## 
 
## PK MODEL PARAMETERS: 
 
DOSE <- 100   #mg/kg 
anchor <- 20  #kg 
CL <- 3.2     #L/h/20kg 
V <- 6.2      #L/20kg 
KA <- 2       #/hr 
FBA <- 1      #100% 
ALLOCL<- 0.75 
A50<- 0.18    #yrs 
ALLOV<-1 
p<-8 
 
vari<-"MV" 
CVCL <- 0.5 
CVV <- 0.5 
SDCL <-round(sqrt(log(1+CVCL**2)),2) 
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SDV <-round(sqrt(log(1+CVV**2)),2) 
SDTHF <- round(sqrt(SDCL**2 + SDV**2),2) 
CVKA <- 0.5 
SDKA <-round(sqrt(log(1+CVKA**2)),2) 
sdtimes <-3 
OMCL <- CVCL**2 
OMV <- CVV**2 
OMKA<-CVKA**2 
SIG <- 0.01 
COV<-c(ALLOCL,ALLOV,A50,OMCL,OMV,SIG) 
lim<-20 
 
## TRIAL CHARACTERISTICS: 
 
nBins<-4 
nAdult<-24 
tAdult<- ifelse(nAdult==12,2.20, ifelse(nAdult==24,2.07, 0)) 
nABins <- ifelse(nAdult==0,nBins,nBins+1) 
nrep1<-250 
nrep2<-300 
nrep <- ifelse(vari=="LV",nrep1,nrep2) 
 
path<-ifelse(nAdult==0, 
paste("/home/lalam/Peds_Sim/ORAL/SPARSE/NoAdult/",vari,"/",sep=""), 
paste("/home/lalam/Peds_Sim/ORAL/SPARSE/Adult/",nAdult,"ad/",vari,"/",sep
="")) 
#path<-ifelse(nAdult==0, 
paste("W:/Peds_Sim/ORAL/SPARSE/NoAdult/",vari,"/",sep=""), 
paste("W:/Peds_Sim/ORAL/SPARSE/Adult/",nAdult,"ad/",vari,"/",sep="")) 
 
Nbin1<-c(4,4,4,4,nAdult) 
t1<-c(3.18,3.18,3.18,3.18,tAdult) 
Nbin2<-c(6,6,6,6,nAdult) 
t2<-c(2.57,2.57,2.57,2.57,tAdult) 
Nbin3<-c(8,8,8,8,nAdult) 
t3<-c(2.36,2.36,2.36,2.36,tAdult) 
Nbin4<-c(10,10,10,10,nAdult) 
t4<-c(2.26,2.26,2.26,2.26,tAdult) 
Nbin5<-c(12,12,12,12,nAdult) 
t5<-c(2.20,2.20,2.20,2.20,tAdult) 
Nbin6<-c(16,16,16,16,nAdult) 
t6<-c(2.13,2.13,2.13,2.13,tAdult) 
Nbin7<-c(20,20,20,20,nAdult) 
t7<-c(2.09,2.09,2.09,2.09,tAdult) 
 
N1<- Nbin1[1]+Nbin1[2]+Nbin1[3]+Nbin1[4]+Nbin1[5] 
N2<- Nbin2[1]+Nbin2[2]+Nbin2[3]+Nbin2[4]+Nbin2[5] 
N3<- Nbin3[1]+Nbin3[2]+Nbin3[3]+Nbin3[4]+Nbin3[5] 
N4<- Nbin4[1]+Nbin4[2]+Nbin4[3]+Nbin4[4]+Nbin4[5] 
N5<- Nbin5[1]+Nbin5[2]+Nbin5[3]+Nbin5[4]+Nbin5[5] 
N6<- Nbin6[1]+Nbin6[2]+Nbin6[3]+Nbin6[4]+Nbin6[5] 
N7<- Nbin7[1]+Nbin7[2]+Nbin7[3]+Nbin7[4]+Nbin7[5] 
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Nsub <- c(N1,N2,N3,N4,N5,N6,N7)    # if other than 7 sizes, also change 
       in modules 6,7 
 
Tsamp1 <- c(0,4)       
Tsamp2 <- c(0,1,3) 
Tsamp3 <- c(0,1,3,4) 
TsampR <- c(0,0.25,0.5,1,1.5,2,2.5,3,4,6,8) 
Nsamp <- c(length(Tsamp2),length(Tsamp3))   # if other than 2  
      schedules, also change in module 2 
RS<-length(TsampR) 
 
Ntrials <- length(Nsub)*length(Nsamp) 
 
 
## DEMOGRAPHICS: 
 
# ages below entered in months 
Bin1lo<-1   #1month 
Bin1hi<-24    #2yrs 
Bin2hi<-72.5  #6yrs 
Bin3hi<-144.5 #12yrs 
Bin4hi<-192.5 #16yrs 
Bin5lo<- 18 # yrs 
Bin5hi<- 65 # yrs 
 
medage1<-1 
medage2<-4 
medage3<-9 
medage4<-14 
medage5<-41 
 
medwt1<-9.9 
medwt2<-16.1 
medwt3<-28.9 
medwt4<-50.5 
medwt5<-74.7 
 
## PREDEFINED OBJECTS: 
 
simdataitems<-c("ID","TIME","AMT","Y","ABIN","AGE","WT","SEX") 
 
parms<-c("CL","V") 
Nparms<-length(parms) 
covar<-c("ALLOCL","ALLOV","A50","OMCL","OMV","SIG") 
Ncovar<-length(covar) 
MEANparms<-paste("MEAN_",parms,sep="") 
RSEparms<-paste("RSE_",parms,sep="") 
UCIparms<-paste("UCI",parms,sep="") 
BIAS1parms<-paste("BIAS1_",parms,sep="") 
EQUIV1parms<-paste("EQUIV1_",parms,sep="") 
BIAS2parms<-paste("BIAS2_",parms,sep="") 
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EQUIV2parms<-paste("EQUIV2_",parms,sep="") 
BIASparms<-c(BIAS1parms,BIAS2parms) 
EQUIVparms<-c(EQUIV1parms,EQUIV2parms) 
PRECparms<-paste("PREC_",parms,sep="") 
ESTcovar<-paste("EST_",covar,sep="") 
BIAScovar<-paste("BIAS_",covar,sep="") 
PRECcovar<-paste("PREC_",covar,sep="") 
popestnames<-c(PRECparms,BIASparms,EQUIVparms) 
poprawnames<-c(MEANparms,RSEparms) 
popest2names<-c(ESTcovar,BIAScovar,PRECcovar) 
Npopest<-length(popestnames)+1 
Npopraw<-length(poprawnames)+1 
Npopest2<-length(popest2names) 
pop1names<-
c("ID","AGE","WT","CL","SECL","RSE_CL","UCICL","V","SEV","RSE_V","UCIV") 
Npop1<-length(pop1names) 
pop2names<-
c("Parameter","Estimate","SE","DF","t","p","alpha","LCI","UCI","gradient"
) 
Npop2<-length(pop2names) 
 
indparms<-c("CLi","Vi") 
Nindparms<-length(indparms) 
MEANposthoc <-paste("MEAN_",indparms,sep="") 
RSEposthoc <-paste("RSE_",indparms,sep="") 
SHRINKposthoc <- paste("SHRINK_",indparms,sep="") 
BIAS1posthoc <- paste("BIAS1_",indparms,sep="") 
BIAS2posthoc <- paste("BIAS2_",indparms,sep="") 
EQUIV1posthoc <- paste("EQUIV1_",indparms,sep="") 
EQUIV2posthoc <- paste("EQUIV2_",indparms,sep="") 
PRECposthoc <- paste("PREC_",indparms,sep="") 
indrawnames<-c(MEANposthoc, RSEposthoc) 
posthocestnames<- 
c(PRECposthoc,BIAS1posthoc,BIAS2posthoc,EQUIV1posthoc,EQUIV2posthoc,SHRIN
Kposthoc) 
Nindraw<-length(indrawnames)+1 
Nposthocest<-length(posthocestnames)+1 
posthocnames<-
c("ID","ABIN","AGE","WT","SEX","dose","CLi","SECLi","UCICLi","Vi","SEVi",
"UCIVi","KAi","SEKAi","UCIKAi","TIME","dv","PPRED","IPRED") 
Nposthoc<-length(posthocnames) 
 
 
## MODULE 1: CREATING BANK OF PEDS WITH CDC-BASED AGE-WT RELATIONSHIP ## 
 
data<-read.csv("CDCwtage.csv") 
names(data) 
 
nsim<-100 
sim<-c() 
for (i in 1:nsim){ 
 data$nrep<-i 
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 sim<-rbind(sim, data)  
} 
set.seed(123) 
sim$rn<-rnorm(nrow(sim)) 
sim$wt<-sim$M*(1+sim$L*sim$S*sim$rn)**(1/sim$L) 
sim$CL<-CL*((sim$wt/anchor)**ALLOCL)*(sim$Agemos/((A50*12)+sim$Agemos)) 
sim$V<-V*((sim$wt/anchor)**ALLOV) 
 
sim1<-sim[sim$Agemos>Bin1lo & sim$Agemos<=Bin1hi,c(1,2,17,18,19)] 
sim2<-sim[sim$Agemos>Bin1hi & sim$Agemos<=Bin2hi,c(1,2,17,18,19)] 
sim3<-sim[sim$Agemos>Bin2hi & sim$Agemos<=Bin3hi,c(1,2,17,18,19)] 
sim4<-sim[sim$Agemos>Bin3hi & sim$Agemos<=Bin4hi,c(1,2,17,18,19)] 
sim1$AgeBin<-1 
sim2$AgeBin<-2 
sim3$AgeBin<-3 
sim4$AgeBin<-4 
 
#edit(bank) 
bank<-rbind(sim1,sim2,sim3,sim4) 
bankmean<-aggregate(log(bank[ ,parms]),by=list(bank$AgeBin),mean,na.rm=T) 
bankmean<-exp(bankmean)[ ,parms] 
bankvar<-aggregate(log(bank[ ,parms]),by=list(bank$AgeBin),var,na.rm=T) 
bankvar<-bankvar[ ,parms] 
 
truemean<-bankmean 
 
meanclad<-CL*((medwt5/anchor)**ALLOCL)*(medage5/(medage5+A50)) 
meanvad<-V*((medwt5/anchor)**ALLOV) 
adultmean<-c(meanclad,meanvad) 
if(nAdult>0) bankmean<-rbind(bankmean,adultmean) 
 
 
## MODULE 1A: SIMULATING COMMON DEMOGRAPHICS FOR ALL CASES ## 
 
simb1a<-sim1a[sample(1:nrow(sim1a),Npbin[1],replace=F), ] 
simb1b<-sim1b[sample(1:nrow(sim1b),Npbin[1],replace=F), ] 
simb1<-sim1[sample(1:nrow(sim1),Npbin[1],replace=F), ] 
simb2<-sim2[sample(1:nrow(sim2),Npbin[1],replace=F), ] 
simb3<-sim3[sample(1:nrow(sim3),Npbin[1],replace=F), ] 
simb4<-sim4[sample(1:nrow(sim4),Npbin[1],replace=F), ] 
 
simbin5<-sim5[sample(1:nrow(sim5),nAdult,replace=F), ] 
 
 
simbn1a<-simb1a 
simbn1b<-simb1b 
simbn1<-simb1 
simbn2<-simb2 
simbn3<-simb3 
simbn4<-simb4 
 
simdemo<-list() 
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allsimdemo<-list(list()) 
k<-7 
for (i in Npbin) { 
  
  simbin1a<-simbn1a[sample(1:nrow(simbn1a),i,replace=F), ] 
  simbin1b<-simbn1b[sample(1:nrow(simbn1b),i,replace=F), ] 
  simbin1<-simbn1[sample(1:nrow(simbn1),i,replace=F), ] 
  simbin2<-simbn2[sample(1:nrow(simbn2),i,replace=F), ] 
  simbin3<-simbn3[sample(1:nrow(simbn3),i,replace=F), ] 
  simbin4<-simbn4[sample(1:nrow(simbn4),i,replace=F), ] 
  simbn1a<-simbin1a 
  simbn1b<-simbin1b 
  simbn1<-simbin1 
  simbn2<-simbin2 
  simbn3<-simbin3 
  simbn4<-simbin4 
  simdemo[[6]]<-simbin1a 
  simdemo[[7]]<-simbin1b 
  simdemo[[1]]<-simbin1 
  simdemo[[2]]<-simbin2 
  simdemo[[3]]<-simbin3 
  simdemo[[4]]<-simbin4 
 allsimdemo[[k]]<-simdemo 
 k<-k-2 
} 
 
## MODULE 1B: CREATING DEMOGRAPHIC DATASETS FOR SIMULATIONS ## 
 
k <- 1 
n <- 4 
 
for (i in Ntot) { 
 if(n==10) n<-12 
  simbin1a<-allsimdemo[[k]][[6]] 
  simbin1b<-allsimdemo[[k]][[7]] 
  simbin1<-allsimdemo[[k]][[1]] 
  simbin2<-allsimdemo[[k]][[2]] 
  simbin3<-allsimdemo[[k]][[3]] 
  simbin4<-allsimdemo[[k]][[4]] 
  simagewt<-rbind(simbin1,simbin2,simbin3,simbin4) 
  if(nBins==5) simagewt<-
rbind(simbin1a,simbin1b,simbin2,simbin3,simbin4) 
  simagewt<-simagewt[,c(6,2,3,1)] 
  names(simagewt)<-c("AgeBin","Age","Weight","Sex") 
  simagewt$Age<-simagewt$Age/12 
  if(nAdult>0) simagewt<-rbind(simagewt,simbin5) 
   
  demog <- data.frame(1:i) 
  names(demog) <- "ID" 
  demog<-cbind(demog,simagewt) 
  names(demog)<-c("ID","AgeBin","AGE","WT","SEX") 
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  demog$AGE<-
ifelse(demog$AGE<1,round(as.numeric(demog$AGE),2),round(as.numeric(demog$
AGE),1)) 
  demog$WT <- round(as.numeric(demog$WT),1) 
   
  plot<-xyplot(demog$WT~demog$AGE, data=demog,xlab="AGE 
(yrs)",ylab="WEIGHT (kg)", 
  
 scales=list(cex=1.5,lwd=2,x=list(log=10,at=c(0,1,2,6,12,16,25,50)))
, 
   panel=function(x,y,...){ 
   panel.xyplot(x,y,type="p",...) 
   panel.curve(5.4095+4.6965*10^x-
0.7261*(10^x)^2+0.0721*(10^x)^3-0.002*(10^x)^4, from=log10(1), 
to=log10(18), lty=2, col=2) 
   panel.curve(3.9364+4.5254*10^x-
0.7279*(10^x)^2+0.0649*(10^x)^3-0.0017*(10^x)^4, from=log10(1), 
to=log10(18), lty=2, col=2) 
   panel.curve(7.5589+4.1842*10^x-
0.4651*(10^x)^2+0.0628*(10^x)^3-0.002*(10^x)^4, from=log10(1), 
to=log10(18), lty=2,col=2) 
   panel.curve(3.5802+10.681*10^x-4.037*(10^x)^2, 
from=log10(0.0001), to=log10(1), lty=3,col=1) 
   panel.curve(2.5787+9.8283*10^x-3.8735*(10^x)^2, 
from=log10(0.0001), to=log10(1), lty=3,col=1) 
   panel.curve(4.4035+12.857*10^x-4.9702*(10^x)^2, 
from=log10(0.0001), to=log10(1), lty=3,col=1) 
   } 
   ) 
  pdf(file=paste("AgeWtPlot",n,".pdf",sep=""),width=9,height=9)  
  print(plot) 
   dev.off() 
  
  write.table(demog, file=paste("demog_N",n,".csv",sep=""), 
  sep=",", quote=F, row.names=F, na=".") 
 
  k <- k+2 
  n <- n+2 
 }  
 
 
## MODULE 2: CREATING DATA TEMPLATES & CONTROL STREAMS FOR NM TO USE FOR 
SIMULATIONS ## 
 
ctlstrm <- scan(file="runsim_oral_trunc.mod", what="character", sep="\n") 
 
d<-1 
k <- 1 
 
for (i in Nsub) { 
 for (j in Nsamp) { 
  if (j==Nsamp[1]) Tsamp <- Tsamp2 
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  if (j==Nsamp[2]) Tsamp <- Tsamp3 
 
  #demog<-
read.csv(file=paste("W:/Peds_Sim/DEMOGS/demog",d,"_",nAdult,"ad.csv",sep=
"")) 
  demog<-
read.csv(file=paste("/home/lalam/Peds_Sim/DEMOGS/demog",d,"_",nAdult,"ad.
csv",sep="")) 
            demog<-demog[!duplicated(demog$ID), ] 
  e<-c(rep(j,each=i-nAdult),rep(RS,each=nAdult)) 
  input<-demog[rep(demog$ID,e), ] 
  input$TIME <- c(rep(Tsamp, i-nAdult),rep(TsampR,nAdult)) 
  input$AMT <- ifelse(input$TIME==0, DOSE*input$WT, 0) 
  input$CONC <- rep(".", nrow(input)) 
  input<-input[ ,c(1,6,7,8,2,3,4,5)] 
  write.table(input, 
file=paste(path,"run_sim_",nAdult,"/input",k,".csv",sep=""), 
  sep=",", quote=F, row.names=F, na=".") 
 
  ctlstrm[3]  <- paste("$DATA input",k,".csv IGNORE=@",sep="") 
  ctlstrm[7] <- paste("SUBPROBLEMS = ",nrep,sep="") 
  ctlstrm[11] <- paste(" ",CL," FIX ; CL (L/h/20kg)",sep="") 
  ctlstrm[12] <- paste(" ",V," FIX ; V (L/20kg)",sep="") 
  ctlstrm[13] <- paste(" ",KA," FIX ; TVKA (/h)",sep="") 
  ctlstrm[14] <- paste(" ",ALLOCL," FIX ; ALLOCL",sep="") 
  ctlstrm[15] <- paste(" ",ALLOV," FIX ; ALLOV",sep="") 
  ctlstrm[16] <- paste(" ",A50," FIX ; A50 (YRS)",sep="") 
  ctlstrm[18] <- paste(" ",OMCL," FIX ; BSVCL",sep="") 
  ctlstrm[19] <- paste(" ",OMV," FIX ; BSVV",sep="") 
  ctlstrm[20] <- paste(" ",OMKA," FIX ; BSVKA",sep="") 
  ctlstrm[22] <- paste(" ",SIG," FIX ; CVCP",sep="") 
  ctlstrm[40] <- paste("      DLTACL = 
",sdtimes,"*",SDCL,sep="") 
  ctlstrm[41] <- paste("      DLTAV = ",sdtimes,"*",SDV,sep="") 
  ctlstrm[42] <- paste("      DLTAKA = 
",sdtimes,"*",SDKA,sep="") 
  ctlstrm[43] <- paste("      DLTATH = 
",sdtimes,"*",SDTHF,sep="") 
  ctlstrm[length(ctlstrm)] <- paste("NOPRINT ONEHEADER NOAPPEND 
FILE=sdtab",k,sep="") 
 
 write(ctlstrm,file=paste(path,"run_sim_",nAdult,"/runsim",k,".mod",
sep="")) 
 
  k <- k+1 
  } 
d<-d+1   
}  
 
 
## MODULE 3: EXECUTE NM RUNS FOR SIMULATIONS THROUGH R ON CLUSTER ## 
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execute <- character() 
execute[1] <- "#!/bin/sh" 
execute[2] <- paste("execute -
threads=32",paste("runsim",1:Ntrials,".mod",collapse=" ",sep=""),sep=" ") 
setwd(paste(path,"run_sim_",nAdult,sep="")) 
write(execute,"sim.pl") 
system("perl sim.pl") 
 
 
## MODULE 4: READ IN THE SIMULATED OUTPUT DATA (sdtab files) FROM NM ## 
## SPLIT THE SIMULATED DATA FOR EACH REPLICATE AND CREATE DATASETS TO 
INPUT BACK TO SAS ## 
## CREATE SAS MODEL FILES FOR FITTING SIMULATED DATA ## 
 
#model <- scan(file="W:/Peds_Sim/fit_oral_sp.sas", what="character", 
sep="\n") 
model <- scan(file="/home/lalam/Peds_Sim/fit_oral_sp.sas", 
what="character", sep="\n") 
 
k <- 1 
test <- list() 
 
simparms<- list() 
allsim<-list(list()) 
 
for (i in Nsub) { 
 for (j in Nsamp) { 
  for(r in 1:nrep){ 
   test[[r]] <- read.table(file=paste("sdtab",k,sep=""), 
    skip=(r-1)*((i*j)+(nAdult*(RS-
j))+1)+(r),header=T,nrows=(i*j)+(nAdult*(RS-j))) 
 
   simparms[[r]]<-
test[[r]][!duplicated(test[[r]]$ID),c("CL","V","ABIN","WT")] 
 
   test[[r]] <- test[[r]][ ,simdataitems] 
   names(test[[r]]) <- 
c("ID","TIME","AMT","CONC","ABIN","AGE","WT","SEX") 
 
   dosing <- test[[r]][!duplicated(test[[r]]$ID), ] 
   dosing$TIME<-0 
   dosing$AMT<-DOSE*dosing$WT 
   dosing$CONC <- "." 
    
   test[[r]]<-test[[r]][test[[r]]$TIME>0 , ] 
   test[[r]] <- rbind(dosing, test[[r]]) 
   test[[r]] <- test[[r]][order(test[[r]]$ID), ] 
   test[[r]]$MDV <- ifelse(test[[r]]$AMT==0,0,1) 
   test[[r]]$EVID <- ifelse(test[[r]]$AMT==0,0,1) 
   write.table(test[[r]], 
file=paste(path,"fit_model/simdata",k,"rep",r,".csv",sep=""),  
    sep=",", quote=F, row.names=F, na=".") 
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   model[7]<- paste("  DATAFILE=\"", 
path,"fit_model/simdata",k,"rep",r,".csv\"",sep="") 
   model[17]<-paste("if id=1001 then do; age=",medage1," ; 
wt=",medwt1,"; end;",sep="") 
   model[18]<-paste("if id=1002 then do; age=",medage2," ; 
wt=",medwt2,"; end;",sep="") 
   model[19]<-paste("if id=1003 then do; age=",medage3," ; 
wt=",medwt3,"; end;",sep="") 
   model[20]<-paste("if id=1004 then do; age=",medage4," ; 
wt=",medwt4,"; end;",sep="") 
   model[65]<-paste("   anchor = ",anchor,";",sep="") 
         
   model[66]<-paste("   TVKA = ",KA,";",sep="") 
   model[67]<-paste("   s2ka = ",OMKA,";",sep="") 
   model[68]<-paste("   F = ",FBA,";",sep="") 
   model[141] <- paste("(pTVCL=",CL,",",sep="") 
   model[142] <- paste("pTVV=",V,",",sep="") 
   model[143] <- paste("pALLOCL=",ALLOCL,",",sep="") 
   model[144] <- paste("pALLOV=",ALLOV,",",sep="") 
   model[145] <- paste("pA50=",A50,",",sep="") 
   model[146] <- paste("ps2cl=",OMCL,",",sep="") 
   model[147] <- paste("ps2v=",OMV,",",sep="") 
   model[148] <- paste("ps2=",SIG,",",sep="") 
   model[149] <- paste("repeats=",lim,")",sep="") 
   model[171] <- paste("proc export data=bins 
outfile=\"",path,"model_output/bins",k,"rep",r,".csv\" DBMS=CSV REPLACE; 
run;",sep="") 
   model[172] <- paste("proc export data=para 
outfile=\"",path,"model_output/parms",k,"rep",r,".csv\" DBMS=CSV REPLACE; 
run;",sep="") 
   model[173] <- paste("proc export data=posthoc 
outfile=\"",path,"model_output/posthoc",k,"rep",r,".csv\" DBMS=CSV 
REPLACE; run;",sep="") 
  
 write(model,file=paste(path,"fit_model/fit",k,"rep",r,".sas",sep=""
)) 
 
   } 
  allsim[[k]]<-simparms 
 
  k <- k+1 
 } 
} 
 
 
## MODULE 5: FITTING MODEL TO SIMULATED DATA USING SAS THROUGH R ## 
 
setwd(paste(path,"fit_model",sep="")) 
 
runsas <- character() 
runsas[1] <- "#!/bin/sh" 
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k<-1 
for (i in Nsub){ 
 for (j in Nsamp) { 
  for (r in 1:nrep) { 
   runsas[2]<-(paste("/opt/sas92/SASFoundation/9.2/sas92 -
noterminal -log ",path,"fit_model -print ",path,"fit_model " 
,path,"fit_model/fit",k,"rep",r,".sas",sep="")) 
   write(runsas,file=paste("fit",k,"rep",r,".bat",sep="")) 
   system(paste("chmod a+x fit",k,"rep",r,".bat",sep="")) 
   system(paste("qsub -o /home/lalam/eofiles -e 
/home/lalam/eofiles fit",k,"rep",r,".bat &",sep="")) 
  } 
 k<-k+1 
 } 
} 
 
## MODULE 6: READ IN SAS ESTIMATION OUTPUT (lst/bin/parm files) FOR 
ANALYSIS : METHOD 1 - POP.MEAN. ##  
 
popest <- list() 
popraw<-list() 
popest2<-list() 
pop1 <- list() 
pop2<-list() 
allpop1<-list(list()) 
allpop2<-list(list()) 
agebin<-1:nBins 
 
k<-1 
f<-1 
g<-1 
finalpop<-data.frame(matrix(NA,ncol=Npopest+2,nrow=Ntrials*nBins*2)) 
names(finalpop)<-c("METRIC","AgeBin",popestnames,"SCENARIO") 
finalpop2<-data.frame(matrix(NA,ncol=Npopest2+2,nrow=Ntrials*2)) 
names(finalpop2)<-c("METRIC",popest2names,"SCENARIO") 
 
for (i in Nsub) { 
  
 t<-qt(0.975,(i-nAdult-p))  
 
 for (j in Nsamp) { 
    
 popest[[k]]<-data.frame(matrix(NA,ncol=Npopest,nrow=nrep*nBins)) 
 names(popest[[k]])<-c("AgeBin",popestnames) 
 popraw[[k]]<-data.frame(matrix(NA,ncol=Npopraw,nrow=nrep*nBins)) 
 names(popraw[[k]])<-c("AgeBin",poprawnames) 
 popest2[[k]]<- data.frame(matrix(NA,ncol=Npopest2,nrow=nrep)) 
 names(popest2[[k]]) <- popest2names 
 
 b<-1  
 for(r in 1:nrep){ 
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  output <- scan(file=paste("fit",k,"rep",r,".lst",sep=""), 
what="character", sep="\n") 
  thetaPos <- grep("Successful", output) 
  ifelse(length(thetaPos)==0, 
   pop1[[r]]<-
data.frame(matrix(NA,ncol=Npop1,nrow=nBins)), 
   pop1[[r]]<-
read.csv(paste(path,"model_output/bins",k,"rep",r,".csv",sep=""))) 
   names(pop1[[r]])<-pop1names 
  ifelse(length(thetaPos)==0, 
   pop2[[r]]<-
data.frame(matrix(NA,ncol=Npop2,nrow=Nparms+Ncovar)), 
   pop2[[r]]<-
read.csv(paste(path,"model_output/parms",k,"rep",r,".csv",sep=""))) 
   names(pop2[[r]])<-pop2names 
 
  allsim[[k]][[r]][ ,parms]<-log(allsim[[k]][[r]][ ,parms]) 
  simmean<-aggregate(allsim[[k]][[r]][ 
,parms],by=list(allsim[[k]][[r]]$ABIN),mean,na.rm=T) 
  simmean<-exp(simmean[1:nBins,parms]) 
 
  popmean<- pop1[[r]][ ,parms] 
  popRSE<-pop1[[r]][ ,RSEparms] 
  popprec<-(100 + t*(popRSE)) 
  popbias1<-((popmean-truemean)/truemean)*100 
  popequiv1<-exp(log(popmean/truemean)) 
  popbias2<-((popmean-simmean)/simmean)*100 
  popequiv2<-exp(log(popmean/truemean)) 
  popparms <- 
cbind(agebin,popprec,popbias1,popbias2,popequiv1,popequiv2) 
  popest[[k]][c(b:(nBins*r)),] <- popparms 
  poprawpar<-cbind(agebin,popmean,popRSE) 
  popraw[[k]][c(b:(nBins*r)),] <- poprawpar 
   
  popcov<-pop2[[r]][(Nparms+1):nrow(pop2[[r]]),pop2names[1:3]] 
  popcov$UCI<-popcov$Estimate + t*(popcov$SE) 
  popcov$Prec<-(popcov$UCI/popcov$Estimate)*100 
  popcov$Bias<-((popcov$Estimate-COV)/COV)*100   
  popcovpar <- c(popcov$Estimate,popcov$Bias,popcov$Prec) 
  popest2[[k]][r,] <- popcovpar 
  
  b<-b+nBins 
 } 
 allpop1[[k]]<-pop1 
 allpop2[[k]]<-pop2 
 
 pass<-c() 
  p.pass<-c() 
  for(a in agebin) { 
   for(p in 2:3) { 
   con<-is.na(popest[[k]][popest[[k]]$AgeBin==a,p]) 
   ncon<-length(con[con==F]) 
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   test1<-
ifelse(is.na(popest[[k]][popest[[k]]$AgeBin==a,p])==T,0, 
    
 ifelse(popest[[k]][popest[[k]]$AgeBin==a,p]<=140,1,0)) 
   test2<-(length(test1[test1==1])/ncon)*100 
   pass[p]<-test2 
   } 
   for(p in 4:7) { 
    pass[p]<-NA 
   } 
   for(p in 8:11) { 
    pass[p]<-NA 
   } 
   p.pass<-rbind(p.pass,pass) 
  }  
  p.pass[,1]<-agebin 
   
  pass2<-c() 
  for(p in 1:6) {  
   pass2[p]<-NA 
   } 
  for(p in 7:12) {  
   pass2[p]<-NA 
   } 
  for(p in 13:18) { 
   con<-is.na(popest2[[k]][,p]) 
   ncon<-length(con[con==F]) 
   test1<-ifelse(is.na(popest2[[k]][,p])==T, 0, 
     ifelse(popest2[[k]][,p]<=140, 1,0)) 
   test2<-(length(test1[test1==1])/ncon)*100 
   pass2[p]<-test2 
   } 
    
 meanpop <- aggregate(popest[[k]][ 
,popestnames],by=list(popest[[k]]$AgeBin),mean,na.rm=T) 
 popest[[k]][c((nrep*nBins+1):(nrep*nBins+nBins)),] <- meanpop 
 popest[[k]][c((nrep*nBins+nBins+1):(nrep*nBins+nBins*2)),] <- 
p.pass 
 popest[[k]][,c(PRECparms,BIASparms)]<-
round(popest[[k]][,c(PRECparms,BIASparms)],0) 
 popest[[k]][,c(EQUIVparms)]<-round(popest[[k]][,c(EQUIVparms)],1) 
 popest[[k]]$REP <- rep(c(1:nrep,"MEAN","POWER"),each=nBins) 
 popest[[k]]<- popest[[k]][ 
,c(ncol(popest[[k]]),1:ncol(popest[[k]])-1)] 
 write.table(popest[[k]], 
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_output",
k,".csv",sep=""), 
  sep=",", quote=F, row.names=F, na=".") 
  
 meanraw <- aggregate(popraw[[k]][ 
,poprawnames],by=list(popraw[[k]]$AgeBin),mean,na.rm=T) 
 popraw[[k]][c((nrep*nBins+1):(nrep*nBins+nBins)),] <- meanraw 
 177
 popraw[[k]]$REP <- rep(c(1:nrep,"MEAN"),each=nBins) 
 popraw[[k]]<- popraw[[k]][ 
,c(ncol(popraw[[k]]),1:ncol(popraw[[k]])-1)] 
 
 popest2[[k]][nrep+1,] <- mean(popest2[[k]][1:nrep,],na.rm=T) 
 popest2[[k]][nrep+2,] <- pass2 
 popest2[[k]][,c(ESTcovar)]<-round(popest2[[k]][,c(ESTcovar)],3) 
 popest2[[k]][,c(PRECcovar,BIAScovar)]<-
round(popest2[[k]][,c(PRECcovar,BIAScovar)],0) 
 popest2[[k]]$REP <- c(c(1:nrep),"MEAN","POWER") 
 popest2[[k]] <- popest2[[k]][ 
,c(ncol(popest2[[k]]),1:ncol(popest2[[k]])-1)] 
 write.table(popest2[[k]], 
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_auxout",
k,".csv",sep=""), 
 sep=",", quote=F, row.names=F, na=".") 
 
  
 finalpop[f:(f+nBins*2-1), ]<-
popest[[k]][(nrep*nBins+1):(nrep*nBins+nBins*2), ] 
 finalpop$SCENARIO[f:(f+nBins*2-1)]<-k 
 f<-f+(nBins*2) 
 
 finalpop2[c(g,g+1), ]<-popest2[[k]][c(nrep+1,nrep+2), ] 
 finalpop2$SCENARIO[c(g,g+1)]<-k 
 g<-g+2 
 
 k<-k+1 
} 
} 
 
finalpop<-finalpop[ ,c(ncol(finalpop),1:ncol(finalpop)-1)] 
write.table(finalpop, 
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_summary.
csv",sep=""),sep=",", quote=F, row.names=F, na=".") 
 
finalpop2<-finalpop2[ ,c(ncol(finalpop2),1:ncol(finalpop2)-1)] 
write.table(finalpop2, 
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_auxsum.c
sv",sep=""),sep=",", quote=F, row.names=F, na=".") 
 
 
 
## MODULE 7: READ IN SAS ESTIMATION OUTPUT (lst/parm/posthoc files) FOR 
ANALYSIS : METHOD 2 - POSTHOC ##  
 
posthocest <- list() 
indraw<-list() 
allposthoc<-list(list()) 
posthoc <- list() 
posthoc.pkg<-list() 
pop2<-list() 
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agebin<-1:nABins 
 
finalposthoc<-
data.frame(matrix(NA,ncol=Nposthocest+2,nrow=Ntrials*nABins*2)) 
names(finalposthoc)<-c("METRIC","AgeBin",posthocestnames,"SCENARIO") 
 
k<-1 
f<-1 
for (i in Nsub) { 
 if (i==Nsub[1]) Nbin <- Nbin1 
 if (i==Nsub[2]) Nbin <- Nbin2 
 if (i==Nsub[3]) Nbin <- Nbin3 
 if (i==Nsub[4]) Nbin <- Nbin4 
 if (i==Nsub[5]) Nbin <- Nbin5 
 if (i==Nsub[6]) Nbin <- Nbin6 
 if (i==Nsub[7]) Nbin <- Nbin7 
 
 Nbin<-Nbin[1:nABins] 
 t<-qt(0.975,(((i-nAdult)/4)-1))  
 
for (j in Nsamp) { 
 
 posthocest[[k]]<-
data.frame(matrix(NA,ncol=Nposthocest,nrow=nrep*nABins)) 
 names(posthocest[[k]]) <- c("AgeBin",posthocestnames) 
 indraw[[k]]<- data.frame(matrix(NA,ncol=Nindraw,nrow=nrep*nABins)) 
 names(indraw[[k]]) <- c("AgeBin",indrawnames) 
 
 b<-1  
 for(r in 1:nrep){ 
  output <- scan(file=paste("fit",k,"rep",r,".lst",sep=""), 
what="character", sep="\n") 
  thetaPos <- grep("Successful", output) 
 
  ifelse(length(thetaPos)==0, 
   pop2[[r]]<-
data.frame(matrix(NA,ncol=Npop2,nrow=Nparms+Ncovar)), 
   pop2[[r]]<-
read.csv(paste(path,"model_output/parms",k,"rep",r,".csv",sep=""))) 
   names(pop2[[r]])<-pop2names 
 
  ifelse(length(thetaPos)==0, 
   posthoc[[r]]<-
data.frame(matrix(NA,ncol=Nposthoc,nrow=i)), 
   posthoc[[r]]<-
read.csv(paste(path,"model_output/posthoc",k,"rep",r,".csv",sep=""))) 
   names(posthoc[[r]])<-posthocnames 
  if(length(thetaPos)!=0) 
   posthoc[[r]]<-
posthoc[[r]][match(unique(posthoc[[r]]$ID),posthoc[[r]]$ID), ] 
   
  posthoc.pkg[[r]]<-posthoc[[r]] 
 179
 
  if(length(thetaPos)!=0) 
   posthoc[[r]][ ,indparms]<-log(posthoc[[r]][ ,indparms]) 
       ifelse(length(thetaPos)==0, 
   posthocmean<-
data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))), 
   posthocmean<- aggregate(posthoc[[r]][ 
,indparms],by=list(posthoc[[r]]$ABIN),mean,na.rm=T)) 
  ifelse(length(thetaPos)==0,posthocmean<-
posthocmean,posthocmean<- exp(posthocmean)[ ,indparms]) 
  posthocbias1<-((posthocmean-bankmean)/bankmean)*100 
  posthocequiv1<-exp(log(posthocmean/bankmean)) 
 
  #allsim[[k]][[r]][ ,parms]<-log(allsim[[k]][[r]][ ,parms]) 
  simmean<-aggregate(allsim[[k]][[r]][ 
,parms],by=list(allsim[[k]][[r]]$ABIN),mean,na.rm=T) 
  simmean<-exp(simmean[ ,parms]) 
  posthocbias2<-((posthocmean-simmean)/simmean)*100 
  posthocequiv2<-exp(log(posthocmean/simmean)) 
 
  posthoc.pkg[[r]][ ,indparms]<- 
   posthoc.pkg[[r]][ 
,indparms]/c(((posthoc.pkg[[r]]$WT**ALLOCL)*(posthoc.pkg[[r]]$AGE/(postho
c.pkg[[r]]$AGE+A50))),posthoc.pkg[[r]]$WT**ALLOV) 
  if(length(thetaPos)!=0) 
   posthoc.pkg[[r]][ ,indparms]<-log(posthoc.pkg[[r]][ 
,indparms]) 
  ifelse(length(thetaPos)==0, 
   posthocmean.pkg<-
data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))), 
   posthocmean.pkg<- aggregate(posthoc.pkg[[r]][ 
,indparms],by=list(posthoc.pkg[[r]]$ABIN),mean,na.rm=T)) 
  ifelse(length(thetaPos)==0, 
   posthocvar.pkg<-
data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))), 
   posthocvar.pkg<- aggregate(posthoc.pkg[[r]][ 
,indparms],by=list(posthoc.pkg[[r]]$ABIN),var,na.rm=T)) 
  ifelse(length(thetaPos)==0, 
   posthocsd.pkg<-
data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))), 
   posthocsd.pkg<- aggregate(posthoc.pkg[[r]][ 
,indparms],by=list(posthoc.pkg[[r]]$ABIN),sd,na.rm=T)) 
   
  posthocse<- sqrt(posthocvar.pkg/Nbin) 
  posthocUCI<-posthocmean.pkg+t*(posthocse) 
  posthocUCI<-exp(posthocUCI)[ ,indparms] 
  if(length(thetaPos)!=0) posthocmean.pkg<- 
exp(posthocmean.pkg)[ ,indparms] 
  posthocprec<-(posthocUCI/posthocmean.pkg)*100 
  posthocRSE<-(posthocse[ ,indparms]/posthocmean.pkg)*100 
   
  posthocsd.pkg<-(posthocsd.pkg)[ ,indparms] 
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  meanvar<-pop2[[r]][(Ncovar:(Ncovar+1)),pop2names[2]] 
  meansdcl<-rep(sqrt(meanvar[1]),nABins) 
  meansdv<-rep(sqrt(meanvar[2]),nABins) 
  popsd<-cbind(meansdcl,meansdv) 
  shrinkage<- (1-posthocsd.pkg/popsd)*100 
 
  indest <- 
cbind(agebin,posthocprec,posthocbias1,posthocbias2,posthocequiv1,posthoce
quiv2,shrinkage) 
  posthocest[[k]][c(b:(nABins*r)),] <- indest 
  indest2<-cbind(agebin,posthocmean,posthocRSE) 
  indraw[[k]][c(b:(nABins*r)),] <- indest2 
  b<-b+nABins   
 } 
 allposthoc[[k]] <- posthoc 
 
 pass<-c() 
 p.pass<-c() 
 for(a in agebin) { 
  for(p in 2:3) { 
   con<-
is.na(posthocest[[k]][posthocest[[k]]$AgeBin==a,p]) 
   ncon<-length(con[con==F]) 
   test1<-
ifelse(is.na(posthocest[[k]][posthocest[[k]]$AgeBin==a,p])==T,0, 
    
 ifelse(posthocest[[k]][posthocest[[k]]$AgeBin==a,p]<=140, 1,0)) 
   test2<-(length(test1[test1==1])/ncon)*100 
   pass[p]<-test2 
   } 
  for(p in 4:7) { 
   pass[p]<-NA 
   } 
  for(p in 8:11) { 
   pass[p]<-NA 
   } 
  for(p in 12:13) { 
   pass[p]<-NA 
   } 
  p.pass<-rbind(p.pass,pass) 
 }  
 p.pass[,1]<-agebin 
 
 meanposthoc <- aggregate(posthocest[[k]][ 
,posthocestnames],by=list(posthocest[[k]]$AgeBin),mean,na.rm=T) 
 posthocest[[k]][c((nrep*nABins+1):(nrep*nABins+nABins)),] <- 
meanposthoc 
 posthocest[[k]][c((nrep*nABins+nABins+1):(nrep*nABins+nABins*2)),] 
<- p.pass 
 posthocest[[k]][,c(PRECposthoc,BIAS1posthoc,BIAS2posthoc)]<-
round(posthocest[[k]][,c(PRECposthoc,BIAS1posthoc,BIAS2posthoc)],0) 
 181
 posthocest[[k]][,c(SHRINKposthoc,EQUIV1posthoc,EQUIV2posthoc)]<-
round(posthocest[[k]][,c(SHRINKposthoc,EQUIV1posthoc,EQUIV2posthoc)],1) 
 posthocest[[k]]$REP <- rep(c(1:nrep,"MEAN","POWER"),each=nABins) 
 posthocest[[k]]<- posthocest[[k]][ 
,c(ncol(posthocest[[k]]),1:ncol(posthocest[[k]])-1)] 
 write.table(posthocest[[k]], 
file=paste(path,"results/method2/",vari,"_Sparse_",nAdult,"ad_M2_output",
k,".csv",sep=""), 
  sep=",", quote=F, row.names=F, na=".") 
 
 meanraw <- aggregate(indraw[[k]][ 
,indrawnames],by=list(indraw[[k]]$AgeBin),mean,na.rm=T) 
 indraw[[k]][c((nrep*nABins+1):(nrep*nABins+nABins)),] <- meanraw 
 indraw[[k]]$REP <- rep(c(1:nrep,"MEAN"),each=nABins) 
 indraw[[k]]<- indraw[[k]][ 
,c(ncol(indraw[[k]]),1:ncol(indraw[[k]])-1)] 
 
 
 finalposthoc[f:(f+nABins*2-1), ]<-
posthocest[[k]][(nrep*nABins+1):(nrep*nABins+nABins*2), ] 
 finalposthoc$SCENARIO[f:(f+nABins*2-1)]<-k 
 f<-f+(nABins*2) 
 k<-k+1 
 } 
} 
 
finalposthoc<-finalposthoc[ ,c(ncol(finalposthoc),1:ncol(finalposthoc)-
1)] 
write.table(finalposthoc, 
file=paste(path,"results/method2/",vari,"_Sparse_",nAdult,"ad_M2_summary.
csv",sep=""),sep=",", quote=F, row.names=F, na=".") 
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NONMEM model 
$PROBLEM sim_NM thru R ; truncated normal wrt t1/2, cl, v, ka 
; PROGRAMMER=MALLIKA 
 
$DATA inputk.csv IGNORE=@ 
 
$INPUT ID TIME AMT DV=CONC ABIN AGE WT SEX 
;TIME=HRS, DV=CONC=ug/mL, AMT=DOSE=MG, ABIN=AgeBin=1-5, AGE=YRS, WT=KG, 
SEX=1=M,2=F 
 
$SIMULATION (12345678 NEW) ONLYSIM 
SUBPROBLEMS = 1 
 
$SUBROUTINE ADVAN2 TRANS2 
;1 COMP. MODEL oral 
 
$THETA 
   3.2 FIX  ; CLTI (L/h/20kg) 
   6.2 FIX  ; VTI  (L/20kg) 
   2   FIX  ; KATI (/h) 
   0.75 FIX ; ALLOCL 
   1 FIX    ; ALLOV 
   0.18 FIX ; A50 (years) 
 
$OMEGA 
   0.49 FIX ; CVCL 
   0.49 FIX ; CVV 
   0.16 FIX ; CVKA 
 
$SIGMA 
   0.01 FIX ; CVCP 
 
 
$PK 
 
 IF (ICALL.EQ.4) THEN  
 
   CLTI   = THETA(1) 
   VTI    = THETA(2) 
   KATI   = THETA(3) 
   ALLOCL = THETA(4) 
   ALLOV  = THETA(5) 
   A50    = THETA(6) 
 
   ETCL   = ETA(1) 
   ETV    = ETA(2) 
   ETKA   = ETA(3) 
 
   TVCL   = CLTI*((WT/20)**ALLOCL)*(AGE/(AGE+A50)) 
   TVV    = VTI*((WT/20)**ALLOV) 
   TVKA   = KATI 
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   TVKE   = TVCL/TVV 
   TVTHF  = 0.693/TVKE 
   
       DLTACL  = 2*0.7        ; MUST BE 3.27*SQRT(CVCL)! 
       DLTAV   = 2*0.7        ; MUST BE 3.27*SQRT(CVV)! 
       DLTAKA  = 2*0.4 
       DLTATH  = 2*0.7 
       LNMUCL  = LOG(TVCL) 
       LOCL    = EXP(LNMUCL-DLTACL) 
       HICL    = EXP(LNMUCL+DLTACL) 
       LNMUV   = LOG(TVV) 
       LOV     = EXP(LNMUV-DLTAV) 
       HIV     = EXP(LNMUV+DLTAV) 
       LNMUKA  = LOG(TVKA) 
       LOKA    = EXP(LNMUKA-DLTAKA) 
       HIKA    = EXP(LNMUKA+DLTAKA) 
       LNMUTH  = LOG(TVTHF) 
       LOTHF   = EXP(LNMUTH-DLTATH) 
       HITHF   = EXP(LNMUTH+DLTATH) 
 
 
       CL=TVCL*EXP(ETCL) 
       IF (CL.GE.LOCL.AND.CL.LE.HICL) THEN 
          CLOK=1 
       ELSE 
          CLOK=0 
       ENDIF 
 
       V=TVV*EXP(ETV) 
       IF (V.GE.LOV.AND.V.LE.HIV) THEN 
          VOK=1 
       ELSE 
          VOK=0 
       ENDIF 
 
       KA=TVKA*EXP(ETKA) 
       IF (KA.GE.LOKA.AND.KA.LE.HIKA) THEN 
          KAOK=1 
       ELSE 
          KAOK=0 
       ENDIF 
 
       KE=CL/V 
       THF=0.693/KE 
       IF (THF.GE.LOTHF.AND.THF.LE.HITHF) THEN 
          THFOK=1 
       ELSE 
          THFOK=0 
       ENDIF 
 
       DOWHILE (CLOK.EQ.0.OR.VOK.EQ.0.OR.KAOK.EQ.0.OR.THFOK.EQ.0) 
          CALL SIMETA(ETA) 
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          ETCL   = ETA(1) 
          ETV    = ETA(2) 
          ETKA   = ETA(3) 
 
          CL=TVCL*EXP(ETCL) 
          IF (CL.GE.LOCL.AND.CL.LE.HICL) THEN 
             CLOK=1 
          ELSE 
             CLOK=0 
          ENDIF 
 
          V=TVV*EXP(ETV) 
          IF (V.GE.LOV.AND.V.LE.HIV) THEN 
             VOK=1 
          ELSE 
             VOK=0 
          ENDIF 
 
          KA=TVKA*EXP(ETKA) 
          IF (KA.GE.LOKA.AND.KA.LE.HIKA) THEN 
             KAOK=1 
          ELSE 
             KAOK=0 
          ENDIF 
 
          KE=CL/V 
          THF=0.693/KE 
          IF (THF.GE.LOTHF.AND.THF.LE.HITHF) THEN 
             THFOK=1 
          ELSE 
             THFOK=0 
          ENDIF 
 
       ENDDO 
 ENDIF 
 
 
S2 = V/1          ;S2 is scaling factor to comp. 2 (for oral); 
Cp(t)=A(t)/S2 
 
REP = IREP 
 
 
$ERROR 
ICP  = F 
IRES = ERR(1) 
 
Y = F + F*ERR(1)  ;proportional error model 
 
 
$TABLE REP ID TIME AMT DV Y CL V KA THF ETCL ETV ABIN AGE WT SEX ICP IRES 
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SAS program 
options mlogic mprint; 
 
*delete all datasets in work; 
proc datasets lib=work kill memtype=data; 
quit; 
 
*import data; 
PROC IMPORT OUT= data  
  DATAFILE="simdatakrepr.csv" 
  DBMS=CSV REPLACE; 
  GETNAMES=YES; 
  DATAROW=2;  
  RUN; 
data dose; set data; if evid; dose=amt; keep id dose;run; 
data data; merge data dose; by id; if evid=0; dv=conc; run; 
   
*create the median age and wt combination within each age group for derived TVCL and TVV; 
data newid; set data; by id ; if first.id; if id<=4; id=1000+id; dv=.;  
if id=1001 then do; age=1 ; wt=9.7; end; 
if id=1002 then do; age=4 ; wt=15.7; end; 
if id=1003 then do; age=9 ; wt=29; end; 
if id=1004 then do; age=14 ; wt=49.5; end; 
run; 
*attach newid to raw data; 
data data; set data newid;run;  
 
*fit model; 
%let flag = 0; 
%macro RunModel(pTVCL=, 
pTVV=, 
pALLOCL=, 
pALLOV=, 
pA50=, 
ps2cl=, 
ps2v=, 
ps2=, 
repeats=); 
 
%let seedi = 18; 
%let count = 0; 
%let itvcl = &ptvcl; 
%let itvv = &pTVV; 
%let iallocl = &pALLOCL; 
%let iallov = &pALLOV; 
%let ia50 = &pA50; 
%let is2cl = &ps2cl; 
%let is2v = &ps2v; 
%let is2 = &ps2; 
%let tvclest = -1; 
%let tvvest = -1; 
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%let alloclest = -1; 
%let allovest = -1; 
%let a50est = -1; 
%let s2clest = -1; 
%let s2vest = -1; 
%let s2est = -1; 
 
%do %while ((&flag = 0 or %sysevalf(&tvclest < 0) or %sysevalf(&tvvest < 0) or 
%sysevalf(&alloclest < 0) or %sysevalf(&allovest < 0 ) or  
  %sysevalf(&a50est < 0) or %sysevalf(&s2clest < 0) or %sysevalf(&s2vest < 0) or 
%sysevalf(&s2est < 0 )) and &count < &repeats); 
 
proc nlmixed data=data  QPOINTS=1;   *QPOINTS=1 is like Laplacian and METHOD=FIRO is like 
FO in NONMEM;  
    parms  
TVCL=&iTVCL 
TVV=&iTVV 
ALLOCL=&iALLOCL 
ALLOV=&iALLOV 
A50=&iA50 
s2cl=&is2cl 
s2v=&is2v 
s2=&is2; 
   anchor = 20; 
   TVKA = 0.6; 
   s2ka = 0.09; 
   F = 1; 
      TVCLI= TVCL*((WT/anchor)**ALLOCL)*(AGE/(AGE+A50)); 
      CL = TVCLI*EXP(ETACL);  
      TVVI=TVV*((WT/anchor)**ALLOV); 
      V = TVVI*EXP(ETAV); 
      KA = TVKA; 
      KE = CL/V; 
      TVKE = TVCL/TVV;  
      pred= log(((F*dose*TVKA)/(TVV*(TVKA-TVKE)))*(exp(-TVKE*time)-exp(-TVKA*time)));  
      ipred = log(((F*dose*KA)/(V*(KA-KE)))*(exp(-KE*time)-exp(-KA*time)));  
      ldv=log(dv); 
      model ldv ~ normal(ipred,s2); 
      random ETACL ETAV ~ normal([0,0],[s2cl,0,s2v]) subject=id;  
      *random ETACL ETAV ETAKA ~ normal([0,0,0],[s2cl,0,s2v,0,0,s2ka]) subject=id;   
predict ipred out=ipred;  
predict pred out=pred;  
predict TVCLI out=TVCLI; 
predict TVVI out=TVVI;  
predict cl out=cl;  
predict v out=v;  
predict ka out=ka; 
ods output  ParameterEstimates=para; 
run; 
 
*reset inital parameter est; 
data _NULL_; 
 set para; 
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 if _N_ = 1 then call symput("tvclest", Estimate); 
    if _N_ = 2 then call symput("tvvest", Estimate); 
    if _N_ = 3 then call symput("alloclest", Estimate); 
 if _N_ = 4 then call symput("allovest", Estimate); 
 if _N_ = 5 then call symput("a50est", Estimate); 
    if _N_ = 6 then call symput("s2clest", Estimate); 
    if _N_ = 7 then call symput("s2vest", Estimate); 
 if _N_ = 8 then call symput("s2est", Estimate); 
run; 
 
data _NULL_; 
 seed = &seedi; 
 call ranuni(seed, rannum1); 
 rannum = 1 + (rannum1 - 0.5) * 0.2; 
 TVCL = &ptvcl * rannum;  
 TVV = &ptvv * rannum;  
 ALLOCL = &pallocl * rannum;  
 ALLOV = &pallov * rannum;  
 A50 = &pa50 * rannum;  
 s2cl = &ps2cl * rannum; 
 s2v = &ps2v * rannum; 
 s2 = &ps2 * rannum; 
 call symput("seedi", seed); 
 call symput("itvcl", tvcl); 
 call symput("itvv", tvv); 
 call symput("iallocl", allocl); 
 call symput("iallov", allov); 
 call symput("ia50", a50); 
 call symput("is2cl", s2cl); 
 call symput("is2v", s2v); 
    call symput("is2", s2); 
run; 
 
data _NULL_; 
 set ipred; 
 if _N_ ^= 0 and %sysevalf(&tvclest > 0) and %sysevalf(&tvvest > 0 ) and 
%sysevalf(&alloclest > 0) and %sysevalf(&allovest > 0 ) and 
      %sysevalf(&a50est > 0) and %sysevalf(&s2clest > 0 ) and %sysevalf(&s2vest > 0) and 
%sysevalf(&s2est > 0 ) then 
  call symput("flag", 1); 
run; 
 
%if &flag = 0 %then 
%do; 
 proc datasets library=work; 
  delete ipred; 
 quit; 
%end; 
 
%let count = &count + 1; 
%end; 
%mend RunModel; 
%RunModel 
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(pTVCL=13.5, 
pTVV=10.4, 
pALLOCL=0.75, 
pALLOV=1, 
pA50=0.18, 
ps2cl=0.09, 
ps2v=0.09, 
ps2=0.01, 
repeats=20) 
 
%macro printRes; 
 
*tailoring output structure; 
 
%if &flag=1 %then 
%do; 
data _NULL_; 
title "Successful"; 
file print; 
put "Successful"; 
run; 
 
data tvcliout; set tvcli; if id>1000; keep id age wt Pred StdErrPred Upper CLbin SECL CVCL 
UCICL; CLbin=Pred; SECL=StdErrPred; CVCL=StdErrPred/Pred*100; UCICL=Upper; run; 
data tvviout; set tvvi; if id>1000; keep id age wt Pred StdErrPred Upper Vbin SEV CVV UCIV; 
Vbin=Pred; SEV=StdErrPred; CVV=StdErrPred/Pred*100; UCIV=Upper; run; 
data cliout; set cl; by id; if first.id; if id<1000; CLi=Pred; SECLi=StdErrPred; 
UCICLi=Upper; run;    *pred in this file is the posthoc CL estimate for each id; 
data viout; set v; by id; if first.id; if id<1000; Vi=Pred; SEVi=StdErrPred; UCIVi=Upper; 
run;         *pred in this file is the posthoc V estimate for each id; 
data kaiout; set ka; by id; if first.id; if id<1000; KAi=Pred; SEKAi=StdErrPred; 
UCIKAi=Upper; run;    *pred in this file is the posthoc KA estimate for each id; 
data pred; set pred; if id<1000; PPRED=exp(Pred); run; 
data ipred; set ipred; if id<1000; IPRED=exp(Pred); run; 
data bins; merge tvcliout tvviout; by id; keep id age wt CLbin SECL CVCL UCICL Vbin SEV CVV 
UCIV; run; 
data posthoc; merge cliout viout kaiout; by id; keep id abin age wt sex dose cli secli 
ucicli vi sevi ucivi kai sekai ucikai; run; 
data preds; merge pred ipred; by id; keep id time abin age wt sex dose dv ppred ipred; run; 
data posthoc; merge posthoc preds; by id; run; 
 
*output; 
proc export data=bins outfile="binskrepr.csv" DBMS=CSV REPLACE; run; 
proc export data=para outfile="parmskrepr.csv" DBMS=CSV REPLACE; run; 
proc export data=posthoc outfile="posthockrepr.csv" DBMS=CSV REPLACE; run; 
%end; 
%mend printRes; 
%printRes 
run; 
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APPENDIX B 
NONMEM model file used for simulations for warfarin 
pediatric model qualification (Chapter 5) 
 
$PROB WARF PEDS PKPD MODEL VALIDATION 
 
$INPUT C ID TIME DAY CMT AMT DV TYPE EVID MDV INRO AGE WT GENO CYP VKOR 
TARG 
 
$DATA nmdata3.csv IGNORE='C' 
 
$SIMULATION (123456 NEW) ONLYSIM 
SUBPROBLEMS = 150 
 
$SUBROUTINE ADVAN6 TOL=6 
;User defined model written as differential equations 
 
$MODEL ; DEFINES THE NO. OF COMPARTMENTS IN THE MODEL 
 
COMP = 1 
COMP = 2 
COMP = 3 
COMP = 4 
 
 
$THETA (0,0.01698,1)  ; TVKOUT 
$THETA (0,0.019527,1) ; TVKIN 
$OMEGA  0.0961        ;BSV CL 
$OMEGA  0.0686        ;BSV V2 
$OMEGA  0.9821        ;BSV V3 
$OMEGA  0.000001      ;BSV EC50 
$OMEGA  0.000025      ;BSV KOUT 
$OMEGA  0.000025      ;BSV KIN 
 
$SIGMA  0.3429        ;sd=0.585662 
 
 
$PK 
 
   TVKA = 2 
   TVCL = 0.1207 
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   TVV2 = 3.45 
   TVQ  = 0.05 
   TVV3 = 1.65 
   F1   = 0.5 
 
   ETCL  = ETA(1)  
   ETV2  = ETA(2)  
   ETV3  = ETA(3)  
 
   CLWT = TVCL*((WT/20)**0.75)*((0.821*AGE/(AGE+0.01))+0.21)*EXP(ETCL) 
   CL   = CLWT 
   IF (CYP.EQ.1)  CL = CLWT*0.685 
    
   IF (CYP.EQ.2)  CL = CLWT*0.547 
    
   IF (CYP.EQ.3)  CL = CLWT*0.28 
 
   IF (CYP.EQ.4)  CL = CLWT*0.31 
   
   IF (CYP.EQ.5)  CL = CLWT*0.148 
 
   KA  = TVKA 
   V2  = TVV2*((WT/20)**0.75)*EXP(ETV2) 
   V3  = TVV3*((WT/20)**0.75)*EXP(ETV3) 
   Q   = TVQ*((WT/20)**0.75) 
 
   S2 = V2  
; S2 is scaling factor to cmpt. 2 (for oral); Cp(t)=A(t)/S2 to get conc 
in MG/L 
 
TVKOUT = THETA(1) 
TVKIN  = THETA(2)  
 
ETEC50 = ETA(4)  
ETKOUT = ETA(5) 
ETKIN  = ETA(6) 
 
TVEC50 = 0.003953 
   IF (VKOR.EQ.1)  TVEC50 = 0.003075 
    
   IF (VKOR.EQ.2)  TVEC50 = 0.002547 
 
EC50 = TVEC50*EXP(ETEC50) 
KOUT = TVKOUT*EXP(ETKOUT) 
KIN  = TVKIN*EXP(ETKIN) 
BSLN = KIN/KOUT         ; R0 baseline INR 
F4   = BSLN 
 
REP  = IREP 
 
 
$DES 
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DADT(1) = -KA*A(1) 
DADT(2) = (KA*A(1))+((Q/V3)*A(3))-((Q/V2)*A(2))-((CL/V2)*A(2)) 
DADT(3) = ((Q/V2)*A(2))-((Q/V3)*A(3)) 
CFREE = A(2)*0.01/S2 
DADT(4) = KIN - KOUT*A(4)*(1-(CFREE/(CFREE+EC50))); 
;INHIBITION OF OUTPUT SINCE INR IS RESPONSE INVERSELY RELATED TO PCA 
(INHIBITORY INDIRECT RESPONSE MODEL) 
 
 
$ERROR 
 
IF (ICALL.EQ.4) THEN  
 
   INR   = A(4) 
   CFRE  = A(2)*0.01/S2 
   IPRE  = INR 
   RESID = ERR(1) 
 
       LOINR = 1 
       HIINR = 6 
 
       Y = IPRE + RESID  
       IF (Y.GE.LOINR.AND.Y.LE.HIINR) THEN 
          INROK=1 
       ELSE 
          INROK=0 
       ENDIF 
  
       DOWHILE (INROK.EQ.0) 
          CALL SIMEPS(EPS)   
          RESID = ERR(1) 
          Y = IPRE + RESID  
          IF (Y.GE.LOINR.AND.Y.LE.HIINR) THEN 
             INROK=1 
          ELSE 
             INROK=0 
          ENDIF 
       ENDDO 
ELSE 
   INR   = A(4) 
   CFRE  = A(2)*0.01/S2 
   IPRE  = INR 
   RESID = ERR(1) 
   Y = IPRE + RESID   ;ADDITIVE ERROR MODEL 
ENDIF 
 
 
$TABLE REP ID TIME DAY CMT AMT DV TYPE CFRE INR RESID Y INRO AGE WT GENO 
CYP VKOR TARG CL EC50 BSLN KOUT KIN ETA1 ETA4 ETA5 ETA6 
NOPRINT ONEHEADER FILE=sdtab8 
APPENDIX C 
Drug Model set-up in Trial Simulator for optimizing pediatric warfarin dosing regimen (Chapter 5) 
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APPENDIX D 
Target INR outcomes for all genotypes (Chapter 5) 
1. Proposed dosing regimen: 
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2. Genotype-independent dosing: 
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3. Proposed dosing regimen with formulation restrictions: 
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4. Initial starting dose estimates - INR-time profile in typical subjects: 
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APPENDIX E 
Population Pharmacokinetic-Pharmacogenetic Analysis of 
Nevirapine in HIV-infected Populations in Uganda and the U.S. 
– A Covariate Exploration 
 
 
 
ABSTRACT  
The aims of this open-label, pharmacokinetic study were to characterize nevirapine 
pharmacokinetics in two geographically distinct populations of HIV- infected patients and 
to assess demographic and genetic covariates on drug exposures, focusing on the CYP2B6, 
CYP3A4, CYP3A5, and MDR1genes.  A total of 46 HIV-infected adults underwent 
nevirapine sampling under steady state conditions.  All data were analyzed using nonlinear 
mixed-effects modeling, and the population pharmacokinetic model was used to assess the 
effects of covariates.  The following homozygous loss-of-function alleles, CYP2B6 
516G>T, CYP3A5*3 and CYP3A4*1B, were associated with 35%, 25% and 18% 
reductions in nevirapine clearance, respectively.  These three genotypes in combination 
with body weight, explained 71% of the interpatient variability in nevirapine apparent 
clearance.  Regardless of CYP genotype, all patients had trough nevirapine concentrations 
above the 3,000 ng/mL threshold.  As previously noted by others, variability in apparent 
nevirapine clearance tended to be low and was heavily influenced by CYP2B6 516G>T.   
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INTRODUCTION 
At the beginning of 2009, approximately 33.4 million people world-wide were infected 
with the human immunodeficiency virus (HIV); 22.5 million of these individuals live in 
sub-Saharan Africa (1).  In recent years, significant progress has been made in providing 
antiretroviral therapy (ART) for HIV-infected patients residing in low and middle income 
countries.  Expanded ART access has resulted in a 10-fold increase in the number of 
people receiving treatment in these underserved areas (2, 3).  The availability of potent 
ART to developing nations has been largely driven by the manufacture and distribution of 
generic ART formulations.  Of these, nevirapine has gained widespread use due to (a) its 
status as a recommended component of combination ART for treatment-naïve individuals 
who meet criteria for initiating therapy (4), (b) its ability to reduce mother-to-child 
transmission (MTCT) of HIV-1 (5) and (c) its availability as an affordable fixed-dose 
combination product (6). 
 
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, which 
binds directly to- and allosterically inhibits viral reverse transcriptase (RT) activity.  Upon 
oral administration, the drug is rapidly absorbed (Tmax = 2 h) with an absolute 
bioavailability of 90-93%.  It has a long half-life of 25-30 hours following repeated dosing 
and is 60% bound to plasma proteins (7).  Nevirapine undergoes oxidative metabolism by 
CYP3A4 and CYP2B6 enzymes, while the role of CYP3A5 in nevirapine metabolism is not 
entirely clear (8).  In addition to CYP2B6 and CYP3A, nevirapine may also be a substrate 
for the ABCB1 (MDR1) gene product and efflux transporter, P-glycoprotein (P-gp) (9).  
Genetic polymorphisms in the CYP2B6, CYP3A4, CYP3A5, and ABCB1 genes may 
contribute to interindividual differences in nevirapine pharmacokinetics among different 
populations.  Indeed, homozygous expression of the CYP2B6 516TT variant allele was 
found by us and others to result in higher nevirapine concentrations in Ugandan and Swiss 
populations, respectively (10, 11). Similarly, a population pharmacokinetic-
pharmacogenetic study in Cambodian patients found that CYP2B6 516TT was associated 
with reduced nevirapine clearance compared with CYP2B6 516GT and 516GG genotypes 
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(12).  Nonetheless, there is still a general paucity of information regarding covariates 
influencing nevirapine pharmacokinetics among different populations.  
 
The purpose of this pharmacokinetic-pharmacogenetic study was to characterize 
nevirapine pharmacokinetics in comparable non-Western (Uganda, Africa) and Western 
(United States) HIV-infected populations.  A population approach was used to identify 
demographic and genetic factors that influence nevirapine disposition; genetic variability 
in CYP2B6, CYP3A4, CYP3A5, and ABCB1 (MDR1) were targeted for this purpose.  Non-
linear mixed-effects modeling was used to characterize the influence of all covariates on 
nevirapine pharmacokinetic parameter values. 
 
 
METHODS 
Patients. Data from this study were sequentially acquired from two pooled cohorts of HIV-
infected patients from Uganda Africa, and the United States, respectively.  To be 
considered for study inclusion, candidates had to be HIV positive, >18 years old, and in 
good general health as determined by medical history, physical examination, and serum 
chemistry values.  There were no minimum or maximum requirements with regard to 
CD4+ counts or HIV-RNA levels, although patients could not have any clinical or 
laboratory evidence of an active opportunistic infection.  Exclusion criteria also included 
receipt of interleukin-2 within 3 months of study participation, receipt of any medications 
known or suspected to modulate CYP2B6 and/or CYP3A4/5 activity, active drug or 
alcohol abuse, pregnancy, chronic diarrhea or loose stools, fever > 38.5 0C within 7 days of 
screening, and a history of poor adherence to antiretroviral therapy.  After the Ugandan 
cohort completed their portion of the study, a comparator group of U.S. subjects was 
selected from the National Institutes of Allergy and Infectious Diseases (NIAID) outpatient 
HIV clinic and included subjects who were matched by gender and BMI to their Ugandan 
counterparts.  
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The study was approved by the Joint Clinical Research Center Institutional Review Board, 
the Uganda National Council for Science and Technology, and the National Institute of 
Allergy and Infectious Diseases Institutional Review Board.  All participants gave written 
informed consent, and clinical research was conducted according to guidelines for human 
experimentation as specified by the US Department of Health and Human Services.  
 
Study procedures.  Because the study was designed to characterize nevirapine 
pharmacokinetics in two different HIV-infected populations, a single nevirapine 
formulation (Viramune™) Boehringer Ingelheim) was administered to both groups to 
eliminate the possibility of a formulation effect on study results.  As such, Ugandan 
participants who were stabilized on a generic nevirapine formulation for at least 28 days 
were switched to brand name nevirapine (Viramune™) 200 mg twice daily; the remainder 
of their antiretroviral regimen remained unchanged.  Due to the unavailability of generic 
nevirapine formulations in the U.S., patients were already stabilized on a Viramune-
containing regimen (200 mg twice daily) for at least 28 days.  To this end, pharmacokinetic 
sampling for both groups occurred under steady state conditions for all study participants.  
 
In the Ugandan cohort, subjects were admitted to the Clinical Research Center the night 
before scheduled pharmacokinetic sampling.  The evening nevirapine dose was observed 
by study personnel for all subjects and the time of administration recorded.  The next 
morning, after an overnight fast, an intravenous catheter was placed into the forearm vein 
of participants for the purposes of blood drawing.  Just prior to taking their morning 
nevirapine dose (12 hrs after the previous night’s dose), blood was collected into 
heparinized tubes for a time 0 hr nevirapine concentration.  Blood was also collected into 
EDTA tubes for determination of CYP2B6, CYP3A4/5, and MDR1 genotypes as described 
below.  Next, subjects took their morning 200 mg dose of nevirapine with 100 mL of water 
and a standardized breakfast provided by the clinic. Four hours after taking nevirapine, 
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subjects were free to eat lunch.  Adherence with antiretroviral medications was assessed by 
patient interview and pill counts. 
  
Sampling and bioanalysis. Blood samples (15 mL) for the determination of nevirapine 
concentrations were collected in heparinized (green top) tubes immediately before (time 0), 
and 2 and 6 hours after dosing.  Blood was centrifuged after collection and plasma was 
harvested and frozen until the time of analysis.  Nevirapine concentrations in human 
plasma were measured using a high-performance liquid chromatography (HPLC) liquid–
liquid extraction method. Percentage errors, as a measure of accuracy, were <10%, and the 
inter- and intra-assay coefficients of variation were 4.35 – 8.55% and 3.54 – 6.52% 
respectively (R2 = 0.998), and the limit of detection was 25 ng/ml.  Blood samples 
collected during the study were also used to determine CYP2B6, CYP3A4/5, and 
MDR1genotypes of the study subjects for further genetic analysis.  
 
Genetic analysis. Venous blood samples were obtained from all subjects, and DNA was 
isolated from peripheral leucocytes with the Qiamp system (Qiagen Inc, Valencia, CA). 
CYP2B6 (516GG, 516GT and 516TT) and CYP3A4*1B genotypes, and/or the CYP3A5*3 
null allele together with the MDR1 genotype at position 2677 were determined by 
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) as 
previously described (23, 24, 25, 26).  Based on CYP2B6, CYP3A4*1B and the 
CYP3A5*3 genotypes, subjects were phenotypically identified as “poor”, “intermediate” 
and “extensive” nevirapine metabolizers.  No ultrarapid metabolizers were identified.  
Further, based on the MDR1 genotype, subjects were phenotypically identified as “poor”, 
“intermediate” and “extensive” nevirapine transporters.  
 
Pharmacokinetic analysis. A population approach was used for the current 
pharmacokinetic analysis.  Previously, population PK models for nevirapine have been 
published (13, 14, 15) that are consistent with regard to the base structural, one-
compartment body model with first order absorption.  The primary objective of this study 
was to mainly update the covariate model.  While we tested for effects of all available 
covariates, the focus was on the effects of four genes – CYP2B6, CYP3A4, CYP3A5 and 
MDR1.  All analyses were carried out using the non-linear mixed-effects modeling 
software NONMEM version VI.  All graphics were generated using R version 2.9.1.   
 
Prior base model. The available pharmacokinetic data were sparse such that we could not 
estimate the oral absorption parameters.  We used prior information on the base model 
from a previous study (13) and fixed the parameter values for the first-order absorption rate 
constant (Ka) and its variability (Ω2Ka) accordingly.  The prior model included a linear 
body weight effect parameter (WTeff) on clearance, using a proportional model.  Between-
subject variability (BSV) was explained using a proportional error model while within-
subject or residual variability (WSV) was accounted for using an additive error model.  We 
adapted our base model from this prior as follows: 
 
( )( ) ( )
iCLieffi WTWTTVCLCL η+−+= ••• 1701        (2) ( )
iVci TVVcVc η+= • 1           (3) 
(
iKai TVKaKa η+= • 1 )          (4) 
Cppredi CpCp ε+=           (5) 
 
where; ηCLi is the difference between individual (CLi) and population mean or typical 
value (TVCL) of clearance for a 70-kg individual, ηVci is the difference between individual 
(Vci) and population mean or typical value (TVVc) of volume of distribution and ηKai is 
the difference between individual (Kai) and population mean or typical value (TVKa) of 
absorption rate constant, while Cpi is the individual observed plasma concentration and 
Cppred is the individual model predicted plasma concentration. ηCLi, ηVci and ηKai were all 
assumed to follow a normal distribution with mean of zero and variances of Ω2CL, Ω2Vc 
and Ω2Ka respectively, and with ηCLi and ηVci having a correlated distribution. εCp is the 
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residual error assumed to follow a normal distribution with mean of zero and variance of 
σ2Cp. 
 
We fit the prior model, without modification, to our study data to determine if it describes 
the observed individual level data well.  We also tested use of an exponential error model 
for explaining BSV on all model parameters rather than a proportional model.  We 
explored estimating BSV on volume with and without a covariance with clearance.  We 
also considered fixing the BSV on volume to the value from the prior model, or leaving 
this parameter out of the model altogether.  
 
Covariate exploration. We first tested the inclusion of each genetic and demographic 
covariate individually into the model.  Covariate significance was assessed based on 
mechanistic plausibility, decrease in model objective function value (ΔOFV ≥ -4), and 
graphical inspection of overall model fit and covariate plots.  While testing for covariate 
effects, we estimated all model parameters other than mean Ka and its variability. 
  
We explored retaining the weight effect parameter on clearance as per the prior 
proportional model and estimating a weight effect parameter.  We also considered an 
allometric scaling model for weight effect.  We then modified the clearance model as 
described in the Results section above.  Based on mechanism, effects of the three CYP450 
isoforms were tested on nevirapine clearance and that of the MDR1 gene on bioavailability.  
We used a stepwise approach for inclusion of multiple gene effects into the model, based 
upon the significance of individual effects.  This approach is outlined in Table 3.  
 
Initially, we ran the model with no gene effect included.  Upon inspection of covariate 
plots for the four genes (vs. predicted apparent clearance (CL/F) residuals) we observed 
gene effects only for the homozygous variant genotypes.  Residuals were similar for the 
wild type (“extensive” metabolizer) and heterozygous (“intermediate” metabolizer) 
genotypes.  Hence for analysis of all gene effects, subjects were categorized into 2 
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genotype groups – “extensive” metabolizers (or transporters in case of MDR1) including 
wild type and heterozygous genotypes or “poor” metabolizers (or transporters in case of 
MDR1) including only the homozygous variant genotype. Since the two MDR1 genotypes 
(2677G>T/A and 3435C>T) on which data were available occur in linkage disequilibrium 
we focused our analysis for gene effects only on the MDR1 2677 polymorphism since 
there were more subjects (n = 4) with this variation than for the silent mutation MDR1 
3435 (n = 2).    
 
Although our study population was comprised of two cohorts, we considered the influence 
of covariate effects based on race (White vs. Black) rather than region (U.S vs. Uganda).  
Gender, age, height and BMI were the other covariates we considered for effects on both 
clearance and volume, although previously published work on nevirapine population 
pharmacokinetics only found either body weight or gender to be of significance.  
 
 
RESULTS 
 
Patients 
A total of 46 patients met inclusion criteria and were included in the final analysis (24 and 
22 subjects from the U.S. and Ugandan cohorts, respectively).  Cohort demographics are 
provided in Table 1. 
 
Table 1 Characteristics of 46 HIV infected participants in this population 
pharmacokinetic analysis from the U.S. and Uganda 
      
  U.S. SUBJECTS 
UGANDAN 
SUBJECTS Total 
  
(mean values and 
range) (mean values and range)   
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N 22 24 46 
AGE 37.23 (21-50) 35.75 (27 - 64) 36.9 (21-64) 
HEIGHT 
(cm) 164.27 (145.7 - 184.8) 166.65 (155.3 - 195) 165.6 (145.7 - 195) 
WEIGHT 
(kg) 72.18 (47.4 - 98.5) 65.33 (40 - 87.5) 68.5 (40-98.5) 
BMI 26.82 (22.01 - 37.75) 23.57 (14.3 - 29.7) 25 (14.3 - 37.76) 
GENDER       
F 14 (63.6%) 16 (66.7%)  30  
M 8 (36.4%) 8 (33.4%) 16 
RACE       
BLACK 9 24   
WHITE 13     
GENOTYPE       
CYP2B6-516       
Extensive 
metabolizers 
GG 11 (50%) 13 (54.2%) 24 (52%)  
Intermediate 
metabolizers 
GT 8 (36.4%) 7 (29.2%) 15 (33%) 
Poor 
metabolizers 
TT 3 (13.6%) 4 (16.7%) 7 (15%) 
CYP3A4*1B       
Extensive 
metabolizers 
AA 12 (54.5%)  0 12 (26%) 
Intermediate 
metabolizers 
AG 3 (13.6%) 15 (62.5%) 18 (39%) 
Poor 
metabolizers 
GG 7 (31.8%) 9 (37.5%) 16 (35%) 
CYP3A5*3       
Extensive 
metabolizers 
AA 6 (27.3%) 14 (58.3%) 20 (44%)  
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Intermediate 
metabolizers 
AG 5 (22.7%) 8 (33.3%) 13 (28%) 
Poor 
metabolizers 
GG 11 (50%) 2 (8.3%) 13 28%) 
MDR1-2677       
Extensive 
transporters 
GG 11 (50%) 23 (95.8%) 34 (74%) 
Intermediate 
transporters 
GT 7 (31.9%) 1 (4.2%) 8 (17%) 
Poor 
transporters 
TT 4 (18.2%) 0 4 (9%) 
 
 
Pharmacokinetic analysis 
Prior base model.  The sparseness of the available pharmacokinetic data precluded 
estimation of oral absorption parameters.  Hence, the base model was adapted from a 
previous study (13).  The prior model, without modification, fit the individual observed 
data well.  Using an exponential error model for between-subject variability (BSV) 
resulted in an increase in objective function value (OFV); hence we retained the 
proportional error model to describe BSV on all primary model parameters.  We also found 
that estimating BSV on volume of distribution along with a covariance with clearance 
yielded the best fit in terms of OFV, standard error (SE) on mean volume estimate and 
predicted volume residual plots (data not shown).  
 
Covariate exploration.  We could not estimate a weight effect parameter for clearance 
since the effective body weight range in both cohorts was limited (60-90 kg).  Nonetheless, 
removing the weight effect on clearance adversely impacted the overall model fit; hence 
we chose to retain this covariate in our model.  However, we used a physiologically more 
plausible allometric scaling model, with an exponent of 0.75 for body weight effect, rather 
than the proportional model used previously.  Besides weight, we did not find any other 
demographic covariate to be of significance.  Thus, our modified base clearance model is 
as follows: 
 
( )
iCLii
WTTVCLCL η+= •
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛
• 1
70
75.0
       (1) 
where; ηCLi is the difference between individual clearance (CLi) and population mean or 
typical value (TVCL) of clearance for a 70-kg individual.  
 
Genetic covariates were initially assessed individually for their effect on nevirapine 
clearance. The CYP2B6 variant genotype was found to be most significant (31% reduction 
in clearance, Decrease in Objective Function Value (ΔOFV) = -8) followed by the CYP3A5 
variant genotype (19% reduction in clearance, ΔOFV= -4).  As lone covariates, the 
CYP3A4 and MDR1 variant genotypes were not found to significantly affect nevirapine 
clearance.  
 
Table 2 summarizes our findings of gene effects on nevirapine clearance.  The plots of 
individual and population predicted vs. observed plasma concentrations are depicted in 
Figure 1. Improved model fits can be observed for the population predictions upon 
addition of significant gene effects.  Figure 2 shows the covariate plots (individual - 
population mean predicted apparent clearance (CL/F) residuals vs. covariate levels) for the 
relevant genotype effects.  
 
Table 2 Step-wise inclusion of gene-effects into model 
              
STEP GENE EFFECT* (on 
CL) 
95%CI OFV 
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1 NONE     247 
2 CYP2B6 -31% -18 to -44% 239 
3 CYP2B6 -31% -19 to -43%   
  CYP3A5 -19% -5 to -32% 235 
4 CYP2B6 -35% -24 to -46 %   
  CYP3A5 -25% -13 to -37%   
  CYP3A4 -18% -5 to 31% 231 
5 CYP2B6 -36% -26 to -46%   
  CYP3A5 -21% -6 to -36%   
  CYP3A4 -18% -1 to -39%   
  MDR1 +22% (eff. on F) -14 to +65% 230 
 
 
Figure 1: Observed vs. predicted nevirapine plasma concentrations 
(a) No gene effect included  (b) CYP2B6, CYP3A5 and CYP3A4 gene effects included 
 
 
Figure 2: Covariate plots showing individual vs. population mean predicted apparent 
clearance (CL/F) residuals for genotype effects 
(a) No gene effect included  (b) CYP2B6 gene effect included 
(c) CYP2B6 and CYP3A5 gene effects included    (d) CYP2B6, CYP3A5 and CYP3A4 gene effects included 
*Extensive metabolizers reflect pooled wild and heterozygous genotypes. Poor metabolizers reflect   
homozygous variant genotypes alone. 
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In the absence of any gene effect in the model, the covariate plots were indicative of a 
genotype effect for CYP2B6 and CYP3A5 genes (Figure 2a).  Hence, we first included the 
CYP2B6 variant genotype effect on nevirapine clearance in our model and found statistical 
significance (ΔOFV = -8, Table 2) and improved graphical model fit.  The average 
exposures (Cavg) were 8.63 ug/ml and 6.33 μg/ml in poor and extensive metabolizers 
respectively. 
  
Following inclusion of CYP2B6 in the model, the covariate plots were still indicative of a 
genotype effect for the CYP3A5 gene (Figure 2b).  We included the CYP3A5 variant 
genotype effect next and found this covariate to be marginally statistically significant  
(ΔOFV= -4, Table 2).  The covariate plots now revealed a CYP3A4 genotype effect that 
was absent earlier (Figure 2c) and a mild, if any, MDR1 genotype effect (not shown).  
Hence the third genetic covariate we added to our model was the CYP3A4 variant genotype 
and again found it to be marginally statistically significant (ΔOFV= -4, Table 2).  Finally, 
the MDR1 genotype effect on bioavailability was tested, since the covariate plots still 
indicated a mild signal (Figure 2d); however, the effect was not found to be statistically 
significant (ΔOFV= -1, Table 2) and did not improve the graphical model fit. 
 
We considered differences in nevirapine clearance across race (White vs. Black).  In 
absence of any gene effect in the model, the covariate plots indicate a potential ‘race 
effect’.  However, upon inclusion of the three CYP450 isoforms into the covariate model 
for clearance, this apparent race effect was no longer present in the covariate plots and the 
variability in apparent clearance residuals within each race was also relatively reduced 
(Figure 3).  
 
 
 
 
Figure 3: Covariate plots showing individual vs. population mean predicted apparent 
clearance (CL/F) residuals for race effects  
(a) No gene effect included (b) CYP2B6, CYP3A5 and CYP3A4 gene effects included 
*Extensive metabolizers reflect pooled wild and heterozygous genotypes. Poor metabolizers reflect   
homozygous variant genotypes alone. 
 
 
 
 
Final model parameters are presented in Table 3.  While our parameter estimate for 
volume of distribution (287 L) is higher when compared with previous models (70-210 L), 
of note is the fact that this parameter estimate appears to vary considerably between 
different models (12, 13, 14, 15).  When mean volume was fixed to the prior model value 
(106 L) (13), there was bias seen in the predicted volume residual (ηVci) plots.  Estimating 
the mean volume parameter eliminated such bias yielding uniformly distributed residuals. 
 
Table 3 Final model parameters 
     
Parameter Estimate (RSE %) Variability (RSE %) 
Mean Clearance (TVCL) 3.62 L/h/70kg (6.6) 29% (22.2) 
Mean Volume (TVVc) 287 L (19.8) 46% (24.8) 
 212
 213
Absorption rate constant (TVKa) 1.68 /h [fixed] 38% [fixed] 
WTeff_CL 0.75 [fixed]   
CYP2B6 effect on CL -35% (16.1)   
CYP3A5 effect on CL -25% (24.8)   
CYP3A4 effect on CL -18% (36)   
Residual error 0.63 ug/ml (43.9)   
RSE%: Relative Standard Error percentage  
 
 
DISCUSSION 
The base model parameters from our population model of nevirapine pharmacokinetics in 
this study are in agreement with previously published accounts (12, 13, 14, 15) and they 
represent the first covariate model to identify significant genotype effects on nevirapine 
disposition in an African cohort.  Our data are in line with prior findings that have linked 
low body weight to an increase in nevirapine exposure (13, 15, 16).  In fact, body weight 
was the only demographic covariate with a significant impact on drug exposure, as no 
differences in nevirapine pharmacokinetics were observed based on race (White vs. Black), 
when accounting for the effects of the CYP genotypes in the model.  Thereby, any 
observed differences in nevirapine exposure among patients of different racial (or regional) 
backgrounds are likely due to differential distribution of variant genotypes among different 
races, particularly CYP2B6 and CYP3A5.  Highlighting this point, the CYP2B6 516TT 
genotype, which is associated with minimal metabolic activity of the CYP2B6 enzyme, 
was more prevalent among White subjects (24%) compared with Black subjects (12%), 
while the CYP3A5*3 genotype, which is associated with minimal CYP3A5 activity, was 
predominant in White subjects (85%) and negligible among Blacks (6%).  The 
CYP3A4*1B variant genotype was absent among Whites and 50% prevalent in the Black 
race. 
 
In an initial study of nevirapine trough concentrations in the same Ugandan cohort reported 
herein, we observed a significant association between nevirapine pre-dose concentration 
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and CYP2B6 genotype (10).  Consistent with these findings, our population analysis 
revealed that the CYP2B6 genotype was the most significant covariate of the population 
model, being associated with a 35% reduction in nevirapine clearance.  After CYP2B6, 
CYP3A5*3 and CYP3A4*1B variant genotypes were identified as secondary covariates, 
each of which explained 25% and 18% reductions in nevirapine clearance, respectively.  
The identification of CYP2B6 and CYP3A5 variant alleles as contributors to nevirapine 
clearance is consistent with previously published data (12).  However, this is the first 
nevirapine population model that included CYP3A4*1B.  Even though the reduction in 
variability in nevirapine clearance explained by CYP3A4*1B was relatively minor, 
inclusion of this polymorphism improved the fit of our model and may be considered in 
future studies assessing the influence of genetic covariates on nevirapine clearance.   
  
Finally, our analysis indicated a non-significant increase of 20% in nevirapine 
bioavailability in patients with the MDR1 2677TT variant genotype, when tested in context 
of all genes.  However, inclusion of the MDR1 gene effect did not improve the graphical 
model fit.  This is likely because nevirapine exhibits high oral bioavailability (> 90%), 
suggesting that drug concentrations in the gastrointestinal tract would likely exceed those 
necessary to saturate P-gp –assuming the nevirapine is in fact a P-gp substrate (17).  To 
this end, any alteration in nevirapine bioavailability due to MDR1 genotype would appear 
to carry little, if any, clinical significance. 
 
Perhaps the most important concern with reduced nevirapine clearance is the risk of 
persisting subtherapeutic concentrations.  This is particularly relevant to pregnant women 
who receive a single dose of nevirapine for the prevention of mother-to-child-transmission 
(MTCT) of HIV in Africa.  Indeed single-dose nevirapine administered intrapartum, has 
been associated with detectable concentrations of the drug in plasma between 1-3 weeks 
after drug administration (18, 19, 20).  Mothers with the CYP2B6 516TT genotype, which 
is associated with reduced nevirapine clearance, may be at particular risk for persisting 
nevirapine concentrations and development of NNRTI resistance mutations (K103N and 
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Y181C) (21).  However, a recent investigation assessed the influence of CYP2B6 516G>T 
on nevirapine concentrations in HIV-infected Thai women and found that this 
polymorphism had only a minor impact on nevirapine concentrations following a single 
intrapartum nevirapine dose (22).  
 
This study has several limitations. Our study design employed a limited sampling strategy 
of 3 samples per subject with one pre-dose trough sample (time 0), and two post-dose 
samples at 2 and 6 hours, respectively.  As a result, our data was missing information on 
the absorption phase of nevirapine and we could not estimate oral absorption parameters.  
Hence we were unable to generate a complete model de novo, so we used a Bayesian-like 
approach where we adopted prior information on these base model parameters from 
previous nevirapine models.  Notably, leveraging prior information where possible is 
considered good practice in model building. Next, we recognize that our sample size of 46 
is comparatively smaller than other nevirapine population pharmacokinetic studies.  
However, our results are consistent with previously reported findings from nevirapine 
population pharmacokinetic studies, and the mechanistic reasoning for including the 
selected genetic covariates is based on solid scientific rationale. Lastly, since all of our 
HIV-infected patients were in good general health, we did not consider creatinine 
clearance or co-morbidities as factors potentially impacting nevirapine apparent clearance.  
Yet, absence of significant co-morbidities in our patient population allowed us to isolate 
the influence of the genetic polymorphisms on nevirapine disposition.  
Despite these limitations, data from this study show that the three genetic polymorphisms, 
CYP2B6, CYP3A4*1B and CYP3A5*3 and body weight collectively explained 71% of 
variability in nevirapine clearance. 
 
Pharmacogenetic-pharmacokinetic data explaining the impact of genetic polymorphisms 
on nevirapine clearance have not been previously reported in a Ugandan - U.S. cohort.  
These data were largely consistent with those recently reported in HIV-infected 
Cambodian patients where CYP2B6 also had the greatest impact on nevirapine clearance 
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(12).  Also similar to patients from other studies, all of our patients had nevirapine trough 
concentrations in excess of 3,000 ng/mL compared to 95% of patients in the Chou et al. 
investigation (12).  The main theoretical concern in individuals with the three genetic 
polymorphisms mentioned above, particularly the CYP2B6 516TT variant, is the potential 
for increased risk of nevirapine toxicity or development of nevirapine resistance due to 
higher and/or persisting plasma concentrations when the drug is used for prevention of 
MTCT.  Further study into the pharmacogenetics and pharmacokinetics of nevirapine in 
diverse patient populations will likely illicit information that will allow clinicians to 
optimize the use of this agent in developing nations.  Model-based dose adjustments may 
also be considered for future study in homozygous variant genotype individuals to avoid 
toxicity due to higher drug exposures. 
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disease and helping in the implementation of proper drug therapy via co‐ordination with 
various retail pharmacists all over the city of Mumbai. (May 2005‐06) 
• Participant  in  workshop  on  Bioinformatics  and  Drug  Design  at  SIES‐Institute  of 
Environmental Management, Mumbai. (April 2005). 
 
 
Employment Record  
 
June ’09  FDA (Office of Clinical Pharmacology)                         Silver Spring, MD 
to date  FELLOW in Division of Pharmacometrics 
• Undertaken two major research projects as part of Ph.D. dissertation. 
• NIH  collaboration  research  project:  derived  a  population  pharmacokinetic‐
pharmacogenetic  model  for  the  drug  Nevirpaine  used  as  HIV  treatment.  Wrote  and 
submitted  manuscript  on  the  project  in  collaboration  with  researchers  from  National 
Instititutes of Health (July’10‐Feb’11). 
• Conducted six pediatric IND reviews. 
• Additional assignments by supervisors. 
 
Aug. ’06 to   Virginia Commonwealth University (VCU)                                            Richmond, VA 
Aug. ‘09  TEACHING ASSISTANT in Dept. of Pharmacy 
• Skills  Labs: Trained 1st  and 2nd  year Pharm.D.  students  in pharmacy  skills  ‐  role playing 
(patient counseling, tele‐ prescription filling with physician etc), services (measuring blood 
pressure,  cholesterol,  blood  glucose  etc),  parenteral  nutrition  bag  preparation  under 
aseptic conditions. 
• Courses  and  Labs:  Prepared  quizzes,  posted quizzes  to  blackboard,  administered  paper 
quizzes and exams  in class, administered clicker quizzes  in class, graded quizzes, exams 
and homework assignments, both MCQ type and subjective essay‐type, posted grades to 
blackboard. 
• Assisted with overall  conduct of  classes and  labs and  co‐ordination of  course activities, 
maintained  blackboard  course  websites  and  handled  course,  instructor,  and  peer 
evaluations. 
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June‐July ’05    Pfizer                                                       Mumbai, India 
  STUDENT INTERN 
• Exposure  to  the  sophisticated  working  environment  of  a  multinational  pharmaceutical 
company.  
• Overview  training of operations  in various departments of  the  industry viz. Production, 
Quality  Control,  cR&D  Pilot  Plant,  Engineering  &  Maintenance,  Pharmacy,  Stores  and 
P.P.I.C. 
• Conducted a comprehensive study and presentation of how a large‐scale pharmaceutical 
plant  functions,  to  support  the knowledge heretofore gained by  coursework and  small‐
scale laboratory work at school. 
 
 
Technical Skills 
• Data analysis and simulation software programs –  
   NONMEM, R, SAS, Trial Simulator, DATA (cost‐effectiveness modeling)  
• Laboratory techniques for genetic testing –  
   PCR and Microarray 
 
 
Achievements 
• Selected  as  Phi  Kappa  Phi  Graduate  School  Scholarship  Recipient  from  School  of 
Pharmacy, VCU for two years – 2008 and 2010. 
• Invited to membership of the Honor Society of Phi Kappa Phi  for academic excellence  ‐ 
October 2007. 
• Elected to the post of Vice President for the Graduate Student Association of the 
   Dept. of Pharmacy, VCU School of Pharmacy ‐ 2007. 
 
